BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Hernán MA, Pérez-Olmeda M, Sanmartín JL, Fernández-García A, Cruz I, Fernández de Larrea N, Molina M, Rodríguez-Cabrera F, Martín M, Merino-Amador P, León Paniagua J, Muñoz-Montalvo JF, Blanco F, Yotti R; ENE-COVID Study Group. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet 2020;396:535-44. [PMID: 32645347 DOI: 10.1016/S0140-6736(20)31483-5] [Cited by in Crossref: 769] [Cited by in F6Publishing: 460] [Article Influence: 384.5] [Reference Citation Analysis]
Number Citing Articles
1 Ramos Álvarez O, Arufe Giráldez V, Cantarero Prieto D, Ibáñez García A. Changes in Physical Fitness, Dietary Habits and Family Habits for Spanish Children during SARS-CoV-2 Lockdown. Int J Environ Res Public Health 2021;18:13293. [PMID: 34948901 DOI: 10.3390/ijerph182413293] [Reference Citation Analysis]
2 Nikolai LA, Meyer CG, Kremsner PG, Velavan TP. Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible. Int J Infect Dis 2020;100:112-6. [PMID: 32891737 DOI: 10.1016/j.ijid.2020.08.076] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 40.0] [Reference Citation Analysis]
3 González-parra G, Cogollo MR, Arenas AJ. Mathematical Modeling to Study Optimal Allocation of Vaccines against COVID-19 Using an Age-Structured Population. Axioms 2022;11:109. [DOI: 10.3390/axioms11030109] [Reference Citation Analysis]
4 Keuning MW, Grobben M, de Groen AC, Berman-de Jong EP, Bijlsma MW, Cohen S, Felderhof M, de Groof F, Molanus D, Oeij N, Rijpert M, van Eijk HWM, Koen G, van der Straten K, Oomen M, Visser R, Linty F, Steenhuis M, Vidarsson G, Rispens T, Plötz FB, van Gils MJ, Pajkrt D. Saliva SARS-CoV-2 Antibody Prevalence in Children. Microbiol Spectr 2021;9:e0073121. [PMID: 34523985 DOI: 10.1128/Spectrum.00731-21] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Johnson M, Wagstaffe HR, Gilmour KC, Mai AL, Lewis J, Hunt A, Sirr J, Bengt C, Grandjean L, Goldblatt D. Evaluation of a novel multiplexed assay for determining IgG levels and functional activity to SARS-CoV-2. J Clin Virol 2020;130:104572. [PMID: 32769024 DOI: 10.1016/j.jcv.2020.104572] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 17.5] [Reference Citation Analysis]
6 Voo TC, Reis AA, Thomé B, Ho CW, Tam CC, Kelly-Cirino C, Emanuel E, Beca JP, Littler K, Smith MJ, Parker M, Kass N, Gobat N, Lei R, Upshur R, Hurst S, Munsaka S. Immunity certification for COVID-19: ethical considerations. Bull World Health Organ 2021;99:155-61. [PMID: 33551509 DOI: 10.2471/BLT.20.280701] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 7.5] [Reference Citation Analysis]
7 Clemente D, Udaondo C, de Inocencio J, Nieto JC, Del Río PG, Fernández AG, Palomo JA, Bachiller-Corral J, Lopez Robledillo JC, Millán Longo C, Leon L, Abasolo L, Boteanu A. Clinical characteristics and COVID-19 outcomes in a regional cohort of pediatric patients with rheumatic diseases. Pediatr Rheumatol Online J 2021;19:162. [PMID: 34838054 DOI: 10.1186/s12969-021-00648-5] [Reference Citation Analysis]
8 Andrés C, Piñana M, Borras-Bermejo B, González-Sánchez A, García-Cehic D, Esperalba J, Rando A, Zules-Oña RG, Campos C, Codina MG, Blanco-Grau A, Colomer-Castell S, Martín MC, Castillo C, García-Comuñas K, Vásquez-Mercado R, Martins-Martins R, Campins-Martí M, Pumarola T, Quer J, Antón A. A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain). Emerg Microbes Infect 2021;:1-30. [PMID: 34842496 DOI: 10.1080/22221751.2021.2011617] [Reference Citation Analysis]
9 Gude-Sampedro F, Fernández-Merino C, Ferreiro L, Lado-Baleato Ó, Espasandín-Domínguez J, Hervada X, Cadarso CM, Valdés L. Development and validation of a prognostic model based on comorbidities to predict COVID-19 severity: a population-based study. Int J Epidemiol 2021;50:64-74. [PMID: 33349845 DOI: 10.1093/ije/dyaa209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
10 COVID-19 Community Research Partnership Study Group. Duration of SARS-CoV-2 sero-positivity in a large longitudinal sero-surveillance cohort: the COVID-19 Community Research Partnership. BMC Infect Dis 2021;21:889. [PMID: 34461847 DOI: 10.1186/s12879-021-06517-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Petersen MS, Kristiansen MF, Reinert HW, Fjallsbak JP, Christiansen DH, Gaini S, Steig BÁ, Møller LF, Strøm M, Weihe P. Seroprevalence of SARS-CoV-2-Specific Antibodies among Quarantined Close Contacts of COVID-19 Patients, Faroe Islands, 2020. Emerg Infect Dis 2021;27:2795-801. [PMID: 34437829 DOI: 10.3201/eid2711.204948] [Reference Citation Analysis]
12 Thompson RN, Hollingsworth TD, Isham V, Arribas-Bel D, Ashby B, Britton T, Challenor P, Chappell LHK, Clapham H, Cunniffe NJ, Dawid AP, Donnelly CA, Eggo RM, Funk S, Gilbert N, Glendinning P, Gog JR, Hart WS, Heesterbeek H, House T, Keeling M, Kiss IZ, Kretzschmar ME, Lloyd AL, McBryde ES, McCaw JM, McKinley TJ, Miller JC, Morris M, O'Neill PD, Parag KV, Pearson CAB, Pellis L, Pulliam JRC, Ross JV, Tomba GS, Silverman BW, Struchiner CJ, Tildesley MJ, Trapman P, Webb CR, Mollison D, Restif O. Key questions for modelling COVID-19 exit strategies. Proc Biol Sci 2020;287:20201405. [PMID: 32781946 DOI: 10.1098/rspb.2020.1405] [Cited by in Crossref: 50] [Cited by in F6Publishing: 31] [Article Influence: 25.0] [Reference Citation Analysis]
13 Olivé-Cirera G, Fonseca E, Cantarín-Extremera V, Vázquez-López M, Jiménez-Legido M, González-Álvarez V, Ribeiro-Constante J, Camacho-Salas A, Martí I, Cancho-Candela R, Martínez-González MJ, Saiz A, Armangué T; Spanish Study Group NeuroimmunoPed-Covid. Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders. Neurol Neuroimmunol Neuroinflamm 2022;9:e1101. [PMID: 34759018 DOI: 10.1212/NXI.0000000000001101] [Reference Citation Analysis]
14 McCulloch DJ, Jackson ML, Hughes JP, Lester S, Mills L, Freeman B, Rasheed MAU, Thornburg NJ, Chu HY. Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020. PLoS One 2021;16:e0252235. [PMID: 34043706 DOI: 10.1371/journal.pone.0252235] [Reference Citation Analysis]
15 Haider N, Yavlinsky A, Chang YM, Hasan MN, Benfield C, Osman AY, Uddin MJ, Dar O, Ntoumi F, Zumla A, Kock R. The Global Health Security index and Joint External Evaluation score for health preparedness are not correlated with countries' COVID-19 detection response time and mortality outcome. Epidemiol Infect 2020;148:e210. [PMID: 32892793 DOI: 10.1017/S0950268820002046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
16 Pollán M, Pérez-Gómez B, Pastor-Barriuso R, Oteo J, Pérez-Olmeda M, Yotti R; ENE-COVID Study Group. SARS-CoV-2 seroprevalence in Spain - Authors' reply. Lancet 2020;396:1484-5. [PMID: 33160561 DOI: 10.1016/S0140-6736(20)32266-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 1] [Article Influence: 11.5] [Reference Citation Analysis]
17 Bravata DM, Myers LJ, Perkins AJ, Keyhani S, Zhang Y, Zillich AJ, Dysangco A, Lindsey R, Sharmitha D, Myers J, Austin C, Sexson A, Arling G. Heterogeneity in COVID-19 patient volume, characteristics and outcomes across US Department of Veterans Affairs facilities: an observational cohort study. BMJ Open 2021;11:e044646. [PMID: 34006034 DOI: 10.1136/bmjopen-2020-044646] [Reference Citation Analysis]
18 Lancet COVID-19 Commissioners, Task Force Chairs, and Commission Secretariat. Lancet COVID-19 Commission Statement on the occasion of the 75th session of the UN General Assembly. Lancet. 2020;396:1102-1124. [PMID: 32941825 DOI: 10.1016/s0140-6736(20)31927-9] [Cited by in Crossref: 48] [Cited by in F6Publishing: 22] [Article Influence: 24.0] [Reference Citation Analysis]
19 Mercado-reyes MM, Daza M, Pacheco A, Meneses-gil MX, Galindo M, Catama J, Botero LS, Muñoz L, Quinche G, Ospina ML. Seroprevalence of SARS-CoV-2 Antibodies in Children and Adolescents: Results From a Population-Based Survey in 10 Colombian Cities. Global Pediatric Health 2022;9:2333794X2210853. [DOI: 10.1177/2333794x221085385] [Reference Citation Analysis]
20 Huamaní C, Velásquez L, Montes S, Mayanga-Herrera A, Bernabé-Ortiz A. SARS-CoV-2 seroprevalence in a high-altitude setting in Peru: adult population-based cross-sectional study. PeerJ 2021;9:e12149. [PMID: 34616616 DOI: 10.7717/peerj.12149] [Reference Citation Analysis]
21 Sánchez-Romero M, di Lego V, Prskawetz A, L Queiroz B. An indirect method to monitor the fraction of people ever infected with COVID-19: An application to the United States. PLoS One 2021;16:e0245845. [PMID: 33508030 DOI: 10.1371/journal.pone.0245845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
22 Kriemler S, Ulyte A, Ammann P, Peralta GP, Berger C, Puhan MA, Radtke T. Surveillance of Acute SARS-CoV-2 Infections in School Children and Point-Prevalence During a Time of High Community Transmission in Switzerland. Front Pediatr 2021;9:645577. [PMID: 33796490 DOI: 10.3389/fped.2021.645577] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
23 Dupraz J, Butty A, Duperrex O, Estoppey S, Faivre V, Thabard J, Zuppinger C, Greub G, Pantaleo G, Pasquier J, Rousson V, Egger M, Steiner-Dubuis A, Vassaux S, Masserey E, Bochud M, Gonseth Nusslé S, D'Acremont V. Prevalence of SARS-CoV-2 in Household Members and Other Close Contacts of COVID-19 Cases: A Serologic Study in Canton of Vaud, Switzerland. Open Forum Infect Dis 2021;8:ofab149. [PMID: 34307723 DOI: 10.1093/ofid/ofab149] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Ioannidis JPA. Precision shielding for COVID-19: metrics of assessment and feasibility of deployment. BMJ Glob Health 2021;6:e004614. [PMID: 33514595 DOI: 10.1136/bmjgh-2020-004614] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
25 Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martín A, Martín-Sánchez FJ, García-Lamberetchs EJ, Jacob J, Alquézar-Arbé A, Mòdol JM, López-Díez MP, Guardiola JM, Cardozo C, Lucas Imbernón FJ, Aguirre Tejedo A, García García Á, Ruiz Grinspan M, Llopis Roca F, González Del Castillo J; Spanish Investigators on Emergency Situations Team (SIESTA) Network. Frequency, Risk Factors, Clinical Characteristics, and Outcomes of Spontaneous Pneumothorax in Patients With Coronavirus Disease 2019: A Case-Control, Emergency Medicine-Based Multicenter Study. Chest 2021;159:1241-55. [PMID: 33227276 DOI: 10.1016/j.chest.2020.11.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
26 Napolitano F, Di Giuseppe G, Montemurro MV, Molinari AM, Donnarumma G, Arnese A, Pavia M, Angelillo IF. Seroprevalence of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy. Int J Environ Res Public Health 2021;18:4761. [PMID: 33947008 DOI: 10.3390/ijerph18094761] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
27 García-Suárez J, de la Cruz J, Cedillo Á, Llamas P, Duarte R, Jiménez-Yuste V, Hernández-Rivas JÁ, Gil-Manso R, Kwon M, Sánchez-Godoy P, Martínez-Barranco P, Colás-Lahuerta B, Herrera P, Benito-Parra L, Alegre A, Velasco A, Matilla A, Aláez-Usón MC, Martos-Martínez R, Martínez-Chamorro C, Susana-Quiroz K, Del Campo JF, de la Fuente A, Herráez R, Pascual A, Gómez E, Pérez-Oteyza J, Ruiz E, Alonso A, González-Medina J, Martín-Buitrago LN, Canales M, González-Gascón I, Vicente-Ayuso MC, Valenciano S, Roa MG, Monteliu PE, López-Jiménez J, Escobar CE, Ortiz-Martín J, Diez-Martin JL, Martinez-Lopez J; Asociación Madrileña de Hematología y Hemoterapia (AMHH). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol 2020;13:133. [PMID: 33032660 DOI: 10.1186/s13045-020-00970-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 37] [Article Influence: 16.5] [Reference Citation Analysis]
28 Kuwelker K, Zhou F, Blomberg B, Lartey S, Brokstad KA, Trieu MC, Bansal A, Madsen A, Krammer F, Mohn KG, Tøndel C, Linchausen DW, Cox RJ, Langeland N; Bergen COVID-19 research group. Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. Lancet Reg Health Eur 2021;3:100014. [PMID: 33871470 DOI: 10.1016/j.lanepe.2020.100014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
29 Espenhain L, Tribler S, Sværke Jørgensen C, Holm Hansen C, Wolff Sönksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. Eur J Epidemiol 2021;36:715-25. [PMID: 34420152 DOI: 10.1007/s10654-021-00796-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Vanroye F, Bossche DVD, Brosius I, Tack B, Esbroeck MV, Jacobs J. COVID-19 Antibody Detecting Rapid Diagnostic Tests Show High Cross-Reactivity When Challenged with Pre-Pandemic Malaria, Schistosomiasis and Dengue Samples. Diagnostics (Basel) 2021;11:1163. [PMID: 34202195 DOI: 10.3390/diagnostics11071163] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Conrad KP. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology? Physiol Rep 2021;8:e14649. [PMID: 33369281 DOI: 10.14814/phy2.14649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Gonik CO, Alonso AM, Gonik B. SARS-CoV-2 Seroprevalence in Florida Department of Health in Palm Beach County Obstetric Clinics: A Cross-Sectional Study during the First Pandemic Surge. Am J Perinatol 2021. [PMID: 34758496 DOI: 10.1055/s-0041-1739353] [Reference Citation Analysis]
33 Li Z, Guan X, Mao N, Luo H, Qin Y, He N, Zhu Z, Yu J, Li Y, Liu J, An Z, Gao W, Wang X, Sun X, Song T, Yang X, Wu M, Wu X, Yao W, Peng Z, Sun J, Wang L, Guo Q, Xiang N, Liu J, Zhang B, Su X, Rodewald L, Li L, Xu W, Shen H, Feng Z, Gao GF. Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. Lancet Reg Health West Pac 2021;8:100094. [PMID: 33585828 DOI: 10.1016/j.lanwpc.2021.100094] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
34 Párraga Martínez I, Pérula de Torres LA, González Lama J, Jiménez García C, Sánchez Montero R, Rider Garrido F; en representación del Grupo EPICOVID. [Clinical and epidemiological characteristics of SARS-CoV-2 infections in family physicians: A case-control study]. Aten Primaria 2021;53:101956. [PMID: 33592533 DOI: 10.1016/j.aprim.2020.12.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Picon RV, Carreno I, da Silva AA, Mossmann M, Laste G, Domingues GC, Heringer LFF, Gheno BR, Alvarenga LL, Conte M. Coronavirus disease 2019 population-based prevalence, risk factors, hospitalization, and fatality rates in southern Brazil. Int J Infect Dis 2020;100:402-10. [PMID: 32949778 DOI: 10.1016/j.ijid.2020.09.028] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Berenguer J, Díez C, Martín-Vicente M, Micán R, Pérez-Elías MJ, García-Fraile LJ, Vidal F, Suárez-García I, Podzamczer D, Del Romero J, Pulido F, Iribarren JA, Gutiérrez F, Poveda E, Galera C, Izquierdo R, Asensi V, Portilla J, López JC, Arribas JR, Moreno S, González-García J, Resino S, Jarrín I. Prevalence and factors associated with SARS-CoV-2 seropositivity in the Spanish HIV Research Network Cohort. Clin Microbiol Infect 2021:S1198-743X(21)00343-8. [PMID: 34186209 DOI: 10.1016/j.cmi.2021.06.023] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Jain V, Gupta MK, Grover M, Nare T, Srivastava S, Bhardwaj P, Goel AD, Saurabh S, Dara S, Kumar A, Sharma P, Nag VL, Misra S. COVID-19 seropositivity among non-medical frontline office staff from two cities in Rajasthan, India. J Family Med Prim Care 2021;10:2400-4. [PMID: 34322445 DOI: 10.4103/jfmpc.jfmpc_2381_20] [Reference Citation Analysis]
38 Omata M, Hirotsu Y, Sugiura H, Maejima M, Nagakubo Y, Amemiya K, Hayakawa M, Tsutsui T, Kakizaki Y, Mochizuki H, Miyashita Y. The dynamic change of antibody index against Covid-19 is a powerful diagnostic tool for the early phase of the infection and salvage PCR assay errors. J Microbiol Immunol Infect 2021:S1684-1182(21)00008-6. [PMID: 33593710 DOI: 10.1016/j.jmii.2020.12.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
39 Stricker RB, Fesler MC. Flattening the Risk: Pre-Exposure Prophylaxis for COVID-19. Infect Drug Resist 2020;13:3689-94. [PMID: 33116688 DOI: 10.2147/IDR.S264831] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
40 Moshe M, Daunt A, Flower B, Simmons B, Brown JC, Frise R, Penn R, Kugathasan R, Petersen C, Stockmann H, Ashby D, Riley S, Atchison C, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Marchesin F, Fernandez N, Sureda-Vives M, Cheeseman H, O'Hara J, Shattock R, Fontana G, Pallett SJC, Rayment M, Jones R, Moore LSP, Ashrafian H, Cherapanov P, Tedder R, McClure M, Ward H, Darzi A, Elliott P, Cooke GS, Barclay WS; React study team. SARS-CoV-2 lateral flow assays for possible use in national covid-19 seroprevalence surveys (React 2): diagnostic accuracy study. BMJ 2021;372:n423. [PMID: 33653694 DOI: 10.1136/bmj.n423] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 14.0] [Reference Citation Analysis]
41 Linares C, Belda F, López-Bueno JA, Luna MY, Sánchez-Martínez G, Hervella B, Culqui D, Díaz J. Short-term associations of air pollution and meteorological variables on the incidence and severity of COVID-19 in Madrid (Spain): a time series study. Environ Sci Eur 2021;33:107. [PMID: 34513550 DOI: 10.1186/s12302-021-00548-1] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Hendy S, Steyn N, James A, Plank MJ, Hannah K, Binny RN, Lustig A. Mathematical modelling to inform New Zealand’s COVID-19 response. Journal of the Royal Society of New Zealand 2021;51:S86-S106. [DOI: 10.1080/03036758.2021.1876111] [Cited by in Crossref: 5] [Article Influence: 5.0] [Reference Citation Analysis]
43 Maier HE, Kuan G, Saborio S, Bustos Carrillo FA, Plazaola M, Barilla C, Sanchez N, Lopez R, Smith M, Kubale J, Ojeda S, Zuniga-Moya JC, Carlson B, Lopez B, Gajewski AM, Chowdhury M, Harris E, Balmaseda A, Gordon A. Clinical spectrum of SARS-CoV-2 infection and protection from symptomatic re-infection. Clin Infect Dis 2021:ciab717. [PMID: 34411230 DOI: 10.1093/cid/ciab717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
44 Andrey DO, Yerly S, Meyer B, Arm-Vernez I, Roux-Lombard P, Togni G, Guessous I, Spechbach H, Stringhini S, Agoritsas T, Stirnemann J, Reny JL, Siegrist CA, Eckerle I, Kaiser L, Vuilleumier N. Head-to-Head Evaluation of Five Automated SARS-CoV-2 Serology Immunoassays in Various Prevalence Settings. J Clin Med 2021;10:1605. [PMID: 33920076 DOI: 10.3390/jcm10081605] [Reference Citation Analysis]
45 Kathe NJ, Wani RJ. Determinants of COVID-19 Case Fatality Rate in the United States: Spatial Analysis Over One Year of the Pandemic. J Health Econ Outcomes Res 2021;8:51-62. [PMID: 34017883 DOI: 10.36469/jheor.2021.22978] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Thamm R, Buttmann-Schweiger N, Fiebig J, Poethko-Müller C, Prütz F, Sarganas G, Neuhauser H. [Seroprevalence of SARS-CoV-2 among children and adolescents in Germany-an overview]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2021. [PMID: 34731291 DOI: 10.1007/s00103-021-03448-0] [Reference Citation Analysis]
47 Piñar Morales R, Ramírez Rivas MA, Barrero Hernández FJ. SARS-CoV-2 infection and seroprevalence in patients with multiple sclerosis. Neurologia (Engl Ed) 2021:S2173-5808(21)00079-1. [PMID: 34103271 DOI: 10.1016/j.nrleng.2021.03.002] [Reference Citation Analysis]
48 Kline D, Li Z, Chu Y, Wakefield J, Miller WC, Norris Turner A, Clark SJ. Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests. Proc Natl Acad Sci U S A 2021;118:e2023947118. [PMID: 34172581 DOI: 10.1073/pnas.2023947118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
49 Stone M, Grebe E, Sulaeman H, Di Germanio C, Dave H, Kelly K, Biggerstaff BJ, Crews BO, Tran N, Jerome KR, Denny TN, Hogema B, Destree M, Jones JM, Thornburg N, Simmons G, Krajden M, Kleinman S, Dumont LJ, Busch MP. Evaluation of Commercially Available High-Throughput SARS-CoV-2 Serologic Assays for Serosurveillance and Related Applications. Emerg Infect Dis 2022;28. [DOI: 10.3201/eid2803.211885] [Reference Citation Analysis]
50 Kaddu-Mulindwa D, Keuser L, Lesan V, Rissland J, Smola S, Werdecker V, Stilgenbauer S, Christofyllakis K, Thurner L, Bewarder M, Lohr B, Lutz J, Lohse S, Rieke A. IgG seroprevalence of COVID-19 among people living with HIV or at high risk of HIV in south-west Germany: A seroprevalence study. HIV Med 2021. [PMID: 34811869 DOI: 10.1111/hiv.13207] [Reference Citation Analysis]
51 El Ouardighi F, Khmelnitsky E, Sethi SP. Epidemic control with endogenous treatment capability under popular discontent and social fatigue. Production & Oper Manag. [DOI: 10.1111/poms.13641] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Solà-Muñoz S, Yuguero O, Azeli Y, Roig G, Prieto-Arruñada JA, Español J, Morales-Álvarez J, Muñoz M, Verge JJ, Jiménez-Fàbrega X. Impact on polytrauma patient prehospital care during the first wave of the COVID-19 pandemic: a cross-sectional study. Eur J Trauma Emerg Surg 2021. [PMID: 34331073 DOI: 10.1007/s00068-021-01748-3] [Reference Citation Analysis]
53 [DOI: 10.1101/2020.07.31.20166249] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
54 El Vally A, Bollahi MA, Ould Ahmedou Salem MS, Deida J, Parola P, Basco L, El Bara A, Ouldabdallahi M, Ould Mohamed Salem Boukhary A. Retrospective overview of a COVID-19 outbreak in Mauritania. New Microbes New Infect 2020;38:100788. [PMID: 33082959 DOI: 10.1016/j.nmni.2020.100788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Adorni F, Jesuthasan N, Perdixi E, Sojic A, Giacomelli A, Noale M, Trevisan C, Franchini M, Pieroni S, Cori L, Mastroianni CM, Bianchi F, Antonelli-incalzi R, Maggi S, Galli M, Prinelli F; on behalf of the EPICOVID19 Working Group. Epidemiology of SARS-CoV-2 Infection in Italy Using Real-World Data: Methodology and Cohort Description of the Second Phase of Web-Based EPICOVID19 Study. IJERPH 2022;19:1274. [DOI: 10.3390/ijerph19031274] [Reference Citation Analysis]
56 Valero C, Barba R, Marcos DP, Puente N, Riancho JA, Santurtún A. Influence of weather factors on the incidence of COVID-19 in Spain. Med Clin (Barc) 2021:S0025-7753(21)00649-7. [PMID: 34887065 DOI: 10.1016/j.medcli.2021.10.010] [Reference Citation Analysis]
57 Lyngse FP, Kirkeby C, Halasa T, Andreasen V, Skov RL, Møller FT, Krause TG, Mølbak K. Nationwide study on SARS-CoV-2 transmission within households from lockdown to reopening, Denmark, 27 February 2020 to 1 August 2020. Euro Surveill 2022;27. [PMID: 35144726 DOI: 10.2807/1560-7917.ES.2022.27.6.2001800] [Reference Citation Analysis]
58 Zhang Y, Yang Z, Tian S, Li B, Feng T, He J, Jiang M, Tang X, Mei S, Li H, Zhong Y, Li G, Tang M, Liu S, Tang T, Wang C, Wang X. A newly identified linear epitope on non-RBD region of SARS-CoV-2 spike protein improves the serological detection rate of COVID-19 patients. BMC Microbiol 2021;21:194. [PMID: 34174835 DOI: 10.1186/s12866-021-02241-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 James J, Rhodes S, Ross CS, Skinner P, Smith SP, Shipley R, Warren CJ, Goharriz H, McElhinney LM, Temperton N, Wright E, Fooks AR, Clark TW, Brookes SM, Brown IH, Banyard AC. Comparison of Serological Assays for the Detection of SARS-CoV-2 Antibodies. Viruses 2021;13:713. [PMID: 33924168 DOI: 10.3390/v13040713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
60 Yates JL, Ehrbar DJ, Hunt DT, Girardin RC, Dupuis AP 2nd, Payne AF, Sowizral M, Varney S, Kulas KE, Demarest VL, Howard KM, Carson K, Hales M, Ejemel M, Li Q, Wang Y, Peredo-Wende R, Ramani A, Singh G, Strle K, Mantis NJ, McDonough KA, Lee WT. Serological analysis reveals an imbalanced IgG subclass composition associated with COVID-19 disease severity. Cell Rep Med 2021;2:100329. [PMID: 34151306 DOI: 10.1016/j.xcrm.2021.100329] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
61 Villalobos C. SARS-CoV-2 Infections in the World: An Estimation of the Infected Population and a Measure of How Higher Detection Rates Save Lives. Front Public Health 2020;8:489. [PMID: 33102412 DOI: 10.3389/fpubh.2020.00489] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
62 Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. Epidemiology of SARS-CoV-2. Infection 2021;49:233-9. [PMID: 33034020 DOI: 10.1007/s15010-020-01531-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 15.5] [Reference Citation Analysis]
63 Chen S, Ren LZ, Ouyang HS, Liu S, Zhang LY. Necessary problems in re-emergence of COVID-19. World J Clin Cases 2021; 9(1): 1-7 [PMID: 33511167 DOI: 10.12998/wjcc.v9.i1.1] [Reference Citation Analysis]
64 Patterson EI, Elia G, Grassi A, Giordano A, Desario C, Medardo M, Smith SL, Anderson ER, Prince T, Patterson GT, Lorusso E, Lucente MS, Lanave G, Lauzi S, Bonfanti U, Stranieri A, Martella V, Solari Basano F, Barrs VR, Radford AD, Agrimi U, Hughes GL, Paltrinieri S, Decaro N. Evidence of exposure to SARS-CoV-2 in cats and dogs from households in Italy. Nat Commun 2020;11:6231. [PMID: 33277505 DOI: 10.1038/s41467-020-20097-0] [Cited by in Crossref: 76] [Cited by in F6Publishing: 82] [Article Influence: 38.0] [Reference Citation Analysis]
65 Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, Weseslindtner L, Stiasny K, Puchhammer-Stöckl E, Schrott A, Födinger M, Binder M, Fiedler M, Wouters EFM, Burghuber OC. Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown. Sci Rep 2021;11:10158. [PMID: 33980950 DOI: 10.1038/s41598-021-89711-5] [Reference Citation Analysis]
66 Mei Q, Wang F, Yang Y, Hu G, Guo S, Zhang Q, Bryant A, Zhang L, Kurts C, Wei L, Yuan X, Li J. Health Issues and Immunological Assessment Related to Wuhan's COVID-19 Survivors: A Multicenter Follow-Up Study. Front Med (Lausanne) 2021;8:617689. [PMID: 34026775 DOI: 10.3389/fmed.2021.617689] [Reference Citation Analysis]
67 Vilar JMG, Saiz L. Reliably quantifying the evolving worldwide dynamic state of the COVID-19 outbreak from death records, clinical parametrization, and demographic data. Sci Rep 2021;11:19952. [PMID: 34620935 DOI: 10.1038/s41598-021-99273-1] [Reference Citation Analysis]
68 Galipeau Y, Greig M, Liu G, Driedger M, Langlois MA. Humoral Responses and Serological Assays in SARS-CoV-2 Infections. Front Immunol 2020;11:610688. [PMID: 33391281 DOI: 10.3389/fimmu.2020.610688] [Cited by in Crossref: 43] [Cited by in F6Publishing: 32] [Article Influence: 21.5] [Reference Citation Analysis]
69 Tseng WP, Wu JL, Wu CC, Kuo KT, Lin CH, Chung MY, Lee YF, Yang BJ, Huang CH, Chen SY, Yu CJ, Chen SC, Hsueh PR. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003. Front Immunol 2021;12:626609. [PMID: 34084161 DOI: 10.3389/fimmu.2021.626609] [Reference Citation Analysis]
70 Wang R, Jin F, Cao S, Yuan H, Qu J, Zhang J, Li Y, Chen X, Song W, Xie Z. Seroprevalence of SARS-CoV-2 infections among children visiting a hospital. Pediatr Investig 2020;4:236-41. [PMID: 33376950 DOI: 10.1002/ped4.12231] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 de Miguel Negro M, González Tallada A, de Nadal M, Biarnes Suñé A, Manrique Muñoz S, Campins Martí M, Álvarez Pérez A, Castellnou Ferré J, Pedregosa Sanz A, Rouras Hurtado G, Martínez Cabañero J, Osorio Salazar E, Montero Matamala A, Saludes J, Binagui Buitureira AV, Farré Tebar C, Baumgartner Lucero ML, Cadena Serramitja M, Lacambra Basil M, Faura A, Ibáñez Trujillo NF, Delgado García R, Santiveri Papiol FJ, Escolano Villén F, Tejedor Navarro A, Deiros García C, Remartínez Fernández F, Tobito Ramírez J, Moret Ferrón ML, Salmerón Zafra Ó, Isern Domingo X, Villalba Blanco N. Pre-operative prevalence of asymptomatic carriers of COVID-19 in hospitals in Catalonia during the first wave after the resumption of surgical activity. Cir Esp (Engl Ed) 2021:S0009-739X(21)00036-1. [PMID: 33610261 DOI: 10.1016/j.ciresp.2021.01.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Marin-Gomez FX, Fàbregas-Escurriola M, Seguí FL, Pérez EH, Camps MB, Peña JM, Comellas AR, Vidal-Alaball J. Assessing the likelihood of contracting COVID-19 disease based on a predictive tree model: A retrospective cohort study. PLoS One 2021;16:e0247995. [PMID: 33657164 DOI: 10.1371/journal.pone.0247995] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Tharayil A, Rajakumari R, Mozetic M, Primc G, Thomas S. Contact transmission of SARS-CoV-2 on fomite surfaces: surface survival and risk reduction. Interface Focus 2022;12:20210042. [PMID: 34956610 DOI: 10.1098/rsfs.2021.0042] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
74 Singh S, McNab C, Olson RM, Bristol N, Nolan C, Bergstrøm E, Bartos M, Mabuchi S, Panjabi R, Karan A, Abdalla SM, Bonk M, Jamieson M, Werner GK, Nordström A, Legido-Quigley H, Phelan A. How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic. Lancet 2021;398:2109-24. [PMID: 34762857 DOI: 10.1016/S0140-6736(21)01897-3] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
75 Sharma N, Sharma P, Basu S, Bakshi R, Gupta E, Agarwal R, Dushyant K, Mundeja N, Marak Z, Singh S, Singh G, Rustagi R. Second Wave of the COVID-19 Pandemic in Delhi, India: High Seroprevalence Not a Deterrent? Cureus 2021;13:e19000. [PMID: 34853742 DOI: 10.7759/cureus.19000] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Kyrychko YN, Blyuss KB, Brovchenko I. Mathematical modelling of the dynamics and containment of COVID-19 in Ukraine. Sci Rep 2020;10:19662. [PMID: 33184338 DOI: 10.1038/s41598-020-76710-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 10.5] [Reference Citation Analysis]
77 Hoffmann C, Wolf E. SARS-CoV-2 seroprevalence in Spain. Lancet 2020;396:1484. [PMID: 33160562 DOI: 10.1016/S0140-6736(20)32272-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
78 Hasan T, Lim HL, Case J, Hueston L, Bag S, Dwyer DE, O'Sullivan MVN. The utility of SARS-CoV-2-specific serology in COVID-19 diagnosis. Aust N Z J Public Health 2021. [PMID: 34761846 DOI: 10.1111/1753-6405.13155] [Reference Citation Analysis]
79 Vilibic-Cavlek T, Stevanovic V, Ilic M, Barbic L, Capak K, Tabain I, Krleza JL, Ferenc T, Hruskar Z, Topic RZ, Kaliterna V, Antolovic-Pozgain A, Kucinar J, Koscak I, Mayer D, Sviben M, Antolasic L, Milasincic L, Bucic L, Ferencak I, Kaic B. SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia. Pathogens 2021;10:774. [PMID: 34203060 DOI: 10.3390/pathogens10060774] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
80 Føns S, Krogfelt KA. How can we interpret SARS-CoV-2 antibody test results? Pathog Dis 2021;79:ftaa069. [PMID: 33512464 DOI: 10.1093/femspd/ftaa069] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
81 Kumar D, Burma A, Kumar Mandal A. A seroprevalence study of Covid 19 antibody after 1st wave of the pandemic in South Andaman district, India. Clin Epidemiol Glob Health 2021;12:100901. [PMID: 34805619 DOI: 10.1016/j.cegh.2021.100901] [Reference Citation Analysis]
82 Canto E Castro L, Pereira AHG, Ribeiro R, Alves C, Veloso L, Vicente V, Alves D, Domingues I, Silva C, Gomes A, Serrano M, Afonso Â, Veldhoen M, de Sousa MJR, de Sousa JGR, de Sousa G, Mota MM, Silva-Santos B, Ribeiro RM. Prevalence of SARS-CoV-2 Antibodies after First 6 Months of COVID-19 Pandemic, Portugal. Emerg Infect Dis 2021;27:2878-81. [PMID: 34437830 DOI: 10.3201/eid2711.210636] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Eckerle I, Meyer B. SARS-CoV-2 seroprevalence in COVID-19 hotspots. Lancet. 2020;396:514-515. [PMID: 32645348 DOI: 10.1016/s0140-6736(20)31482-3] [Cited by in Crossref: 66] [Cited by in F6Publishing: 37] [Article Influence: 33.0] [Reference Citation Analysis]
84 Merckx J, Labrecque JA, Kaufman JS. Transmission of SARS-CoV-2 by Children. Dtsch Arztebl Int 2020;117:553-60. [PMID: 32705983 DOI: 10.3238/arztebl.2020.0553] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
85 Engelbrecht FA, Scholes RJ. Test for Covid-19 seasonality and the risk of second waves. One Health 2021;12:100202. [PMID: 33283035 DOI: 10.1016/j.onehlt.2020.100202] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
86 Chvatal-Medina M, Mendez-Cortina Y, Patiño PJ, Velilla PA, Rugeles MT. Antibody Responses in COVID-19: A Review. Front Immunol 2021;12:633184. [PMID: 33936045 DOI: 10.3389/fimmu.2021.633184] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
87 Llupià A, Borràs-Santos A, Guinovart C, Utzet M, Moriña D, Puig J. SARS-CoV-2 transmission in students of public schools of Catalonia (Spain) after a month of reopening. PLoS One 2021;16:e0251593. [PMID: 33979410 DOI: 10.1371/journal.pone.0251593] [Reference Citation Analysis]
88 Velicu MA, Furlanetti L, Jung J, Ashkan K. Epidemiological trends in COVID-19 pandemic: prospective critical appraisal of observations from six countries in Europe and the USA. BMJ Open 2021;11:e045782. [PMID: 34010140 DOI: 10.1136/bmjopen-2020-045782] [Reference Citation Analysis]
89 Ventura PC, Aleta A, Aparecido Rodrigues F, Moreno Y. Modeling the effects of social distancing on the large-scale spreading of diseases. Epidemics 2022. [DOI: 10.1016/j.epidem.2022.100544] [Reference Citation Analysis]
90 Trentini F, Guzzetta G, Galli M, Zardini A, Manenti F, Putoto G, Marziano V, Gamshie WN, Tsegaye A, Greblo A, Melegaro A, Ajelli M, Merler S, Poletti P. Modeling the interplay between demography, social contact patterns, and SARS-CoV-2 transmission in the South West Shewa Zone of Oromia Region, Ethiopia. BMC Med 2021;19:89. [PMID: 33832497 DOI: 10.1186/s12916-021-01967-w] [Reference Citation Analysis]
91 Maraqa B, Basha W, Khayyat R, Abdul-Hadi AR, Jabareen J, Al-Shakhra K, Al-Kaila M, Nazzal Z. Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study. PLoS One 2021;16:e0258255. [PMID: 34624024 DOI: 10.1371/journal.pone.0258255] [Reference Citation Analysis]
92 Eyre DW, Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Cornall RJ, Stuart DI, Screaton G, Ebner D, Crook DW, Conlon CP, Jeffery K, Walker TM, Peto TEA. Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections. BMC Infect Dis 2021;21:187. [PMID: 33602152 DOI: 10.1186/s12879-021-05878-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
93 Gonzalez-parra G. Analysis of Delayed Vaccination Regimens: A Mathematical Modeling Approach. Epidemiologia 2021;2:271-93. [DOI: 10.3390/epidemiologia2030021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Carrat F, de Lamballerie X, Rahib D, Blanché H, Lapidus N, Artaud F, Kab S, Renuy A, de Edelenyi FS, Meyer L, Lydié N, Charles MA, Ancel PY, Jusot F, Rouquette A, Priet S, Villarroel PMS, Fourié T, Lusivika-Nzinga C, Nicol J, Legot S, Druesne-Pecollo N, Esseddik Y, Lai C, Gagliolo JM, Deleuze JF, Bajos N, Severi G, Touvier M, Zins M; SAPRIS and SAPRIS-SERO study groups. Antibody status and cumulative incidence of SARS-CoV-2 infection among adults in three regions of France following the first lockdown and associated risk factors: a multicohort study. Int J Epidemiol 2021:dyab110. [PMID: 34293141 DOI: 10.1093/ije/dyab110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
95 Willeit P, Krause R, Lamprecht B, Berghold A, Hanson B, Stelzl E, Stoiber H, Zuber J, Heinen R, Köhler A, Bernhard D, Borena W, Doppler C, von Laer D, Schmidt H, Pröll J, Steinmetz I, Wagner M. Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study. Lancet Reg Health Eur 2021;5:100086. [PMID: 34396360 DOI: 10.1016/j.lanepe.2021.100086] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
96 Andina-Martinez D, Nieto-Moro M, Alonso-Cadenas JA, Añon-Hidalgo J, Hernandez-Martin A, Perez-Suarez E, Colmenero-Blanco I, Iglesias-Bouza MI, Cano-Fernandez J, Mateos-Mayo A, Torrelo A. Mucocutaneous manifestations in children hospitalized with COVID-19. J Am Acad Dermatol 2021;85:88-94. [PMID: 33819537 DOI: 10.1016/j.jaad.2021.03.083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
97 Pagani G, Giacomelli A, Conti F, Bernacchia D, Rondanin R, Prina A, Scolari V, Rizzo A, Beltrami M, Caimi C, Gandolfi CE, Castaldi S, Rivieccio BA, Buonanno G, Marano G, Ottomano C, Boracchi P, Biganzoli E, Galli M. Prevalence of SARS-CoV-2 in an area of unrestricted viral circulation: Mass seroepidemiological screening in Castiglione d'Adda, Italy. PLoS One 2021;16:e0246513. [PMID: 33626045 DOI: 10.1371/journal.pone.0246513] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
98 Ganslmeier A, Engelmann T, Lucke M, Täger G, Pfeifer M, Scherer MA. [Attitude of health care workers towards SARS-CoV-2 vaccination]. MMW Fortschr Med 2021;163:12-6. [PMID: 34383282 DOI: 10.1007/s15006-021-0139-6] [Reference Citation Analysis]
99 Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Ochola-oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng’ang’a W, Tsofa B, Bejon P, Barasa E, Keeling MJ, Nokes DJ. Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data. Wellcome Open Res 2021;6:127. [DOI: 10.12688/wellcomeopenres.16748.2] [Reference Citation Analysis]
100 Khan SMS, Qurieshi MA, Haq I, Majid S, Bhat AA, Nabi S, Ganai NA, Zahoor N, Nisar A, Chowdri IN, Qazi TB, Kousar R, Lone AA, Sabah I, Nabi S, Sumji IA, Kawoosa MF, Ayoub S. Seroprevalence of SARS-CoV-2 specific IgG antibodies in District Srinagar, northern India - A cross-sectional study. PLoS One 2020;15:e0239303. [PMID: 33175878 DOI: 10.1371/journal.pone.0239303] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
101 Reno C, Lenzi J, Golinelli D, Gori D, Signorelli C, Kraemer J, Stoto MA, Avitabile E, Landini MP, Lazzarotto T, Re MC, Rucci P, Taliani G, Trerè D, Vocale C, Fantini MP. SARS-CoV-2/COVID-19 Testing: The Tower of Babel. Acta Biomed 2020;91:e2020144. [PMID: 33525202 DOI: 10.23750/abm.v91i4.10911] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
102 Acurio-Páez D, Vega B, Orellana D, Charry R, Gómez A, Obimpeh M, Verhoeven V, Colebunders R. Seroprevalence of SARS-CoV-2 Infection and Adherence to Preventive Measures in Cuenca, Ecuador, October 2020, a Cross-Sectional Study. Int J Environ Res Public Health 2021;18:4657. [PMID: 33925680 DOI: 10.3390/ijerph18094657] [Reference Citation Analysis]
103 Fuentes B, Alonso de Leciñana M, Rigual R, García-Madrona S, Díaz-Otero F, Aguirre C, Calleja P, Egido-Herrero JA, Carneado-Ruiz J, Ruiz-Ares G, Rodríguez-Pardo J, Rodríguez-López Á, Ximénez-Carrillo Á, de Felipe A, Ostos F, González-Ortega G, Simal P, Gómez Escalonilla CI, Gómez-Porro-Sánchez P, Cabal-Paz B, Reig G, Gil-Núñez A, Masjuán J, Díez Tejedor E. Fewer COVID-19-associated strokes and reduced severity during the second COVID-19 wave: The Madrid Stroke Network. Eur J Neurol 2021;28:4078-89. [PMID: 34528353 DOI: 10.1111/ene.15112] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
104 Alkurt G, Murt A, Aydin Z, Tatli O, Agaoglu NB, Irvem A, Aydin M, Karaali R, Gunes M, Yesilyurt B, Turkez H, Mardinoglu A, Doganay M, Basinoglu F, Seyahi N, Dinler Doganay G, Doganay HL. Seroprevalence of coronavirus disease 2019 (COVID-19) among health care workers from three pandemic hospitals of Turkey. PLoS One 2021;16:e0247865. [PMID: 33657142 DOI: 10.1371/journal.pone.0247865] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
105 Selvaraju S, Kumar MS, Thangaraj JWV, Bhatnagar T, Saravanakumar V, Kumar CPG, Sekar K, Ilayaperumal E, Sabarinathan R, Jagadeesan M, Hemalatha MS, Murhekar MV; Chennai COVID Sero-Surveillance Team. Population-Based Serosurvey for Severe Acute Respiratory Syndrome Coronavirus 2 Transmission, Chennai, India. Emerg Infect Dis 2021;27:586-9. [PMID: 33496222 DOI: 10.3201/eid2702.203938] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
106 López-Mendoza H, Montañés A, Moliner-Lahoz FJ. Disparities in the Evolution of the COVID-19 Pandemic between Spanish Provinces. Int J Environ Res Public Health 2021;18:5085. [PMID: 34064938 DOI: 10.3390/ijerph18105085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
107 Sughayer MA, Mansour A, Al Nuirat A, Souan L, Ghanem M, Siag M. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. Int J Infect Dis 2021;107:116-20. [PMID: 33892190 DOI: 10.1016/j.ijid.2021.04.059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
108 Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, Schmidt ML, Schmidt TH, de Vries FM, Drosten C, Breteler MMB. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun 2021;12:2117. [PMID: 33837204 DOI: 10.1038/s41467-021-22351-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
109 Boey L, Roelants M, Merckx J, Hens N, Desombere I, Duysburgh E, Vandermeulen C. Age-dependent seroprevalence of SARS-CoV-2 antibodies in school-aged children from areas with low and high community transmission. Eur J Pediatr 2021. [PMID: 34455523 DOI: 10.1007/s00431-021-04222-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Fernandez-Diaz E, Perez-Vicente JA, Villaverde-Gonzalez R, Berenguer-Ruiz L, Candeliere Merlicco A, Martinez-Navarro ML, Gracia Gil J, Romero-Sanchez CM, Alfaro-Saez A, Diaz I, Gimenez-Martinez J, Mendez-Miralles MA, Millan-Pascual J, Jimenez-Pancho J, Mola S, Sempere AP. Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population. Ann Clin Transl Neurol 2021;8:385-94. [PMID: 33369288 DOI: 10.1002/acn3.51282] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
111 Prakash O, Solanki B, Sheth JK, Joshi B, Kadam M, Vyas S, Shukla A, Tiwari H, Rathod S, Rajput A, Trivedi T, Ramanuj V, Solanki A. Assessing seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city of India: a cross-sectional study. BMJ Open 2021;11:e044101. [PMID: 33402413 DOI: 10.1136/bmjopen-2020-044101] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 12.0] [Reference Citation Analysis]
112 Zuñiga M, Lagomarcino AJ, Muñoz S, Alonso AP, Rodriguez MA, O'Ryan ML. A cross sectional study found differential risks for COVID-19 seropositivity amongst health care professionals in Chile. J Clin Epidemiol 2021:S0895-4356(21)00433-9. [PMID: 34965480 DOI: 10.1016/j.jclinepi.2021.12.026] [Reference Citation Analysis]
113 Gómez i Prat J, Essadek HO, Esperalba J, Serrat FZ, Guiu IC, Goterris L, Zules-oña R, Choque E, Pastoret C, Ponces NC, de los Santos JJ, Pons JS, Dehousse A, Albajar-viñas P, Pumarola T, Campins M, Sulleiro E. COVID-19: an opportunity of systematic integration for Chagas disease. Example of a community-based approach within the Bolivian population in Barcelona. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07305-6] [Reference Citation Analysis]
114 Traini MC, Caponi C, Ferrari R, De Socio GV. Modelling SARS-CoV-2 unreported cases in Italy: Analysis of serological survey and vaccination scenarios. Infect Dis Model 2021;6:909-23. [PMID: 34278058 DOI: 10.1016/j.idm.2021.06.002] [Reference Citation Analysis]
115 Savirón-Cornudella R, Villalba A, Zapardiel J, Andeyro-Garcia M, Esteban LM, Pérez-López FR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) universal screening in gravids during labor and delivery. Eur J Obstet Gynecol Reprod Biol 2021;256:400-4. [PMID: 33285496 DOI: 10.1016/j.ejogrb.2020.11.069] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
116 Nah EH, Cho S, Park H, Hwang I, Cho HI. Nationwide seroprevalence of antibodies to SARS-CoV-2 in asymptomatic population in South Korea: a cross-sectional study. BMJ Open 2021;11:e049837. [PMID: 33895722 DOI: 10.1136/bmjopen-2021-049837] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
117 Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis 2020;20:640. [PMID: 32867706 DOI: 10.1186/s12879-020-05371-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 16.5] [Reference Citation Analysis]
118 Samore MH, Looney A, Orleans B, Greene T, Seegert N, Delgado JC, Presson A, Zhang C, Ying J, Zhang Y, Shen J, Slev P, Gaulin M, Yang MJ, Pavia AT, Alder SC. Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA. Emerg Infect Dis 2021;27:2786-94. [PMID: 34469285 DOI: 10.3201/eid2711.204435] [Reference Citation Analysis]
119 Gujski M, Jankowski M, Pinkas J, Wierzba W, Samel-Kowalik P, Zaczyński A, Jędrusik P, Pańkowski I, Juszczyk G, Rakocy K, Raciborski F. Prevalence of Current and Past SARS-CoV-2 Infections among Police Employees in Poland, June-July 2020. J Clin Med 2020;9:E3245. [PMID: 33050603 DOI: 10.3390/jcm9103245] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
120 Cabezón-Gutiérrez L, Custodio-Cabello S, Palka-Kotlowska M, Oliveros-Acebes E, García-Navarro MJ, Khosravi-Shahi P. Seroprevalence of SARS-CoV-2-specific antibodies in cancer outpatients in Madrid (Spain): A single center, prospective, cohort study and a review of available data. Cancer Treat Rev 2020;90:102102. [PMID: 32947121 DOI: 10.1016/j.ctrv.2020.102102] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
121 Chisale MRO, Ramazanu S, Mwale SE, Kumwenda P, Chipeta M, Kaminga AC, Nkhata O, Nyambalo B, Chavura E, Mbakaya BC. Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis. Rev Med Virol 2021;:e2271. [PMID: 34228851 DOI: 10.1002/rmv.2271] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Ling RJ, Yu YH, He JY, Zhang JX, Xu S, Sun RR, Zhu WC, Chen MF, Li T, Ji HL, Wang HQ. Seroprevalence of IgM and IgG Antibodies against SARS-CoV-2 in Asymptomatic People in Wuhan: Data from a General Hospital Near South China Seafood Wholesale Market during March to April in 2020. Biomed Environ Sci 2021;34:743-9. [PMID: 34530966 DOI: 10.3967/bes2021.103] [Reference Citation Analysis]
123 Álvarez-Esteban PC, Del Barrio E, Rueda OM, Rueda C. Predicting COVID-19 progression from diagnosis to recovery or death linking primary care and hospital records in Castilla y León (Spain). PLoS One 2021;16:e0257613. [PMID: 34543345 DOI: 10.1371/journal.pone.0257613] [Reference Citation Analysis]
124 Zheng J, Deng Y, Zhao Z, Mao B, Lu M, Lin Y, Huang A. Characterization of SARS-CoV-2-specific humoral immunity and its potential applications and therapeutic prospects. Cell Mol Immunol 2021. [PMID: 34645940 DOI: 10.1038/s41423-021-00774-w] [Reference Citation Analysis]
125 Cárdaba-García RM, Pérez Pérez L, Niño Martín V, Cárdaba-García I, Durantez-Fernández C, Olea E. Evaluation of the Risk of Anxiety and/or Depression during Confinement Due to COVID-19 in Central Spain. Int J Environ Res Public Health 2021;18:5732. [PMID: 34071791 DOI: 10.3390/ijerph18115732] [Reference Citation Analysis]
126 Nelson SM, Ehnert S, Gromski PS, Child T, Trew G. SARS-Cov-2 viral and serological screening of staff in 31 European fertility units. Hum Reprod Open 2020;2020:hoaa056. [PMID: 34056138 DOI: 10.1093/hropen/hoaa056] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
127 Getz WM, Salter R, Luisa Vissat L, Horvitz N. A versatile web app for identifying the drivers of COVID-19 epidemics. J Transl Med 2021;19:109. [PMID: 33726787 DOI: 10.1186/s12967-021-02736-2] [Reference Citation Analysis]
128 Pinilla YT, Friessinger E, Griesbaum JM, Berner L, Heinzel C, Elsner K, Fendel R, Held J, Kreidenweiss A. Prevalence of SARS-CoV-2 Infection in Children by Antibody Detection in Saliva: Protocol for a Prospective Longitudinal Study (Coro-Buddy). JMIR Res Protoc 2021;10:e27739. [PMID: 34533472 DOI: 10.2196/27739] [Reference Citation Analysis]
129 He Z, Ren L, Yang J, Guo L, Feng L, Ma C, Wang X, Leng Z, Tong X, Zhou W, Wang G, Zhang T, Guo Y, Wu C, Wang Q, Liu M, Wang C, Jia M, Hu X, Wang Y, Zhang X, Hu R, Zhong J, Yang J, Dai J, Chen L, Zhou X, Wang J, Yang W, Wang C. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study. Lancet 2021;397:1075-84. [PMID: 33743869 DOI: 10.1016/S0140-6736(21)00238-5] [Cited by in Crossref: 101] [Cited by in F6Publishing: 54] [Article Influence: 101.0] [Reference Citation Analysis]
130 Philip AA, Patton JT. Rotavirus as an Expression Platform of Domains of the SARS-CoV-2 Spike Protein. Vaccines (Basel) 2021;9:449. [PMID: 34063562 DOI: 10.3390/vaccines9050449] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
131 Meyer B. Waning antibodies to SARS-CoV-2 - Don't panic. Lancet Reg Health Eur 2021;4:100115. [PMID: 33972935 DOI: 10.1016/j.lanepe.2021.100115] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Li H, Cheng C, Shi S, Wu Y, Gao Y, Liu Z, Liu M, Li Z, Huo L, Pan X, Liu S, Song G. Identification, optimization, and biological evaluation of 3-O-β-chacotriosyl ursolic acid derivatives as novel SARS-CoV-2 entry inhibitors by targeting the prefusion state of spike protein. Eur J Med Chem 2022;238:114426. [PMID: 35551037 DOI: 10.1016/j.ejmech.2022.114426] [Reference Citation Analysis]
133 Heavey L, Garvey P, Colgan AM, Thornton L, Connell J, Roux T, Hunt M, O'Callaghan F, Culkin F, Keogan M, O'Connor N, O'Sullivan MB, O'Sullivan S, Tait M, De Gascun CF, Igoe D. The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020. Euro Surveill 2021;26. [PMID: 34857067 DOI: 10.2807/1560-7917.ES.2021.26.48.2001741] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Ojal J, Brand SPC, Were V, Okiro EA, Kombe IK, Mburu C, Aziza R, Ogero M, Agweyu A, Warimwe GM, Uyoga S, Adetifa IMO, Scott JAG, Otieno E, Ochola-oyier LI, Agoti CN, Kasera K, Amoth P, Mwangangi M, Aman R, Ng’ang’a W, Tsofa B, Bejon P, Barasa E, Keeling MJ, Nokes DJ. Revealing the extent of the first wave of the COVID-19 pandemic in Kenya based on serological and PCR-test data. Wellcome Open Res 2021;6:127. [DOI: 10.12688/wellcomeopenres.16748.1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
135 Allen N, Brady M, Carrion Martin AI, Domegan L, Walsh C, Houlihan E, Kerr C, Doherty L, King J, Doheny M, Griffin D, Molloy M, Dunne J, Crowley V, Holmes P, Keogh E, Naughton S, Kelly M, O'Rourke F, Lynagh Y, Crowley B, de Gascun C, Holder P, Bergin C, Fleming C, Ni Riain U, Conlon N; PRECISE Study Steering Group. SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays. Microbiol Spectr 2021;9:e0039121. [PMID: 34585976 DOI: 10.1128/Spectrum.00391-21] [Reference Citation Analysis]
136 Idrovo ÁJ, Moreno-Montoya J, Pinzón-Flórez CE. Performance of rapid IgM-IgG combined antibody tests in the occupational surveillance of COVID-19 in Colombian enterprises. Biomedica 2020;40:139-47. [PMID: 33152197 DOI: 10.7705/biomedica.5829] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
137 Nomah DK, Reyes-Urueña J, Díaz Y, Moreno S, Aceiton J, Bruguera A, Vivanco-Hidalgo RM, Llibre JM, Domingo P, Falcó V, Imaz A, Cortés C, Force L, Letang E, Vilaró I, Casabona J, Miro JM; PISCIS study group. Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study. Lancet HIV 2021;8:e701-10. [PMID: 34655549 DOI: 10.1016/S2352-3018(21)00240-X] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Lastrucci V, Lorini C, Del Riccio M, Gori E, Chiesi F, Sartor G, Zanella B, Boccalini S, Bechini A, Puggelli F, Bonanni P, Bonaccorsi G. SARS-CoV-2 Seroprevalence Survey in People Involved in Different Essential Activities during the General Lock-Down Phase in the Province of Prato (Tuscany, Italy). Vaccines (Basel) 2020;8:E778. [PMID: 33352743 DOI: 10.3390/vaccines8040778] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
139 Wamonje FO. Post-COVID-19 Action: Guarding Africa's Crops against Viral Epidemics Requires Research Capacity Building That Unifies a Trio of Transdisciplinary Interventions. Viruses 2020;12:E1276. [PMID: 33182262 DOI: 10.3390/v12111276] [Reference Citation Analysis]
140 Oliver N, Barber X, Roomp K, Roomp K. Assessing the Impact of the COVID-19 Pandemic in Spain: Large-Scale, Online, Self-Reported Population Survey. J Med Internet Res 2020;22:e21319. [PMID: 32870159 DOI: 10.2196/21319] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
141 Vila-Corcoles A, Satue-Gracia E, Vila-Rovira A, de Diego-Cabanes C, Forcadell-Peris MJ, Hospital-Guardiola I, Ochoa-Gondar O, Basora-Gallisa J. COVID19-related and all-cause mortality risk among middle-aged and older adults across the first epidemic wave of SARS-COV-2 infection: a population-based cohort stuJune 2020.dy in Southern Catalonia, Spain, March-. BMC Public Health 2021;21:1795. [PMID: 34615512 DOI: 10.1186/s12889-021-11879-2] [Reference Citation Analysis]
142 Sasisekharan V, Pentakota N, Jayaraman A, Tharakaraman K, Wogan GN, Narayanasami U. Orthogonal immunoassays for IgG antibodies to SARS-CoV-2 antigens reveal that immune response lasts beyond 4 mo post illness onset. Proc Natl Acad Sci U S A 2021;118:e2021615118. [PMID: 33446512 DOI: 10.1073/pnas.2021615118] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
143 Guilger-Casagrande M, de Barros CT, Antunes VAN, de Araujo DR, Lima R. Perspectives and Challenges in the Fight Against COVID-19: The Role of Genetic Variability. Front Cell Infect Microbiol 2021;11:598875. [PMID: 33791232 DOI: 10.3389/fcimb.2021.598875] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Martínez-Piédrola MM, Guadarrama-Ortega D, Pérez-Fernández E, Ortigosa-Barriola A, Parra-García S, Molinares-Juarrero B, Díaz-Cuasante AI; Grupo de trabajo COVID-19 Alcorcón. [Strategy for planning and execution of a large-scale SARS-CoV-2 seroprevalence study on teaching hospital workers during a pandemic situation]. J Healthc Qual Res 2021;36:3-11. [PMID: 33384270 DOI: 10.1016/j.jhqr.2020.11.003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
145 Gelanew T, Seyoum B, Mulu A, Mihret A, Abebe M, Wassie L, Gelaw B, Sorsa A, Merid Y, Muchie Y, Teklemariam Z, Tesfaye B, Osman M, Jebessa G, Atinafu A, Hailu T, Habte A, Kenea D, Gadisa A, Admasu D, Tesfaye E, Bates TA, Bulcha JT, Tschopp R, Tsehay D, Mullholand K, Howe R, Genetu A, Tafesse FG, Abdissa A. High seroprevalence of anti-SARS-CoV-2 antibodies among Ethiopian healthcare workers. BMC Infect Dis 2022;22:261. [PMID: 35296265 DOI: 10.1186/s12879-022-07247-z] [Reference Citation Analysis]
146 Wu P, Ding L, Li X, Liu S, Cheng F, He Q, Xiao M, Wu P, Hou H, Jiang M, Long P, Wang H, Liu L, Qu M, Shi X, Jiang Q, Mo T, Ding W, Fu Y, Han S, Huo X, Zeng Y, Zhou Y, Zhang Q, Ke J, Xu X, Ni W, Shao Z, Wang J, Liu P, Li Z, Jin Y, Zheng F, Wang F, Liu L, Li W, Liu K, Peng R, Xu X, Lin Y, Gao H, Shi L, Geng Z, Mu X, Yan Y, Wang K, Wu D, Hao X, Cheng S, Qiu G, Guo H, Li K, Chen G, Sun Z, Lin X, Jin X, Wang F, Sun C, Wang C. Trans-ethnic genome-wide association study of severe COVID-19. Commun Biol 2021;4:1034. [PMID: 34465887 DOI: 10.1038/s42003-021-02549-5] [Reference Citation Analysis]
147 Arenas A, Borge C, Carbonero A, Garcia-Bocanegra I, Cano-Terriza D, Caballero J, Arenas-Montes A. Bovine Coronavirus Immune Milk Against COVID-19. Front Immunol 2021;12:637152. [PMID: 33833758 DOI: 10.3389/fimmu.2021.637152] [Reference Citation Analysis]
148 Nogueira López J, Grasa Lozano C, Ots Ruiz C, Alonso García L, Falces-Romero I, Calvo C, García-López Hortelano M; Grupo de Trabajo de SARS-CoV-2 del Servicio dePediatría del Hospital Universitario La Paz. Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital. An Pediatr (Engl Ed) 2021;95:336-44. [PMID: 34649834 DOI: 10.1016/j.anpede.2020.10.007] [Reference Citation Analysis]
149 West EA, Anker D, Amati R, Richard A, Wisniak A, Butty A, Albanese E, Bochud M, Chiolero A, Crivelli L, Cullati S, d'Acremont V, Epure AM, Fehr J, Flahault A, Fornerod L, Frank I, Frei A, Michel G, Gonseth S, Guessous I, Imboden M, Kahlert CR, Kaufmann L, Kohler P, Mösli N, Paris D, Probst-Hensch N, Rodondi N, Stringhini S, Vermes T, Vollrath F, Puhan MA; Corona Immunitas Research Group. Corona Immunitas: study protocol of a nationwide program of SARS-CoV-2 seroprevalence and seroepidemiologic studies in Switzerland. Int J Public Health 2020;65:1529-48. [PMID: 33098441 DOI: 10.1007/s00038-020-01494-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 8] [Article Influence: 8.5] [Reference Citation Analysis]
150 Card L, Litwin CM, Curry S, Mack EH, Nietert PJ, Meissner EG. Self-Administered, Remote Assessment of SARS-CoV-2 Seroprevalence in Health Care Workers. The American Journal of the Medical Sciences 2022. [DOI: 10.1016/j.amjms.2022.01.025] [Reference Citation Analysis]
151 Qutob N, Awartani F, Salah Z, Asia M, Abu Khader I, Herzallah K, Balqis N, Sallam H. Seroprevalence of SARS-CoV-2 in the West Bank region of Palestine: a cross-sectional seroepidemiological study. BMJ Open 2021;11:e044552. [PMID: 33542045 DOI: 10.1136/bmjopen-2020-044552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
152 Ahmed ZB, Razu MH, Akter F, Rabby MRI, Karmaker P, Khan M, Angelillo IF. Seropositivity of SARS-CoV-2 IgG Antibody among People in Dhaka City during the Prevaccination Period. BioMed Research International 2022;2022:1-6. [DOI: 10.1155/2022/4451144] [Reference Citation Analysis]
153 Vinceti M, Filippini T, Rothman KJ, Di Federico S, Orsini N. SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy. Environ Res 2021;197:111097. [PMID: 33811866 DOI: 10.1016/j.envres.2021.111097] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
154 Vos ERA, den Hartog G, Schepp RM, Kaaijk P, van Vliet J, Helm K, Smits G, Wijmenga-Monsuur A, Verberk JDM, van Boven M, van Binnendijk RS, de Melker HE, Mollema L, van der Klis FRM. Nationwide seroprevalence of SARS-CoV-2 and identification of risk factors in the general population of the Netherlands during the first epidemic wave. J Epidemiol Community Health 2020:jech-2020-215678. [PMID: 33249407 DOI: 10.1136/jech-2020-215678] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 12.0] [Reference Citation Analysis]
155 Villalaín C, Herraiz I, Luczkowiak J, Pérez-Rivilla A, Folgueira MD, Mejía I, Batllori E, Felipe E, Risco B, Galindo A, Delgado R. Seroprevalence analysis of SARS-CoV-2 in pregnant women along the first pandemic outbreak and perinatal outcome. PLoS One 2020;15:e0243029. [PMID: 33253283 DOI: 10.1371/journal.pone.0243029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
156 Levorson RE, Christian E, Hunter B, Sayal J, Sun J, Bruce SA, Garofalo S, Southerland M, Ho S, Levy S, Defillipi C, Peake L, Place FC, Hourigan SK. A cross-sectional investigation of SARS-CoV-2 seroprevalence and associated risk factors in children and adolescents in the United States. PLoS One 2021;16:e0259823. [PMID: 34748615 DOI: 10.1371/journal.pone.0259823] [Reference Citation Analysis]
157 Hammadi S, AlKanan AK, Fares M, Mohammed NK, Hashim AR, Habeeb A, Mansour AA. Basrah Preliminary Experience With COVID-19: A Report on 6404 Patients. Cureus 2021;13:e13012. [PMID: 33659142 DOI: 10.7759/cureus.13012] [Reference Citation Analysis]
158 Abdella S, Riou S, Tessema M, Assefa A, Seifu A, Blachman A, Abera A, Moreno N, Irarrazaval F, Tollera G, Browning D, Tasew G. Prevalence of SARS-CoV-2 in urban and rural Ethiopia: Randomized household serosurveys reveal level of spread during the first wave of the pandemic. EClinicalMedicine 2021;35:100880. [PMID: 34124630 DOI: 10.1016/j.eclinm.2021.100880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
159 Miró Ò, Jiménez S, Mebazaa A, Freund Y, Burillo-Putze G, Martín A, Martín-Sánchez FJ, García-Lamberechts EJ, Alquézar-Arbé A, Jacob J, Llorens P, Piñera P, Gil V, Guardiola J, Cardozo C, Mòdol Deltell JM, Tost J, Aguirre Tejedo A, Palau-Vendrell A, LLauger García L, Adroher Muñoz M, Del Arco Galán C, Agudo Villa T, López-Laguna N, López Díez MP, Beddar Chaib F, Quero Motto E, González Tejera M, Ponce MC, González Del Castillo J. Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome. Eur Heart J 2021:ehab314. [PMID: 34164664 DOI: 10.1093/eurheartj/ehab314] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Tsitsilonis OE, Paraskevis D, Lianidou E, Pierros V, Akalestos A, Kastritis E, Moutsatsou P, Scorilas A, Sphicopoulos T, Terpos E, Thomaidis N, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostaki EG, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Trougakos IP, Tsiodras S, Sfikakis PP, Dimopoulos MA. Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report. Life (Basel) 2020;10:E214. [PMID: 32967110 DOI: 10.3390/life10090214] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
161 Rodriguez-Gonzalez M, Castellano-Martinez A, Cascales-Poyatos HM, Perez-Reviriego AA. Cardiovascular impact of COVID-19 with a focus on children: A systematic review. World J Clin Cases 2020; 8(21): 5250-5283 [PMID: 33269260 DOI: 10.12998/wjcc.v8.i21.5250] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
162 Xu W, Li X, Dozier M, He Y, Kirolos A, Lang Z, Mathews C, Siegfried N, Theodoratou E; UNCOVER. What is the evidence for transmission of COVID-19 by children in schools? A living systematic review. J Glob Health 2020;10:021104. [PMID: 33437465 DOI: 10.7189/jogh.10.021104] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
163 Hernán MA, Yotti R. Two Pandemics, Two Surveys in the United States and in Spain. Am J Public Health 2021;111:414-5. [PMID: 33566650 DOI: 10.2105/AJPH.2020.306105] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Working group for the surveillance and control of COVID-19 in Spain., Members of the Working group for the surveillance and control of COVID-19 in Spain. The first wave of the COVID-19 pandemic in Spain: characterisation of cases and risk factors for severe outcomes, as at 27 April 2020. Euro Surveill 2020;25. [PMID: 33334400 DOI: 10.2807/1560-7917.ES.2020.25.50.2001431] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
165 Elnasser Z, Obeidat H, Amarin Z, Alrabadi N, Jaradat A, Alomarat D, BaniSalem M, Almomani R. Prevalence of COVID-19 among blood donors: The Jordan University of Science and Technology experience. Medicine (Baltimore) 2021;100:e27537. [PMID: 34731151 DOI: 10.1097/MD.0000000000027537] [Reference Citation Analysis]
166 Girgis SA, Hafez HM, Elarab HE, Sherif B, Sabry MH, Afifi I, Hassan FE, Reda A, Elsayed S, Mahmoud A, Habeb P, Habil IS, Hussein RS, Mossad IM, Mansour O, Omar A, Saleh AM, El-Meteini M. SARS-CoV-2 PCR positivity rate and seroprevalence of related antibodies among a sample of patients in Cairo: Pre-wave 2 results of a screening program in a university hospital. PLoS One 2021;16:e0254581. [PMID: 34265021 DOI: 10.1371/journal.pone.0254581] [Reference Citation Analysis]
167 Bellizzi S, Alsawalha L, Sheikh Ali S, Sharkas G, Muthu N, Ghazo M, Hayajneh W, Profili MC, Obeidat NM. A three-phase population based sero-epidemiological study: Assessing the trend in prevalence of SARS-CoV-2 during COVID-19 pandemic in Jordan. One Health 2021;13:100292. [PMID: 34295958 DOI: 10.1016/j.onehlt.2021.100292] [Reference Citation Analysis]
168 Fischer B, Knabbe C, Vollmer T. SARS-CoV-2 IgG seroprevalence in blood donors located in three different federal states, Germany, March to June 2020. Euro Surveill 2020;25. [PMID: 32700672 DOI: 10.2807/1560-7917.ES.2020.25.28.2001285] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 15.0] [Reference Citation Analysis]
169 Cruz-Arenas E, Cabrera-Ruiz E, Laguna-Barcenas S, Colin-Castro CA, Chavez T, Franco-Cendejas R, Ibarra C, Perez-Orive J. Serological prevalence of SARS-CoV-2 infection and associated factors in healthcare workers in a "non-COVID" hospital in Mexico City. PLoS One 2021;16:e0255916. [PMID: 34383842 DOI: 10.1371/journal.pone.0255916] [Reference Citation Analysis]
170 Pouwels KB, House T, Pritchard E, Robotham JV, Birrell PJ, Gelman A, Vihta KD, Bowers N, Boreham I, Thomas H, Lewis J, Bell I, Bell JI, Newton JN, Farrar J, Diamond I, Benton P, Walker AS; COVID-19 Infection Survey Team. Community prevalence of SARS-CoV-2 in England from April to November, 2020: results from the ONS Coronavirus Infection Survey. Lancet Public Health 2021;6:e30-8. [PMID: 33308423 DOI: 10.1016/S2468-2667(20)30282-6] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 14.5] [Reference Citation Analysis]
171 Baumgarth N, Nikolich-Žugich J, Lee FE, Bhattacharya D. Antibody Responses to SARS-CoV-2: Let's Stick to Known Knowns. J Immunol 2020;205:2342-50. [PMID: 32887754 DOI: 10.4049/jimmunol.2000839] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 15.5] [Reference Citation Analysis]
172 Tang X, Sharma A, Pasic M, Brown P, Colwill K, Gelband H, Birnboim HC, Nagelkerke N, Bogoch II, Bansal A, Newcombe L, Slater J, Rodriguez PS, Huang G, Fu SH, Meh C, Wu DC, Kaul R, Langlois MA, Morawski E, Hollander A, Eliopoulos D, Aloi B, Lam T, Abe KT, Rathod B, Fazel-Zarandi M, Wang J, Iskilova M, Pasculescu A, Caldwell L, Barrios-Rodiles M, Mohammed-Ali Z, Vas N, Santhanam DR, Cho ER, Qu K, Jha S, Jha V, Suraweera W, Malhotra V, Mastali K, Wen R, Sinha S, Reid A, Gingras AC, Chakraborty P, Slutsky AS, Jha P; Ab-C Study Investigators. Assessment of SARS-CoV-2 Seropositivity During the First and Second Viral Waves in 2020 and 2021 Among Canadian Adults. JAMA Netw Open 2022;5:e2146798. [PMID: 35171263 DOI: 10.1001/jamanetworkopen.2021.46798] [Reference Citation Analysis]
173 Tsai AC, Harling G, Reynolds Z, Gilbert RF, Siedner MJ. Coronavirus Disease 2019 (COVID-19) Transmission in the United States Before Versus After Relaxation of Statewide Social Distancing Measures. Clin Infect Dis 2021;73:S120-6. [PMID: 33009800 DOI: 10.1093/cid/ciaa1502] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
174 Barallat J, Fernández-Rivas G, Quirant-Sánchez B, González V, Doladé M, Martinez-Caceres E, Piña M, Matllo J, Estrada O, Blanco I. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave. PLoS One 2020;15:e0244348. [PMID: 33370363 DOI: 10.1371/journal.pone.0244348] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
175 Maruntelu I, Caragea AM, Tizu M, Constantinescu I. SARS-CoV-2 diagnosis: a single-centre experience. J Med Life 2021;14:257-61. [PMID: 34104250 DOI: 10.25122/jml-2021-0064] [Reference Citation Analysis]
176 Raoult D. How useful is serology for COVID-19? Int J Infect Dis 2021;102:170-1. [PMID: 33129960 DOI: 10.1016/j.ijid.2020.10.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
177 Giraud-Gatineau A, Gautret P, Colson P, Chaudet H, Raoult D. Evaluation of Strategies to Fight COVID-19: The French Paradigm. J Clin Med 2021;10:2942. [PMID: 34209087 DOI: 10.3390/jcm10132942] [Reference Citation Analysis]
178 Mercer TR, Salit M. Testing at scale during the COVID-19 pandemic. Nat Rev Genet 2021;22:415-26. [PMID: 33948037 DOI: 10.1038/s41576-021-00360-w] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
179 Chen F, Liu Y, Ya B, He J, Leng T, Sun Y, Xin Q. Latest Effective Measures to Combat COVID-19: A Review. Iran J Public Health 2021;50:640-8. [PMID: 34183914 DOI: 10.18502/ijph.v50i4.5989] [Reference Citation Analysis]
180 Irfan O, Li J, Tang K, Wang Z, Bhutta ZA. Risk of infection and transmission of SARS-CoV-2 among children and adolescents in households, communities and educational settings: A systematic review and meta-analysis. J Glob Health 2021;11:05013. [PMID: 34326997 DOI: 10.7189/jogh.11.05013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
181 McDonald L, Wise H, Muecksch F, Poston D, Mavin S, Templeton K, Furrie E, Richardson C, McGuire J, Jarvis L, Malloy K, McAuley A, Palmateer N, Dickson E, Hatziioannou T, Bieniasz P, Jenks S. Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. J Clin Virol Plus 2021;1:100028. [PMID: 35262014 DOI: 10.1016/j.jcvp.2021.100028] [Reference Citation Analysis]
182 Capai L, Masse S, Fourié T, Decarreaux D, Canarelli J, Simeoni MH, Amroun A, Mohammed-Ali S, Saba Villarroel PM, de Lamballerie X, Charrel R, Falchi A. Impact of the Second Epidemic Wave of SARS-CoV-2: Increased Exposure of Young People. Front Public Health 2021;9:715192. [PMID: 34381756 DOI: 10.3389/fpubh.2021.715192] [Reference Citation Analysis]
183 Houštecká A, Koh D, Santaeulàlia-llopis R. Contagion at work: Occupations, industries and human contact. Journal of Public Economics 2021;200:104456. [DOI: 10.1016/j.jpubeco.2021.104456] [Reference Citation Analysis]
184 Martínez-Caballero CM, Cárdaba-García RM, Varas-Manovel R, García-Sanz LM, Martínez-Piedra J, Fernández-Carbajo JJ, Pérez-Pérez L, Madrigal-Fernández MA, Barba-Pérez MÁ, Olea E, Durantez-Fernández C, Herrero-Frutos MT. Analyzing the Impact of COVID-19 Trauma on Developing Post-Traumatic Stress Disorder among Emergency Medical Workers in Spain. Int J Environ Res Public Health 2021;18:9132. [PMID: 34501726 DOI: 10.3390/ijerph18179132] [Reference Citation Analysis]
185 Almudarra S, Kamel S, Saleh E, Alaswad R, Alruwaily A, Almowald S, Alqunaibet AM, Almudiaheem A, Almutlaq H, Alserehi H, Almalki S, Bahlaq MA, Alsahafi AJ, Alsaif F, Khojah AT, Al-Tawfiq JA, Asiri SI, Assiri A, Jokhdar H. High seroprevalence of SARS-CoV-2 among high-density communities in Saudi Arabia. Infection 2021. [PMID: 34881415 DOI: 10.1007/s15010-021-01726-2] [Reference Citation Analysis]
186 Vaselli NM, Hungerford D, Shenton B, Khashkhusha A, Cunliffe NA, French N. The seroprevalence of SARS-CoV-2 during the first wave in Europe 2020: A systematic review. PLoS One 2021;16:e0250541. [PMID: 34727115 DOI: 10.1371/journal.pone.0250541] [Reference Citation Analysis]
187 Paredes I, Castaño Leon AM, Lagares A, Jimenez Roldan L, Perez-Nuñez A, González-Leon P, Delgado-Fernandez J, Eiriz C, García-Pérez D, Moreno-Gomez LM, Esteban-Sinovas O, Delgado-López P, Martín-Alonso J, Kaen A, Tirado-Caballero J, Ordóñez Carmona M, Arteaga Romero F, Gonzalez Pombo M, Alén JF, Gil-Simoes R, Torres CV, Navas Garcia M, Blasco G, Frade-Porto N, González-Tarno P, Martin Segura A, Gelabert-Gonzalez M, Menendez Cortezon B, Rodriguez Botana B, Pérez-Alfayate R, Fernandez Garcia C, Ferrandez Pujante B, Vargas-Jiménez A, Cotúa C, de la Lama A, Calero L, Ruiz-Juretschke F, Garcia Leal R, Valera Mele M, Casitas Hernando V, Rivero Martín B, Orduna J, Casado Pellejero J, Fustero De Miguel D, Diaz-Molina J, Moles Herbera J, Castello Ruiz MJ, Gomar Alba M, Garcia Perez F, Hernandez Garcia BJ, Villaseñor Ledezma J, Otero Rodríguez Á, Ailagas JJ, Goncalves-Estella J, Sousa Casasnovas P, Pascual Argente D, Ruiz Martín L, Roa Montes de Oca JC, Arandia Guzmán D, García Martín A, Torres Carretero L, Garrido Ruíz PA, Calvo M, Miranda-Lloret P, Rodriguez-Cadarso Suarez-Vence M, Anotn Oltra J, Roca Barber A, Quiroz Tejada A, Carbayo Lozano G, Bermudez Vilar G, Paternain Martin C, Dela FuenteVilla P, Fidalgo De la Rosa M, Sistiaga García ÍL, Zabalo San Juan G. Impact of the first wave of the SARS-CoV-2 pandemic on the outcome of neurosurgical patients: a nationwide study in Spain. BMJ Open 2021;11:e053983. [PMID: 34893486 DOI: 10.1136/bmjopen-2021-053983] [Reference Citation Analysis]
188 Alicandro G, Daccó V, Cariani L, Contarini M, Morlacchi LC, Rosazza C, Sciarrabba CS, Ferraro F, Orena BS, Gramegna A, Blasi F, Colombo C. SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy. J Cyst Fibros 2021:S1569-1993(21)02170-6. [PMID: 34949558 DOI: 10.1016/j.jcf.2021.12.011] [Reference Citation Analysis]
189 Dudel C, Riffe T, Acosta E, van Raalte A, Strozza C, Myrskylä M. Monitoring trends and differences in COVID-19 case-fatality rates using decomposition methods: Contributions of age structure and age-specific fatality. PLoS One 2020;15:e0238904. [PMID: 32913365 DOI: 10.1371/journal.pone.0238904] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 15.0] [Reference Citation Analysis]
190 Briz-Redón Á. The impact of modelling choices on modelling outcomes: a spatio-temporal study of the association between COVID-19 spread and environmental conditions in Catalonia (Spain). Stoch Environ Res Risk Assess 2021;:1-13. [PMID: 33424434 DOI: 10.1007/s00477-020-01965-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Sharif N, Sarkar MK, Ahmed SN, Ferdous RN, Nobel NU, Parvez AK, Talukder AA, Dey SK. Environmental correlation and epidemiologic analysis of COVID-19 pandemic in ten regions in five continents. Heliyon 2021;7:e06576. [PMID: 33817387 DOI: 10.1016/j.heliyon.2021.e06576] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
192 Ulyte A, Radtke T, Abela IA, Haile SR, Blankenberger J, Jung R, Capelli C, Berger C, Frei A, Huber M, Schanz M, Schwarzmueller M, Trkola A, Fehr J, Puhan MA, Kriemler S. Variation in SARS-CoV-2 seroprevalence across districts, schools and classes: baseline measurements from a cohort of primary and secondary school children in Switzerland. BMJ Open 2021;11:e047483. [PMID: 34312201 DOI: 10.1136/bmjopen-2020-047483] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
193 Holenya P, Lange PJ, Reimer U, Woltersdorf W, Panterodt T, Glas M, Wasner M, Eckey M, Drosch M, Hollidt JM, Naumann M, Kern F, Wenschuh H, Lange R, Schnatbaum K, Bier FF. Peptide microarray-based analysis of antibody responses to SARS-CoV-2 identifies unique epitopes with potential for diagnostic test development. Eur J Immunol 2021;51:1839-49. [PMID: 33772767 DOI: 10.1002/eji.202049101] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
194 Sil BK, Jamiruddin MR, Haq MA, Khondoker MU, Jahan N, Khandker SS, Ali T, Oishee MJ, Kaitsuka T, Mie M, Tomizawa K, Kobatake E, Haque M, Adnan N. AuNP Coupled Rapid Flow-Through Dot-Blot Immuno-Assay for Enhanced Detection of SARS-CoV-2 Specific Nucleocapsid and Receptor Binding Domain IgG. Int J Nanomedicine 2021;16:4739-53. [PMID: 34267520 DOI: 10.2147/IJN.S313140] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
195 Borud EK, Nakstad ER, Håberg SE, Lind A, Fadum EA, Taxt AM, Steens A, Gjein GE, Sunde MW, Iversen P, Svanevik M, Ahmad BM, Waldow T, Norheim AJ. Severe acute respiratory syndrome coronavirus 2 prevalence in 1170 asymptomatic Norwegian conscripts. Health Sci Rep 2021;4:e233. [PMID: 33490637 DOI: 10.1002/hsr2.233] [Reference Citation Analysis]
196 Tiwari S, Vyasarayani CP, Chatterjee A. Data suggest COVID-19 affected numbers greatly exceeded detected numbers, in four European countries, as per a delayed SEIQR model. Sci Rep 2021;11:8106. [PMID: 33854165 DOI: 10.1038/s41598-021-87630-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. Science 2021;371:79-82. [PMID: 33177105 DOI: 10.1126/science.abe1916] [Cited by in Crossref: 76] [Cited by in F6Publishing: 64] [Article Influence: 38.0] [Reference Citation Analysis]
198 Barchuk A, Skougarevskiy D, Titaev K, Shirokov D, Raskina Y, Novkunkskaya A, Talantov P, Isaev A, Pomerantseva E, Zhikrivetskaya S, Barabanova L, Volkov V. Seroprevalence of SARS-CoV-2 antibodies in Saint Petersburg, Russia: a population-based study. Sci Rep 2021;11:12930. [PMID: 34155259 DOI: 10.1038/s41598-021-92206-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
199 Toth DJA, Beams AB, Keegan LT, Zhang Y, Greene T, Orleans B, Seegert N, Looney A, Alder SC, Samore MH. High variability in transmission of SARS-CoV-2 within households and implications for control. PLoS One 2021;16:e0259097. [PMID: 34758042 DOI: 10.1371/journal.pone.0259097] [Reference Citation Analysis]
200 Spellberg B, Nielsen TB, Casadevall A. Antibodies, Immunity, and COVID-19. JAMA Intern Med 2021;181:460-2. [PMID: 33231673 DOI: 10.1001/jamainternmed.2020.7986] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
201 Khalagi K, Gharibzadeh S, Khalili D, Mirab Samiee S, Hashemi SM, Aghamohamadi S, Mir-Mohammad-Ali Roodaki M, Tayeri K, Namdari Tabar H, Azadmanesh K, Tabrizi JS, Mohammad K, Goudarzi S, Hajipour F, Namaki S, Raeisi A, Ostovar A. Nationwide population-based surveys of Iranian COVID-19 Serological Surveillance (ICS) program: The surveys protocol. Med J Islam Repub Iran 2021;35:61. [PMID: 34277498 DOI: 10.47176/mjiri.35.61] [Reference Citation Analysis]
202 Pla B, Arranz A, Knott C, Sampedro M, Jiménez S, Hernando I, Marazuela M. Impact of COVID-19 Lockdown on Glycemic Control in Adults with Type 1 Diabetes Mellitus. J Endocr Soc 2020;4:bvaa149. [PMID: 33173841 DOI: 10.1210/jendso/bvaa149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
203 Alcázar-Arroyo R, Portolés J, López-Sánchez P, Zalamea F, Furaz K, Méndez Á, Nieto L, Sánchez-Hernández R, Pizarro S, García A, Pereira M, Gallego-Valcárcel E, Llópez-Carratala R, Gadea-Gironés I, Martín R, Miranda B; COVID-FRIAT study group . Rapid decline of anti-SARS-CoV-2 antibodies in patients on haemodialysis: the COVID-FRIAT study. Clin Kidney J 2021;14:1835-44. [PMID: 34211708 DOI: 10.1093/ckj/sfab048] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Ioannidis JPA. Infection fatality rate of COVID-19 inferred from seroprevalence data. Bull World Health Organ 2021;99:19-33F. [PMID: 33716331 DOI: 10.2471/BLT.20.265892] [Cited by in Crossref: 61] [Cited by in F6Publishing: 43] [Article Influence: 30.5] [Reference Citation Analysis]
205 Bajema KL, Wiegand RE, Cuffe K, Patel SV, Iachan R, Lim T, Lee A, Moyse D, Havers FP, Harding L, Fry AM, Hall AJ, Martin K, Biel M, Deng Y, Meyer WA 3rd, Mathur M, Kyle T, Gundlapalli AV, Thornburg NJ, Petersen LR, Edens C. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. JAMA Intern Med 2021;181:450-60. [PMID: 33231628 DOI: 10.1001/jamainternmed.2020.7976] [Cited by in Crossref: 92] [Cited by in F6Publishing: 84] [Article Influence: 92.0] [Reference Citation Analysis]
206 Martínez-Taboada VM, López-Hoyos M, Crespo J, Cacho PM, Hernández JL. Thoughts From the Trenches: Should We Look at the "Healthy"? Front Public Health 2020;8:490. [PMID: 33014980 DOI: 10.3389/fpubh.2020.00490] [Reference Citation Analysis]
207 Flamand C, Alves Sarmento C, Enfissi A, Bailly S, Beillard E, Gaillet M, Michaud C, Servas V, Clement N, Perilhou A, Carage T, Musso D, Carod JF, Eustache S, Tourbillon C, Boizon E, James S, Djossou F, Salje H, Cauchemez S, Rousset D. Seroprevalence of anti-SARS-CoV-2 IgG at the first epidemic peak in French Guiana, July 2020. PLoS Negl Trop Dis 2021;15:e0009945. [PMID: 34767549 DOI: 10.1371/journal.pntd.0009945] [Reference Citation Analysis]
208 Domènech-Montoliu S, Pac-Sa MR, Vidal-Utrillas P, Latorre-Poveda M, Del Rio-González A, Ferrando-Rubert S, Ferrer-Abad G, Sánchez-Urbano M, Aparisi-Esteve L, Badenes-Marques G, Cervera-Ferrer B, Clerig-Arnau U, Dols-Bernad C, Fontal-Carcel M, Gomez-Lanas L, Jovani-Sales D, León-Domingo MC, Llopico-Vilanova MD, Moros-Blasco M, Notari-Rodríguez C, Ruíz-Puig R, Valls-López S, Arnedo-Pena A. "Mass gathering events and COVID-19 transmission in Borriana (Spain): A retrospective cohort study". PLoS One 2021;16:e0256747. [PMID: 34437628 DOI: 10.1371/journal.pone.0256747] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
209 Vigón L, Fuertes D, García-Pérez J, Torres M, Rodríguez-Mora S, Mateos E, Corona M, Saez-Marín AJ, Malo R, Navarro C, Murciano-Antón MA, Cervero M, Alcamí J, García-Gutiérrez V, Planelles V, López-Huertas MR, Coiras M. Impaired Cytotoxic Response in PBMCs From Patients With COVID-19 Admitted to the ICU: Biomarkers to Predict Disease Severity. Front Immunol 2021;12:665329. [PMID: 34122423 DOI: 10.3389/fimmu.2021.665329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
210 Massarweh A, Eliakim-Raz N, Stemmer A, Levy-Barda A, Yust-Katz S, Zer A, Benouaich-Amiel A, Ben-Zvi H, Moskovits N, Brenner B, Bishara J, Yahav D, Tadmor B, Zaks T, Stemmer SM. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer. JAMA Oncol 2021;7:1133-40. [PMID: 34047765 DOI: 10.1001/jamaoncol.2021.2155] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
211 Walker AG, Sibbel S, Wade C, Moulton N, Marlowe G, Young A, Fadem SZ, Brunelli SM. SARS-CoV-2 Antibody Seroprevalence Among Maintenance Dialysis Patients in the United States. Kidney Med 2021;3:216-222.e1. [PMID: 33564746 DOI: 10.1016/j.xkme.2021.01.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
212 Neumann M, Aigner A, Rossow E, Schwarz D, Marschallek M, Steinmann J, Stücker R, Koenigs I, Stock P. Low SARS-CoV-2 seroprevalence but high perception of risk among healthcare workers at children's hospital before second pandemic wave in Germany. World J Pediatr 2021;17:484-94. [PMID: 34415560 DOI: 10.1007/s12519-021-00447-8] [Reference Citation Analysis]
213 Phipps SJ, Grafton RQ, Kompas T. Robust estimates of the true (population) infection rate for COVID-19: a backcasting approach. R Soc Open Sci 2020;7:200909. [PMID: 33391791 DOI: 10.1098/rsos.200909] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
214 Ramos-Álvarez O, Arufe-Giráldez V, Cantarero-Prieto D, Ibáñez-García A. Impact of SARS-CoV-2 Lockdown on Anthropometric Parameters in Children 11/12 Years Old. Nutrients 2021;13:4174. [PMID: 34836427 DOI: 10.3390/nu13114174] [Reference Citation Analysis]
215 Vena A, Berruti M, Adessi A, Blumetti P, Brignole M, Colognato R, Gaggioli G, Giacobbe DR, Bracci-Laudiero L, Magnasco L, Signori A, Taramasso L, Varelli M, Vendola N, Ball L, Robba C, Battaglini D, Brunetti I, Pelosi P, Bassetti M. Prevalence of Antibodies to SARS-CoV-2 in Italian Adults and Associated Risk Factors. J Clin Med 2020;9:E2780. [PMID: 32867328 DOI: 10.3390/jcm9092780] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 15.5] [Reference Citation Analysis]
216 Giacomelli A, Pagani G, Conti F, Bassoli C, Galli M. Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy. J Hepatol. 2021;. [PMID: 33453329 DOI: 10.1016/j.jhep.2020.12.026] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
217 Guerra I, Algaba A, Jiménez L, Mar Aller M, Garza D, Bonillo D, Molina Esteban LM, Bermejo F. Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. Inflamm Bowel Dis 2021;27:25-33. [PMID: 32830267 DOI: 10.1093/ibd/izaa221] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
218 Doraiswamy S, Mamtani R, Cheema S. An in-depth analysis of 10 epidemiological terminologies used in the context of COVID-19. Scand J Public Health 2021;:14034948211057736. [PMID: 34903120 DOI: 10.1177/14034948211057736] [Reference Citation Analysis]
219 Chen M, Qin R, Jiang M, Yang Z, Wen W, Li J. Clinical applications of detecting IgG, IgM or IgA antibody for the diagnosis of COVID-19: A meta-analysis and systematic review. Int J Infect Dis 2021;104:415-22. [PMID: 33450372 DOI: 10.1016/j.ijid.2021.01.016] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
220 Royo-Cebrecos C, Vilanova D, López J, Arroyo V, Pons M, Francisco G, Carrasco MG, Piqué JM, Sanz S, Dobaño C, García-Basteiro AL. Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra. Lancet Reg Health Eur 2021;5:100119. [PMID: 34557824 DOI: 10.1016/j.lanepe.2021.100119] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
221 Keller N, Jenny MA. How to Determine When SARS-CoV-2 Antibody Testing Is or Is Not Useful for Population Screening: A Tutorial. MDM Policy Pract 2020;5:2381468320963068. [PMID: 33225066 DOI: 10.1177/2381468320963068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
222 Alquézar-Arbé A, Piñera P, Jacob J, González Del Castillo J, Miró Ò; Spanish Investigators on Emergency Situations TeAm (SIESTA) network. ENCOVUR-3 study: Spanish emergency departments' participation in hospital decision-making committees during the first peak of the coronavirus disease 2019 pandemic. Eur J Emerg Med 2021;28:317-20. [PMID: 34187996 DOI: 10.1097/MEJ.0000000000000794] [Reference Citation Analysis]
223 Videla S, Otero A, Martí S, Domínguez MÁ, Fabrellas N, Delgado-Hito MP, Cruz I, Tebé C, Vinuesa T, Ardila F, Sancho M, Fernández E, Figuerola M, Ciruela F. Prevalence of SARS-CoV-2 Infection at the University of Barcelona during the Third COVID-19 Pandemic Wave in Spain. Int J Environ Res Public Health 2021;18:6526. [PMID: 34204383 DOI: 10.3390/ijerph18126526] [Reference Citation Analysis]
224 Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO, Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B, Kristjansdottir S, Birgisdottir K, Kristinsdottir AM, Sigurdsson MI, Arnadottir GA, Ivarsdottir EV, Andresdottir M, Jonsson F, Agustsdottir AB, Berglund J, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Gottfredsson M, Gretarsdottir OS, Gudmundsdottir S, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Helgason A, Jensson BO, Jonasdottir A, Jonsson H, Kristjansson T, Kristinsson KG, Magnusdottir DN, Magnusson OT, Olafsdottir LB, Rognvaldsson S, le Roux L, Sigmundsdottir G, Sigurdsson A, Sveinbjornsson G, Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Thordardottir M, Saemundsdottir J, Kristjansson SH, Josefsdottir KS, Masson G, Georgsson G, Kristjansson M, Moller A, Palsson R, Gudnason T, Thorsteinsdottir U, Jonsdottir I, Sulem P, Stefansson K. Humoral Immune Response to SARS-CoV-2 in Iceland. N Engl J Med 2020;383:1724-34. [PMID: 32871063 DOI: 10.1056/NEJMoa2026116] [Cited by in Crossref: 405] [Cited by in F6Publishing: 239] [Article Influence: 202.5] [Reference Citation Analysis]
225 Cazelles B, Nguyen-Van-Yen B, Champagne C, Comiskey C. Dynamics of the COVID-19 epidemic in Ireland under mitigation. BMC Infect Dis 2021;21:735. [PMID: 34344318 DOI: 10.1186/s12879-021-06433-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
226 Matabuena M, Rodríguez-Mier P, García-Meixide C, Leborán V. COVID-19: Estimation of the transmission dynamics in Spain using a stochastic simulator and black-box optimization techniques. Comput Methods Programs Biomed 2021;211:106399. [PMID: 34607036 DOI: 10.1016/j.cmpb.2021.106399] [Reference Citation Analysis]
227 Prazuck T, Colin M, Giachè S, Gubavu C, Seve A, Rzepecki V, Chevereau-Choquet M, Kiani C, Rodot V, Lionnet E, Courtellemont L, Guinard J, Pialoux G, Hocqueloux L. Evaluation of performance of two SARS-CoV-2 Rapid IgM-IgG combined antibody tests on capillary whole blood samples from the fingertip. PLoS One 2020;15:e0237694. [PMID: 32941461 DOI: 10.1371/journal.pone.0237694] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
228 Bassi F, Arbia G, Falorsi PD. Observed and estimated prevalence of Covid-19 in Italy: How to estimate the total cases from medical swabs data. Sci Total Environ 2021;764:142799. [PMID: 33066965 DOI: 10.1016/j.scitotenv.2020.142799] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 12.0] [Reference Citation Analysis]
229 Badanta B, Acevedo-Aguilera R, Lucchetti G, de Diego-Cordero R. 'A picture is worth a thousand words'-A photovoice study exploring health professionals' experiences during the COVID-19 pandemic. J Clin Nurs 2021. [PMID: 34056768 DOI: 10.1111/jocn.15887] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
230 Guzmán-Merino M, Durán C, Marinescu MC, Delgado-Sanz C, Gomez-Barroso D, Carretero J, Singh DE. Assessing population-sampling strategies for reducing the COVID-19 incidence. Comput Biol Med 2021;139:104938. [PMID: 34678482 DOI: 10.1016/j.compbiomed.2021.104938] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
231 Tönshoff B, Müller B, Elling R, Renk H, Meissner P, Hengel H, Garbade SF, Kieser M, Jeltsch K, Grulich-Henn J, Euler J, Stich M, Chobanyan-Jürgens K, Zernickel M, Janda A, Wölfle L, Stamminger T, Iftner T, Ganzenmueller T, Schmitt C, Görne T, Laketa V, Olberg S, Plaszczyca A, Cortese M, Bartenschlager R, Pape C, Remme R, Huzly D, Panning M, Weigang S, Giese S, Ciminski K, Ankerhold J, Kochs G, Schwemmle M, Handgretinger R, Niemeyer CM, Engel C, Kern WV, Hoffmann GF, Franz AR, Henneke P, Debatin KM, Kräusslich HG. Prevalence of SARS-CoV-2 Infection in Children and Their Parents in Southwest Germany. JAMA Pediatr 2021;175:586-93. [PMID: 33480966 DOI: 10.1001/jamapediatrics.2021.0001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
232 Palka-Kotlowska M, Custodio-Cabello S, Oliveros-Acebes E, Khosravi-Shahi P, Cabezón-Gutierrez L. Review of risk of COVID-19 in cancer patients and their cohabitants. Int J Infect Dis 2021;105:15-20. [PMID: 33556611 DOI: 10.1016/j.ijid.2021.01.072] [Reference Citation Analysis]
233 Tuells J, Egoavil CM, Pena Pardo MA, Montagud AC, Montagud E, Caballero P, Zapater P, Puig-Barberá J, Hurtado-Sanchez JA. Seroprevalence Study and Cross-Sectional Survey on COVID-19 for a Plan to Reopen the University of Alicante (Spain). Int J Environ Res Public Health 2021;18:1908. [PMID: 33669412 DOI: 10.3390/ijerph18041908] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
234 Al-Abri SS, Al-Wahaibi A, Al-Kindi H, Kurup PJ, Al-Maqbali A, Al-Mayahi Z, Al-Tobi MH, Al-Katheri SH, Albusaidi S, Al-Sukaiti MH, Al Balushi AYM, Abdelgadir IO, Al-Shehi N, Morkos E, Al-Maani A, Al-Rawahi B, Alyaquobi F, Alqayoudhi A, Al-Harthy K, Al-Khalili S, Al-Rashdi A, Al-Shukri I, Al Ghafri TS, Al-Hashmi F, Al Jassasi SM, Alshaqsi N, Mitra N, Al Aamry HS, Shah P, Al Marbouai HH, Al Araimi AH, Kair IM, Al Manji AM, Almallak AS, Al Alawi FK, Vaidya V, Muqeetullah M, Alrashdi H, Al Jamoudi SSN, Alshaqsi A, Al Sharji A, Al Shukeiri H, Al-Abri B, Al-Rawahi S, Al-Lamki SH, Al-Manji A, Al-Jardani A. Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman: results from four successive nationwide sero-epidemiological surveys. Int J Infect Dis 2021;112:269-77. [PMID: 34601146 DOI: 10.1016/j.ijid.2021.09.062] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
235 Wagner A, Guzek A, Ruff J, Jasinska J, Scheikl U, Zwazl I, Kundi M, Stockinger H, Farcet MR, Kreil TR, Hoeltl E, Wiedermann U. Neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independently of symptoms in adults. Commun Med 2021;1. [DOI: 10.1038/s43856-021-00012-4] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
236 Erber J, Kappler V, Haller B, Mijočević H, Galhoz A, Prazeres da Costa C, Gebhardt F, Graf N, Hoffmann D, Thaler M, Lorenz E, Roggendorf H, Kohlmayer F, Henkel A, Menden MP, Ruland J, Spinner CD, Protzer U, Knolle P, Lingor P; on behalf of the SeCoMRI Study Group2. Infection Control Measures and Prevalence of SARS-CoV-2 IgG among 4,554 University Hospital Employees, Munich, Germany. Emerg Infect Dis 2022;28. [DOI: 10.3201/eid2803.204436] [Reference Citation Analysis]
237 Accorsi EK, Qiu X, Rumpler E, Kennedy-Shaffer L, Kahn R, Joshi K, Goldstein E, Stensrud MJ, Niehus R, Cevik M, Lipsitch M. How to detect and reduce potential sources of biases in studies of SARS-CoV-2 and COVID-19. Eur J Epidemiol 2021;36:179-96. [PMID: 33634345 DOI: 10.1007/s10654-021-00727-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
238 Fisman DN, Greer AL, Brankston G, Hillmer M, O'Brien SF, Drews SJ, Tuite AR. COVID-19 Case Age Distribution: Correction for Differential Testing by Age. Ann Intern Med 2021. [PMID: 34399059 DOI: 10.7326/M20-7003] [Reference Citation Analysis]
239 Mo Y, Eyre DW, Lumley SF, Walker TM, Shaw RH, O'Donnell D, Butcher L, Jeffery K, Donnelly CA, Cooper BS; Oxford COVID infection review team. Transmission of community- and hospital-acquired SARS-CoV-2 in hospital settings in the UK: A cohort study. PLoS Med 2021;18:e1003816. [PMID: 34637439 DOI: 10.1371/journal.pmed.1003816] [Reference Citation Analysis]
240 Gonçalves J, Sousa RL, Jacinto MJ, Silva DA, Paula F, Sousa R, Zahedi S, Carvalho J, Cabral MG, Costa M, Branco JC, Canhão H, Alves JD, Rodrigues AM, Soares H. Evaluating SARS-CoV-2 Seroconversion Following Relieve of Confinement Measures. Front Med (Lausanne) 2020;7:603996. [PMID: 33392225 DOI: 10.3389/fmed.2020.603996] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
241 Beaumont A, Durand C, Ledrans M, Schwoebel V, Noel H, Le Strat Y, Diulius D, Colombain L, Médus M, Gueudet P, Mouly D, Aumaître H. Seroprevalence of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in a vulnerable population in France: a cross-sectional study. BMJ Open 2021;11:e053201. [PMID: 34815286 DOI: 10.1136/bmjopen-2021-053201] [Reference Citation Analysis]
242 Reiners N, Schnurra C, Trawinski H, Kannenberg J, Hermsdorf T, Aebischer A, Schöneberg T, Reiche S, Jassoy C. Performance of a SARS CoV-2 antibody ELISA based on simultaneous measurement of antibodies against the viral nucleoprotein and receptor-binding domain. Eur J Clin Microbiol Infect Dis 2021. [PMID: 34085159 DOI: 10.1007/s10096-021-04284-5] [Reference Citation Analysis]
243 Stella L, Martínez AP, Bauso D, Colaneri P. The Role of Asymptomatic Infections in the COVID-19 Epidemic via Complex Networks and Stability Analysis. SIAM J Control Optim . [DOI: 10.1137/20m1373335] [Reference Citation Analysis]
244 Simon A, Huebner J, Berner R, Munro APS, Exner M, Huppertz HI, Walger P. Measures to maintain regular operations and prevent outbreaks of SARS-CoV-2 in childcare facilities or schools under pandemic conditions and co-circulation of other respiratory pathogens. GMS Hyg Infect Control 2020;15:Doc22. [PMID: 32974120 DOI: 10.3205/dgkh000357] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
245 Yang Y, Wang X, Du RH, Zhang W, Si HR, Zhu Y, Shen XR, Li Q, Li B, Men D, Zhou YN, Wang H, Tong XL, Zhang XE, Shi ZL, Zhou P. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses. Emerg Microbes Infect 2021;10:905-12. [PMID: 33870851 DOI: 10.1080/22221751.2021.1919032] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
246 Feehan AK, Velasco C, Fort D, Burton JH, Price-Haywood EG, Katzmarzyk PT, Garcia-Diaz J, Seoane L. Racial and Workplace Disparities in Seroprevalence of SARS-CoV-2, Baton Rouge, Louisiana, USA. Emerg Infect Dis 2021;27. [PMID: 33171096 DOI: 10.3201/eid2701.203808] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
247 Leister I, Ponocny-Seliger E, Kollaritsch H, Dungel P, Holzer B, Grillari J, Redl H, Ponocny I, Wilfing C, Aigner L, Exner M, Stainer M, Hackl M, Hausner T, Mittermayr R, Schaden W. Antibody seroprevalence and rate of asymptomatic infections with SARS-CoV-2 in Austrian hospital personnel. BMC Infect Dis 2021;21:915. [PMID: 34488680 DOI: 10.1186/s12879-021-06586-7] [Reference Citation Analysis]
248 Vetrugno G, La Milia DI, D'Ambrosio F, Di Pumpo M, Pastorino R, Boccia S, Ricci R, De-Giorgio F, Cicconi M, Foti F, Pascucci D, Castrini F, Carini E, Cambieri A, D'Alfonso ME, Capalbo G, Fantoni M, Moscato U, Staiti D, De Simone FM, Berloco F, Damiani G, Zega M, Cattani P, Posteraro B, Sanguinetti M, Laurenti P. COVID-19 Seroprevalence among Healthcare Workers of a Large COVID-19 Hospital in Rome Reveals Strengths and Limits of Two Different Serological Tests. Int J Environ Res Public Health 2021;18:2650. [PMID: 33800721 DOI: 10.3390/ijerph18052650] [Reference Citation Analysis]
249 Martínez-rodríguez D, Gonzalez-parra G, Villanueva R. Analysis of Key Factors of a SARS-CoV-2 Vaccination Program: A Mathematical Modeling Approach. Epidemiologia 2021;2:140-61. [DOI: 10.3390/epidemiologia2020012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 7.0] [Reference Citation Analysis]
250 Bousali M, Dimadi A, Kostaki EG, Tsiodras S, Nikolopoulos GK, Sgouras DN, Magiorkinis G, Papatheodoridis G, Pogka V, Lourida G, Argyraki A, Angelakis E, Sourvinos G, Beloukas A, Paraskevis D, Karamitros T. SARS-CoV-2 Molecular Transmission Clusters and Containment Measures in Ten European Regions during the First Pandemic Wave. Life (Basel) 2021;11:219. [PMID: 33803490 DOI: 10.3390/life11030219] [Reference Citation Analysis]
251 Garcia-Calavaro C, Paternina-Caicedo A, Smith AD, Harrison LH, De la Hoz-Restrepo F, Acosta E, Riffe T. COVID-19 mortality needs age adjusting for international comparisons. J Med Virol 2021;93:4127-9. [PMID: 33837989 DOI: 10.1002/jmv.27007] [Reference Citation Analysis]
252 Chen H, Zhang X, Liu W, Xue M, Liao C, Huang Z, Hu H, Sun B. The role of serum specific- SARS-CoV-2 antibody in COVID-19 patients. Int Immunopharmacol 2021;91:107325. [PMID: 33401205 DOI: 10.1016/j.intimp.2020.107325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
253 Reyes-Vega MF, Soto-Cabezas MG, Cárdenas F, Martel KS, Valle A, Valverde J, Vidal-Anzardo M, Falcón ME, Munayco CV; Peru COVID-19 Working Group. SARS-CoV-2 prevalence associated to low socioeconomic status and overcrowding in an LMIC megacity: A population-based seroepidemiological survey in Lima, Peru. EClinicalMedicine 2021;34:100801. [PMID: 33817611 DOI: 10.1016/j.eclinm.2021.100801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
254 Moncunill G, Mayor A, Santano R, Jiménez A, Vidal M, Tortajada M, Sanz S, Méndez S, Llupià A, Aguilar R, Alonso S, Barrios D, Carolis C, Cisteró P, Chóliz E, Cruz A, Fochs S, Jairoce C, Hecht J, Lamoglia M, Martínez MJ, Moreno J, Mitchell RA, Ortega N, Pey N, Puyol L, Ribes M, Rosell N, Figueroa-Romero A, Sotomayor P, Torres S, Williams S, Barroso S, Vilella A, Trilla A, Varela P, Dobaño C, Garcia-Basteiro AL. SARS-CoV-2 Seroprevalence and Antibody Kinetics Among Health Care Workers in a Spanish Hospital After 3 Months of Follow-up. J Infect Dis 2021;223:62-71. [PMID: 33175145 DOI: 10.1093/infdis/jiaa696] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 17.0] [Reference Citation Analysis]
255 Tsuboi M, Hachiya M, Ohtsu H, Akashi H, Miyoshi C, Umeda T. Epidemiology and risk of COVID-19 among travelers at airport and port quarantine stations across Japan: a nationwide descriptive analysis and an individually matched case-control study. Clin Infect Dis 2021:ciab659. [PMID: 34318872 DOI: 10.1093/cid/ciab659] [Reference Citation Analysis]
256 Aranda-Reneo I, Pedraz-Marcos A, Pulido-Fuentes M. Management of burnout among the staff of primary care centres in Spain during the pandemic caused by the SARS-CoV-2. Hum Resour Health 2021;19:133. [PMID: 34724937 DOI: 10.1186/s12960-021-00679-9] [Reference Citation Analysis]
257 Kuster AC, Overgaard HJ. A novel comprehensive metric to assess effectiveness of COVID-19 testing: Inter-country comparison and association with geography, government, and policy response. PLoS One 2021;16:e0248176. [PMID: 33667280 DOI: 10.1371/journal.pone.0248176] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
258 De Salazar PM, Lu F, Hay JA, Gómez-Barroso D, Fernández-Navarro P, Martínez E, Astray-Mochales J, Amillategui R, García-Fulgueiras A, Chirlaque MD, Sánchez-Migallón A, Larrauri A, Sierra MJ, Lipsitch M, Simón F, Santillana M, Hernán MA. Near real-time surveillance of the SARS-CoV-2 epidemic with incomplete data. medRxiv 2021:2021. [PMID: 33532788 DOI: 10.1101/2021.01.25.20230094] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Fonzo M, Bertoncello C, Baldo V. Mortality from COVID-19: are we getting closer to the true value? Pathog Glob Health 2020;114:347-8. [PMID: 33012277 DOI: 10.1080/20477724.2020.1827617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
260 Jeremijenko A, Chemaitelly H, Ayoub HH, Alishaq M, Abou-Samra AB, Al Ajmi JAAA, Al Ansari NAA, Al Kanaani Z, Al Khal A, Al Kuwari E, Al-Mohammed A, Al Molawi NHA, Al Naomi HM, Butt AA, Coyle P, El Kahlout RA, Gillani I, Kaleeckal AH, Masoodi NA, Thomas AG, Nafady-Hego H, Latif AN, Shaik RM, Younes NBM, Rahim HFA, Yassine HM, Al Kuwari MG, Al Romaihi HE, Al-Thani MH, Bertollini R, Abu-Raddad LJ. Herd Immunity against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 10 Communities, Qatar. Emerg Infect Dis 2021;27:1343-52. [PMID: 33900174 DOI: 10.3201/eid2705.204365] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
261 Odriozola A, San Segundo D, Cuadrado A, Hernáez T, Escrich V, Fortea JI, Martínez Á, Puente Á, Lapeña B, Del Barrio M, López-Hoyos M, Crespo J, Fábrega E. SARS-CoV-2 and Liver Transplant: How Has It Behaved in This Sixth Wave? Transplantation 2022. [PMID: 35394994 DOI: 10.1097/TP.0000000000004157] [Reference Citation Analysis]
262 Loubiere S, Monfardini E, Allaria C, Mosnier M, Allibert A, Ninove L, Bosetti T, Farnarier C, Hamouda I, Auquier P, Mosnier E, Tinland A. Seroprevalence of SARS-CoV-2 antibodies among homeless people living rough, in shelters and squats: A large population-based study in France. PLoS One 2021;16:e0255498. [PMID: 34525096 DOI: 10.1371/journal.pone.0255498] [Reference Citation Analysis]
263 Makatsa MS, Tincho MB, Wendoh JM, Ismail SD, Nesamari R, Pera F, de Beer S, David A, Jugwanth S, Gededzha MP, Mampeule N, Sanne I, Stevens W, Scott L, Blackburn J, Mayne ES, Keeton RS, Burgers WA. SARS-CoV-2 Antigens Expressed in Plants Detect Antibody Responses in COVID-19 Patients. Front Plant Sci 2021;12:589940. [PMID: 33868324 DOI: 10.3389/fpls.2021.589940] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
264 Viedma E, Dahdouh E, González-Alba JM, González-Bodi S, Martínez-García L, Lázaro-Perona F, Recio R, Rodríguez-Tejedor M, Folgueira MD, Cantón R, Delgado R, García-Rodríguez J, Galán JC, Mingorance J, On Behalf Of The Sars-CoV-Working Groups. Genomic Epidemiology of SARS-CoV-2 in Madrid, Spain, during the First Wave of the Pandemic: Fast Spread and Early Dominance by D614G Variants. Microorganisms 2021;9:454. [PMID: 33671631 DOI: 10.3390/microorganisms9020454] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
265 Souverein D, Mank TG, Euser SM, Herpers BL. Clinical Sensitivity, Specificity and Epidemiology of SARS-CoV-2 Serological Testing Using the Biozek COVID-19 Test. Diagnostics 2022;12:60. [DOI: 10.3390/diagnostics12010060] [Reference Citation Analysis]
266 Manouchehri N, Steinman L, Stuve O. Biological Significance of Anti-SARS-CoV-2 Antibodies: Lessons Learned From Progressive Multifocal Leukoencephalopathy. Neurol Neuroimmunol Neuroinflamm 2021;8:e935. [PMID: 33361386 DOI: 10.1212/NXI.0000000000000935] [Reference Citation Analysis]
267 Piccoli L, Ferrari P, Piumatti G, Jovic S, Rodriguez BF, Mele F, Giacchetto-Sasselli I, Terrot T, Silacci-Fregni C, Cameroni E, Jaconi S, Sprugasci N, Bartha I, Corti D, Uguccioni M, Lanzavecchia A, Garzoni C, Giannini O, Bernasconi E, Elzi L, Albanese E, Sallusto F, Ceschi A. Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lancet Reg Health Eur 2021;1:100013. [PMID: 34173621 DOI: 10.1016/j.lanepe.2020.100013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
268 Meis-Pinheiro U, Lopez-Segui F, Walsh S, Ussi A, Santaeugenia S, Garcia-Navarro JA, San-Jose A, Andreu AL, Campins M, Almirante B. Clinical characteristics of COVID-19 in older adults. A retrospective study in long-term nursing homes in Catalonia. PLoS One 2021;16:e0255141. [PMID: 34297774 DOI: 10.1371/journal.pone.0255141] [Reference Citation Analysis]
269 Campbell H, Gustafson P. Inferring the COVID-19 infection fatality rate in the community-dwelling population: a simple Bayesian evidence synthesis of seroprevalence study data and imprecise mortality data. Epidemiol Infect 2021;149. [DOI: 10.1017/s0950268821002405] [Reference Citation Analysis]
270 Hoballah A, El Haidari R, Siblany G, Abdel Sater F, Mansour S, Hassan H, Abou-Abbas L. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey. BMC Infect Dis 2022;22:42. [PMID: 35012464 DOI: 10.1186/s12879-022-07031-z] [Reference Citation Analysis]
271 Hughes EC, Amat JAR, Haney J, Parr YA, Logan N, Palmateer N, Nickbakhsh S, Ho A, Cherepanov P, Rosa A, McAuley A, Broos A, Herbert I, Arthur U, Szemiel AM, Roustan C, Dickson E, Gunson RN, Viana M, Willett BJ, Murcia PR. Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in a Patient Population Reveals Differences in Virus Exposure and Antibody-Mediated Immunity According to Host Demography and Healthcare Setting. J Infect Dis 2021;223:971-80. [PMID: 33367847 DOI: 10.1093/infdis/jiaa788] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
272 [DOI: 10.1101/2020.07.21.20159038] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
273 González-mesa E, García-fuentes E, Carvia-pontiasec R, Lavado-fernández AI, Cuenca-marín C, Suárez-arana M, Blasco-alonso M, Benítez-lara B, Mozas-benítez L, González-cazorla A, Egeberg-neverdal H, Jiménez-lópez JS. Transmitted Fetal Immune Response in Cases of SARS-CoV-2 Infections during Pregnancy. Diagnostics 2022;12:245. [DOI: 10.3390/diagnostics12020245] [Reference Citation Analysis]
274 Bohk-Ewald C, Dudel C, Myrskylä M. A demographic scaling model for estimating the total number of COVID-19 infections. Int J Epidemiol 2021;49:1963-71. [PMID: 33349859 DOI: 10.1093/ije/dyaa198] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
275 Ramatillah DL, Gan SH, Sulaiman SAS, Puja D, Abubakar U, Jaber AAS, Lukas S, Jusnita N. Evaluation of Treatment Outcome for Pneumonia among Pre-Vaccinated COVID-19 Patients with/without Comorbidity in a Public Hospital in Bengkulu, Indonesia. Vaccines (Basel) 2021;9:1411. [PMID: 34960157 DOI: 10.3390/vaccines9121411] [Reference Citation Analysis]
276 Olbrich L, Castelletti N, Schälte Y, Garí M, Pütz P, Bakuli A, Pritsch M, Kroidl I, Saathoff E, Guggenbuehl Noller JM, Fingerle V, Le Gleut R, Gilberg L, Brand I, Falk P, Markgraf A, Deák F, Riess F, Diefenbach M, Eser T, Weinauer F, Martin S, Quenzel EM, Becker M, Durner J, Girl P, Müller K, Radon K, Fuchs C, Wölfel R, Hasenauer J, Hoelscher M, Wieser A, On Behalf Of The KoCo-Study Group. Head-to-head evaluation of seven different seroassays including direct viral neutralisation in a representative cohort for SARS-CoV-2. J Gen Virol 2021;102. [PMID: 34623233 DOI: 10.1099/jgv.0.001653] [Reference Citation Analysis]
277 Rodriguez A, Arrizabalaga-Asenjo M, Fernandez-Baca V, Lainez MP, Al Nakeeb Z, Garcia JD, Payeras A. Seroprevalence of SARS-CoV-2 antibody among healthcare workers in a university hospital in Mallorca, Spain, during the first wave of the COVID-19 pandemic. Int J Infect Dis 2021;105:482-6. [PMID: 33647507 DOI: 10.1016/j.ijid.2021.02.104] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
278 Wang W, Wu Q, Yang J, Dong K, Chen X, Bai X, Chen X, Chen Z, Viboud C, Ajelli M, Yu H. Global, regional, and national estimates of target population sizes for covid-19 vaccination: descriptive study. BMJ 2020;371:m4704. [PMID: 33323388 DOI: 10.1136/bmj.m4704] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 20.5] [Reference Citation Analysis]
279 Wu DC, Jha P, Lam T, Brown P, Gelband H, Nagelkerke N, Birnboim HC, Reid A; Action to Beat Coronavirus in Canada/Action pour Battre le Coronavirus (Ab-C) Study Group. Predictors of self-reported symptoms and testing for COVID-19 in Canada using a nationally representative survey. PLoS One 2020;15:e0240778. [PMID: 33085714 DOI: 10.1371/journal.pone.0240778] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
280 Goss CW, Maricque BB, Anwuri VV, Cohen RE, Donaldson K, Johnson KJ, Powderly WG, Schechtman KB, Schmidt S, Thompson JJ, Trolard AM, Wang J, Geng E. SARS-CoV-2 active infection prevalence and seroprevalence in the adult population of St. Louis County. Ann Epidemiol 2022:S1047-2797(22)00036-9. [PMID: 35276338 DOI: 10.1016/j.annepidem.2022.03.002] [Reference Citation Analysis]
281 Hu S, Wang W, Wang Y, Litvinova M, Luo K, Ren L, Sun Q, Chen X, Zeng G, Li J, Liang L, Deng Z, Zheng W, Li M, Yang H, Guo J, Wang K, Chen X, Liu Z, Yan H, Shi H, Chen Z, Zhou Y, Sun K, Vespignani A, Viboud C, Gao L, Ajelli M, Yu H. Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. Nat Commun 2021;12:1533. [PMID: 33750783 DOI: 10.1038/s41467-021-21710-6] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 20.0] [Reference Citation Analysis]
282 Casas-Deza D, Bernal-Monterde V, Aranda-Alonso AN, Montil-Miguel E, Julián-Gomara AB, Letona-Giménez L, Arbones-Mainar JM. Age-related mortality in 61,993 confirmed COVID-19 cases over three epidemic waves in Aragon, Spain. Implications for vaccination programmes. PLoS One 2021;16:e0261061. [PMID: 34882740 DOI: 10.1371/journal.pone.0261061] [Reference Citation Analysis]
283 Morabia A. The US Public Health Service House-to-House Canvass Survey of the Morbidity and Mortality of the 1918 Influenza Pandemic. Am J Public Health 2021;111:438-45. [PMID: 33290084 DOI: 10.2105/AJPH.2020.306025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Sebastião CS, Galangue M, Gaston C, Van-Dunen R, Quivinja J, Lunbungululo E, Alfredo D, Sozinho A, Teixeira A, Manico E, Machado D, Mateus A, David Z, Paixão J, Neto Z, de Vasconcelos JN, Morais J. Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola. BMC Infect Dis 2021;21:1131. [PMID: 34727874 DOI: 10.1186/s12879-021-06814-0] [Reference Citation Analysis]
285 Candel FJ, San-Román J, Barreiro P, Canora J, Zapatero A, Carretero M, Lastra A, Martínez-Peromingo FJ. Integral management of COVID-19 in Madrid: Turning things around during the second wave. Lancet Reg Health Eur 2021;2:100039. [PMID: 34056629 DOI: 10.1016/j.lanepe.2021.100039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
286 Pritsch M, Radon K, Bakuli A, Le Gleut R, Olbrich L, Guggenbüehl Noller JM, Saathoff E, Castelletti N, Garí M, Pütz P, Schälte Y, Frahnow T, Wölfel R, Rothe C, Pletschette M, Metaxa D, Forster F, Thiel V, Rieß F, Diefenbach MN, Fröschl G, Bruger J, Winter S, Frese J, Puchinger K, Brand I, Kroidl I, Hasenauer J, Fuchs C, Wieser A, Hoelscher M, On Behalf Of The KoCo Study Group. Prevalence and Risk Factors of Infection in the Representative COVID-19 Cohort Munich. Int J Environ Res Public Health 2021;18:3572. [PMID: 33808249 DOI: 10.3390/ijerph18073572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
287 Lorent D, Nowak R, Roxo C, Lenartowicz E, Makarewicz A, Zaremba B, Nowak S, Kuszel L, Stefaniak J, Kierzek R, Zmora P. Prevalence of Anti-SARS-CoV-2 Antibodies in Poznań, Poland, after the First Wave of the COVID-19 Pandemic. Vaccines (Basel) 2021;9:541. [PMID: 34064028 DOI: 10.3390/vaccines9060541] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Cuñarro-López Y, Pintado-Recarte P, Hernández-Martín C, Paya-Martínez P, López-Pérez R, Cueto-Hernández I, Ruiz-Labarta J, Cano-Valderrama Ó, Martínez-Pérez Ó, Bravo-Arribas C, Ortega MA, De León-Luis JA. Comparing Infection Profiles of Expectant Mothers with COVID-19 and Impacts on Maternal and Perinatal Outcomes between the First Two Waves of the Pandemic. J Pers Med 2021;11:599. [PMID: 34201923 DOI: 10.3390/jpm11070599] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
289 Castilla J, Fresán U, Trobajo-Sanmartín C, Guevara M. Altitude and SARS-CoV-2 Infection in the First Pandemic Wave in Spain. Int J Environ Res Public Health 2021;18:2578. [PMID: 33806642 DOI: 10.3390/ijerph18052578] [Reference Citation Analysis]
290 Salzberger B, Buder F, Lampl B, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. [SARS-CoV-2/COVID-19-epidemiology and prevention]. Nephrologe 2020;:1-7. [PMID: 33343742 DOI: 10.1007/s11560-020-00472-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, Kumar MS, Rade K, Sabarinathan R, Asthana S, Balachandar R, Bangar SD, Bansal AK, Bhat J, Chopra V, Das D, Deb AK, Devi KR, Dwivedi GR, Khan SMS, Kumar CPG, Kumar MS, Laxmaiah A, Madhukar M, Mahapatra A, Mohanty SS, Rangaraju C, Turuk A, Baradwaj DK, Chahal AS, Debnath F, Haq I, Kalliath A, Kanungo S, Kshatri JS, Lakshmi GGJN, Mitra A, Nirmala AR, Prasad GV, Qurieshi MA, Sahay S, Sangwan RK, Sekar K, Shukla VK, Singh PK, Singh P, Singh R, Varma DS, Viramgami A, Panda S, Reddy DCS, Bhargava B; ICMR Serosurveillance Group. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health 2021;9:e257-66. [PMID: 33515512 DOI: 10.1016/S2214-109X(20)30544-1] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 47.0] [Reference Citation Analysis]
292 Busa F, Bardanzellu F, Pintus MC, Fanos V, Marcialis MA. COVID-19 and School: To Open or Not to Open, That Is the Question. The First Review on Current Knowledge. Pediatr Rep 2021;13:257-78. [PMID: 34205837 DOI: 10.3390/pediatric13020035] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Ma KC, Menkir TF, Kissler S, Grad YH, Lipsitch M. Modeling the impact of racial and ethnic disparities on COVID-19 epidemic dynamics. Elife 2021;10:e66601. [PMID: 34003112 DOI: 10.7554/eLife.66601] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
294 Brunner J, Chia N. Confidence in the dynamic spread of epidemics under biased sampling conditions. PeerJ 2020;8:e9758. [PMID: 32864224 DOI: 10.7717/peerj.9758] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
295 Keeling MJ, Dyson L, Guyver-Fletcher G, Holmes A, Semple MG, Tildesley MJ, Hill EM; ISARIC4C Investigators. Fitting to the UK COVID-19 outbreak, short-term forecasts and estimating the reproductive number. Stat Methods Med Res 2022;:9622802211070257. [PMID: 35037796 DOI: 10.1177/09622802211070257] [Reference Citation Analysis]
296 Romay-Barja M, Pascual-Carrasco M, De Tena-Dávila MJ, Falcón M, Rodriguez-Blazquez C, Forjaz MJ, Ayala A, Molina-de la Fuente I, Burgos A, Muñoz A, Benito A. How patients with COVID-19 managed the disease at home during the first wave in Spain: a cross-sectional study. BMJ Open 2021;11:e048702. [PMID: 34016666 DOI: 10.1136/bmjopen-2021-048702] [Reference Citation Analysis]
297 Jeewandara C, Guruge D, Abyrathna IS, Danasekara S, Gunasekera B, Pushpakumara PD, Madhusanka D, Jayathilaka D, Ranasinghe T, Somathilake G, Tanussiya S, Jayadas TT, Kuruppu H, Thashmi N, Harvie M, Wijayamuni R, Schimanski L, Tan TK, Rijal P, Xiao J, Ogg GS, Townsend A, Malavige GN. Seroprevalence of SARS-CoV-2 Infection in the Colombo Municipality Region, Sri Lanka. Front Public Health 2021;9:724398. [PMID: 34869146 DOI: 10.3389/fpubh.2021.724398] [Reference Citation Analysis]
298 van den Broek-Altenburg EM, Atherly AJ, Diehl SA, Gleason KM, Hart VC, MacLean CD, Barkhuff DA, Levine MA, Carney JK. Jobs, Housing, and Mask Wearing: Cross-Sectional Study of Risk Factors for COVID-19. JMIR Public Health Surveill 2021;7:e24320. [PMID: 33315576 DOI: 10.2196/24320] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
299 Stringhini S, Zaballa ME, Pullen N, de Mestral C, Perez-Saez J, Dumont R, Picazio A, Pennacchio F, Dibner Y, Yerly S, Baysson H, Vuilleumier N, Balavoine JF, Bachmann D, Trono D, Pittet D, Chappuis F, Kherad O, Kaiser L, Azman AS, Guessous I; SEROCoV-WORK + Study Group. Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland. Nat Commun 2021;12:3455. [PMID: 34103517 DOI: 10.1038/s41467-021-23796-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
300 Rai B, Shukla A, Dwivedi LK. Incubation period for COVID-19: a systematic review and meta-analysis. Z Gesundh Wiss 2021;:1-8. [PMID: 33643779 DOI: 10.1007/s10389-021-01478-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
301 Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan B C, Neelima S, Jawahar Reddy KS, Radhakrishnan J, Lewnard JA. Epidemiology and transmission dynamics of COVID-19 in two Indian states. Science 2020;370:691-7. [PMID: 33154136 DOI: 10.1126/science.abd7672] [Cited by in Crossref: 148] [Cited by in F6Publishing: 122] [Article Influence: 74.0] [Reference Citation Analysis]
302 Ramos A, Cardoso MJ, Ribeiro L, Guimarães JT. Assessing SARS-CoV-2 Neutralizing Antibodies after BNT162b2 Vaccination and Their Correlation with SARS-CoV-2 IgG Anti-S1, Anti-RBD and Anti-S2 Serological Titers. Diagnostics 2022;12:205. [DOI: 10.3390/diagnostics12010205] [Reference Citation Analysis]
303 Meyerowitz EA, Richterman A, Bogoch II, Low N, Cevik M. Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2. Lancet Infect Dis. 2020;. [PMID: 33301725 DOI: 10.1016/s1473-3099(20)30837-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 33] [Article Influence: 26.0] [Reference Citation Analysis]
304 Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson MR, Bradshaw C, Weinkauf CC, Bime C, Erickson HL, Knox K, Bixby B, Parthasarathy S, Chaudhary S, Natt B, Cristan E, El Aini T, Rischard F, Campion J, Chopra M, Insel M, Sam A, Knepler JL, Capaldi AP, Spier CM, Dake MD, Edwards T, Kaplan ME, Scott SJ, Hypes C, Mosier J, Harris DT, LaFleur BJ, Sprissler R, Nikolich-Žugich J, Bhattacharya D. Orthogonal SARS-CoV-2 Serological Assays Enable Surveillance of Low-Prevalence Communities and Reveal Durable Humoral Immunity. Immunity 2020;53:925-933.e4. [PMID: 33129373 DOI: 10.1016/j.immuni.2020.10.004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 129] [Article Influence: 72.5] [Reference Citation Analysis]
305 Naiyar I, Anjum AF, Khalid AM, Noor I, Abdullah MS, Anwar MZ. Seroprevalence of COVID-19 and associated factors in a medical institution in Pakistan. J Taibah Univ Med Sci 2021;16:619-23. [PMID: 34093105 DOI: 10.1016/j.jtumed.2021.04.004] [Reference Citation Analysis]
306 Ridgway J. Covid and data science: Understanding R0 could change your life. Teaching Statistics 2021;43. [DOI: 10.1111/test.12273] [Reference Citation Analysis]
307 Farronato M, Dolci C, Boccalari E, Izadi S, Salvatierra Rios LH, Festa M, Panetta V, De Vito D, Tartaglia GM. Serological Profile of Children and Young Adults with at Least One SARS-CoV-2 Positive Cohabitant: An Observational Study. Int J Environ Res Public Health 2021;18:1488. [PMID: 33557402 DOI: 10.3390/ijerph18041488] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
308 Fiore VG, DeFelice N, Glicksberg BS, Perl O, Shuster A, Kulkarni K, O'Brien M, Pisauro MA, Chung D, Gu X. Containment of COVID-19: Simulating the impact of different policies and testing capacities for contact tracing, testing, and isolation. PLoS One 2021;16:e0247614. [PMID: 33788852 DOI: 10.1371/journal.pone.0247614] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
309 Della Valle P, Fabbri M, Madotto F, Ferrara P, Cozzolino P, Calabretto E, D'Orso MI, Longhi E, Polosa R, Riva MA, Mazzaglia G, Sommese C, Mantovani LG, The Mustang-Occupation-Covid-Study Group. Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG-OCCUPATION-COVID-19 Study. Int J Environ Res Public Health 2021;18:2567. [PMID: 33806578 DOI: 10.3390/ijerph18052567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
310 Klein C, Borsche M, Balck A, Föh B, Rahmöller J, Peters E, Knickmann J, Lane M, Vollstedt EJ, Elsner SA, Käding N, Hauswaldt S, Lange T, Hundt JE, Lehrian S, Giese J, Mischnik A, Niemann S, Maurer F, Homolka S, Paulowski L, Kramer J, Twesten C, Sina C, Gillessen-Kaesbach G, Busch H, Ehlers M, Taube S, Rupp J, Katalinic A. One-year surveillance of SARS-CoV-2 transmission of the ELISA cohort: A model for population-based monitoring of infection risk. Sci Adv 2022;8:eabm5016. [PMID: 35427158 DOI: 10.1126/sciadv.abm5016] [Reference Citation Analysis]
311 Brito-Zerón P, Gracia-Tello B, Robles A, Alguacil A, Bonet M, De-Escalante B, Noblejas-Mosso A, Gómez-de-la-Torre R, Akasbi M, Pérez-de-Lis M, Pérez-Alvarez R, Ramos-Casals M, On Behalf Of The SarcoGEAS-Semi Registry. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses 2021;13:1000. [PMID: 34071924 DOI: 10.3390/v13061000] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
312 Barreiro NL, Govezensky T, Bolcatto PG, Barrio RA. Detecting infected asymptomatic cases in a stochastic model for spread of Covid-19: the case of Argentina. Sci Rep 2021;11:10024. [PMID: 33976342 DOI: 10.1038/s41598-021-89517-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
313 Osayomi T, Adeleke R, Taiwo OJ, Gbadegesin AS, Fatayo OC, Akpoterai LE, Ayanda JT, Moyin-jesu J, Isioye A. Cross-national variations in COVID-19 outbreak in West Africa: Where does Nigeria stand in the pandemic? Spat Inf Res 2021;29:535-43. [DOI: 10.1007/s41324-020-00371-5] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
314 V MS, A CM, A BG, F VS, A SF, V OQ, A SC; COVID-19 Group of the Spanish Society of Primary Care Physicians (SEMERGEN). Analysis of case fatality rate of SARS-CoV-2 infection in the Spanish Autonomous Communities between March and May 2020. PLoS One 2021;16:e0260769. [PMID: 34860848 DOI: 10.1371/journal.pone.0260769] [Reference Citation Analysis]
315 Vial P, González C, Icaza G, Ramirez-santana M, Quezada-gaete R, Núñez-franz L, Apablaza M, Vial C, Rubilar P, Correa J, Pérez C, Florea A, Guzmán E, Lavín M, Concha P, Nájera M, Aguilera X. Seroprevalence, spatial distribution, and social determinants of SARS-CoV-2 in three urban centers of Chile. BMC Infect Dis 2022;22. [DOI: 10.1186/s12879-022-07045-7] [Reference Citation Analysis]
316 Herrera-Esposito D, de Los Campos G. Age-specific rate of severe and critical SARS-CoV-2 infections estimated with multi-country seroprevalence studies. BMC Infect Dis 2022;22:311. [PMID: 35351016 DOI: 10.1186/s12879-022-07262-0] [Reference Citation Analysis]
317 Gonzalez-Mendez R, Díaz M. Volunteers' compassion fatigue, compassion satisfaction, and post-traumatic growth during the SARS-CoV-2 lockdown in Spain: Self-compassion and self-determination as predictors. PLoS One 2021;16:e0256854. [PMID: 34469473 DOI: 10.1371/journal.pone.0256854] [Reference Citation Analysis]
318 Findeisen P, Stiegler H, Lopez-Calle E, Schneider T, Urlaub E, Hayer J, Zemmrich C. Clinical performance evaluation of a SARS-CoV-2 Rapid Antibody Test for determining past exposure to SARS-CoV-2. Int J Infect Dis 2021;103:636-41. [PMID: 33227517 DOI: 10.1016/j.ijid.2020.11.164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
319 Mirò Ò, Sabaté M, Jiménez S, Mebazaa A, Martínez-Nadal G, Piñera P, Burillo-Putze G, Martín A, Martín-Sánchez FJ, Jacob J, Alquézar-Arbé A, García-Lamberechts EJ, Llorens P, González Del Castillo J; Spanish Investigators on Emergency Situations TeAm (SIESTA) network., SIESTA network. A case-control, multicentre study of consecutive patients with COVID-19 and acute (myo)pericarditis: incidence, risk factors, clinical characteristics and outcomes. Emerg Med J 2022:emermed-2020-210977. [PMID: 35304388 DOI: 10.1136/emermed-2020-210977] [Reference Citation Analysis]
320 Atchison C, Pristerà P, Cooper E, Papageorgiou V, Redd R, Piggin M, Flower B, Fontana G, Satkunarajah S, Ashrafian H, Lawrence-Jones A, Naar L, Chigwende J, Gibbard S, Riley S, Darzi A, Elliott P, Ashby D, Barclay W, Cooke GS, Ward H. Usability and Acceptability of Home-based Self-testing for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies for Population Surveillance. Clin Infect Dis 2021;72:e384-93. [PMID: 32785665 DOI: 10.1093/cid/ciaa1178] [Cited by in Crossref: 12] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
321 Ristić M, Milosavljević B, Vapa S, Marković M, Petrović V. Seroprevalence of antibodies against SARS-CoV-2 virus in Northern Serbia (Vojvodina): A four consecutive sentinel population-based survey study. PLoS One 2021;16:e0254516. [PMID: 34242377 DOI: 10.1371/journal.pone.0254516] [Reference Citation Analysis]
322 Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, Redd R, Ashby D, Donnelly CA, Barclay W, Darzi A, Cooke G, Riley S, Elliott P. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat Commun 2021;12:905. [PMID: 33568663 DOI: 10.1038/s41467-021-21237-w] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 40.0] [Reference Citation Analysis]
323 Viana K, Zarpelon L, Leandro A, Terencio M, Lopes R, Martins C, Silva I, Sibim A, Marques F, da Silva R, Rivas A, Souza A, Dos-Santos A, Torres S, Garcia M, Giunchetti R, Chiba-de-Castro W. Infection in asymptomatic carriers of SARS-CoV-2 can interfere with the achievement of robust immunity on a population scale. J Gen Virol 2021;102. [PMID: 34788210 DOI: 10.1099/jgv.0.001684] [Reference Citation Analysis]
324 Sughayer MA, Mansour A, Al Nuirat A, Souan L, Ghanem M, Siag M. Dramatic rise in seroprevalence rates of SARS-CoV-2 antibodies among healthy blood donors: The evolution of a pandemic. Int J Infect Dis 2021;107:116-20. [PMID: 33892190 DOI: 10.1016/j.ijid.2021.04.059] [Reference Citation Analysis]
325 Albuquerque JOM, Kamioka GA, Madalosso G, Costa SA, Ferreira PB, Pino FA, Sato APS, Carvalho ACA, Amorim ABP, Aires CC, Kataoka APAG, Savani ESMM, Bessa TAF, Aguiar BS, Failla MA, Santos EAD, Brito EMT, Santos MCHD, Silva SMSE, Caldeira LAV, Zamarco LC, Fonseca SMS, Lima MMC, Marques IA, Silva FÉVD, Glasser PR, Burihan PCPR, Cavazzana CL, Mello DS, Pellini ACG, Nishio FY, Kian FM, Braga ES, Bertelli NMP, Fracini W, Gonçalves MDÁ, Zular PS, Piva RS, Masi E. Prevalence evolution of SARS-CoV-2 infection in the city of São Paulo, 2020-2021. Rev Saude Publica 2021;55:62. [PMID: 34706038 DOI: 10.11606/s1518-8787.2021055003970] [Reference Citation Analysis]
326 Elyanow R, Snyder TM, Dalai SC, Gittelman RM, Boonyaratanakornkit J, Wald A, Selke S, Wener MH, Morishima C, Greninger AL, Holbrook MR, Kaplan IM, Zahid HJ, Carlson JM, Baldo L, Manley T, Robins HS, Koelle DM. T-cell receptor sequencing identifies prior SARS-CoV-2 infection and correlates with neutralizing antibody titers and disease severity. medRxiv 2021:2021. [PMID: 33791723 DOI: 10.1101/2021.03.19.21251426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Feikin DR, Widdowson MA, Mulholland K. Estimating the Percentage of a Population Infected with SARS-CoV-2 Using the Number of Reported Deaths: A Policy Planning Tool. Pathogens 2020;9:E838. [PMID: 33066231 DOI: 10.3390/pathogens9100838] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
328 Li X, Xu W, Dozier M, He Y, Kirolos A, Lang Z, Song P, Theodoratou E; UNCOVER. The role of children in the transmission of SARS-CoV2: updated rapid review. J Glob Health 2020;10:021101. [PMID: 33312511 DOI: 10.7189/jogh.10.021101] [Cited by in F6Publishing: 11] [Reference Citation Analysis]
329 Wilkins JT, Gray EL, Wallia A, Hirschhorn LR, Zembower TR, Ho J, Kalume N, Agbo O, Zhu A, Rasmussen-Torvik LJ, Khan SS, Carnethon M, Huffman M, Evans CT. Seroprevalence and Correlates of SARS-CoV-2 Antibodies in Health Care Workers in Chicago. Open Forum Infect Dis 2021;8:ofaa582. [PMID: 33447642 DOI: 10.1093/ofid/ofaa582] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
330 Barrett TJ, Patterson KC, James TM, Krüger P. Impact of reduction of susceptibility to SARS-CoV-2 on epidemic dynamics in four early-seeded metropolitan regions. Sci Rep 2021;11:12213. [PMID: 34108496 DOI: 10.1038/s41598-021-91247-7] [Reference Citation Analysis]
331 Tadesse EB, Endris AA, Solomon H, Alayu M, Kebede A, Eshetu K, Teka G, Seid BE, Ahmed J, Abayneh SA, Moges B, Gerawork H, Sugerman D, Assefa Z, Abayneh A, Abate E, Taddese L. Seroprevalence and risk factors for SARS-CoV-2 Infection in selected urban areas in Ethiopia: a cross-sectional evaluation during July 2020. Int J Infect Dis 2021;111:179-85. [PMID: 34411720 DOI: 10.1016/j.ijid.2021.08.028] [Reference Citation Analysis]
332 Martin J, Klapsa D, Wilton T, Zambon M, Bentley E, Bujaki E, Fritzsche M, Mate R, Majumdar M. Tracking SARS-CoV-2 in Sewage: Evidence of Changes in Virus Variant Predominance during COVID-19 Pandemic. Viruses 2020;12:E1144. [PMID: 33050264 DOI: 10.3390/v12101144] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 23.5] [Reference Citation Analysis]
333 Carballada AM, Balsa-barreiro J. Geospatial Analysis and Mapping Strategies for Fine-Grained and Detailed COVID-19 Data with GIS. IJGI 2021;10:602. [DOI: 10.3390/ijgi10090602] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Salzberger B, Buder F, Lampl BT, Ehrenstein B, Hitzenbichler F, Holzmann T, Schmidt B, Hanses F. [Epidemiology of SARS-CoV-2/COVID-19]. Gastroenterologe 2020;:1-7. [PMID: 33144889 DOI: 10.1007/s11377-020-00479-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
335 Gong X, Cui P, Wu H, Pan H, Teng Z, Yuan F, Mao S, Kong D, Han R, Zhao X, Zheng Y, Xiao W, Zhu Y, Fang Q, Lin S, Jin B, Chu R, Jiang C, Yu X, Qiu Q, Lu Y, Wang W, Fu C, Sun X. Long-term immune responses in patients with confirmed novel coronavirus disease-2019: a 9-month prospective cohort study in Shanghai, China. BMC Infect Dis 2022;22:240. [PMID: 35272627 DOI: 10.1186/s12879-022-07173-0] [Reference Citation Analysis]
336 Kahre E, Galow L, Unrath M, Haag L, Blankenburg J, Dalpke AH, Lück C, Berner R, Armann JP. Kinetics and seroprevalence of SARS-CoV-2 antibodies: a comparison of 3 different assays. Sci Rep 2021;11:14893. [PMID: 34290329 DOI: 10.1038/s41598-021-94453-5] [Reference Citation Analysis]
337 Sarría-santamera A, Abdukadyrov N, Glushkova N, Russell Peck D, Colet P, Yeskendir A, Asúnsolo A, Ortega MA. Towards an Accurate Estimation of COVID-19 Cases in Kazakhstan: Back-Casting and Capture–Recapture Approaches. Medicina 2022;58:253. [DOI: 10.3390/medicina58020253] [Reference Citation Analysis]
338 Morikane K, Satoh N, Hatano K, Kanouchi K, Kakehata S, Satoh S, Uyeki TM, Ueno Y. Seroepidemiology of SARS-CoV-2, Yamagata, Japan, June 2020. Western Pac Surveill Response J 2021;12:69-71. [PMID: 34094628 DOI: 10.5365/wpsar.2020.11.3.012] [Reference Citation Analysis]
339 Anderson RM, Vegvari C, Hollingsworth TD, Pi L, Maddren R, Ng CW, Baggaley RF. The SARS-CoV-2 pandemic: remaining uncertainties in our understanding of the epidemiology and transmission dynamics of the virus, and challenges to be overcome. Interface Focus 2021;11:20210008. [PMID: 34956588 DOI: 10.1098/rsfs.2021.0008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
340 Pérez-Tanoira R, Lledó García L, Torralba González de Suso M, Rodríguez Zapata M, Arroyo Serrano T, Giménez Pardo C, Rodríguez Pedrosa MI, Romero Badía MN, Pérez-García F, González López P, Villaescusa García C, Cuadros González J. High Seroprevalence Against SARS-CoV-2 Among Faculty of Medicine and Health Sciences Personnel and Students of the University of Alcalá, Spain: Contributing Factors. Int J Gen Med 2021;14:7017-24. [PMID: 34707393 DOI: 10.2147/IJGM.S332803] [Reference Citation Analysis]
341 Kabir H, Hasan MK, Bhuya MTR. Recommendations for school-going students post CoVid-19 in Bangladesh. Bioinformation 2021;17:500-5. [PMID: 34602777 DOI: 10.6026/97320630017500] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
342 Hicks SM, Pohl K, Neeman T, McNamara HA, Parsons KM, He JS, Ali SA, Nazir S, Rowntree LC, Nguyen THO, Kedzierska K, Doolan DL, Vinuesa CG, Cook MC, Coatsworth N, Myles PS, Kurth F, Sander LE, Mann GJ, Gruen RL, George AJ, Gardiner EE, Cockburn IA; SARS-CoV-2 Testing in Elective Surgery Collaborators. A Dual-Antigen Enzyme-Linked Immunosorbent Assay Allows the Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Seroprevalence in a Low-Transmission Setting. J Infect Dis 2021;223:10-4. [PMID: 33009908 DOI: 10.1093/infdis/jiaa623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
343 Paleker M, Tembo YA, Davies MA, Mahomed H, Pienaar D, Madhi SA, McCarthy K. Asymptomatic COVID-19 in South Africa - implications for the control of transmission. Public Health Action 2021;11:58-60. [PMID: 34159063 DOI: 10.5588/pha.20.0069] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
344 Garcia-Agundez A, Ojo O, Hernández-Roig HA, Baquero C, Frey D, Georgiou C, Goessens M, Lillo RE, Menezes R, Nicolaou N, Ortega A, Stavrakis E, Fernandez Anta A. Estimating the COVID-19 Prevalence in Spain With Indirect Reporting via Open Surveys. Front Public Health 2021;9:658544. [PMID: 33898383 DOI: 10.3389/fpubh.2021.658544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
345 Cushnan D, Bennett O, Berka R, Bertolli O, Chopra A, Dorgham S, Favaro A, Ganepola T, Halling-Brown M, Imreh G, Jacob J, Jefferson E, Lemarchand F, Schofield D, Wyatt JC; NCCID Collaborative. An overview of the National COVID-19 Chest Imaging Database: data quality and cohort analysis. Gigascience 2021;10:giab076. [PMID: 34849869 DOI: 10.1093/gigascience/giab076] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
346 Milhinhos A, Costa PM. On the Progression of COVID-19 in Portugal: A Comparative Analysis of Active Cases Using Non-linear Regression. Front Public Health 2020;8:495. [PMID: 33014981 DOI: 10.3389/fpubh.2020.00495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
347 Colmenares-Mejía CC, Serrano-Díaz N, Quintero-Lesmes DC, Meneses L, Salazar Acosta I, Idrovo ÁJ, Sanabria-Echeverry DY, Cordero-Rebolledo H, Castillo V. Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia. Int J Environ Res Public Health 2021;18:4172. [PMID: 33920843 DOI: 10.3390/ijerph18084172] [Reference Citation Analysis]
348 Rodríguez-Rey R, Garrido-Hernansaiz H, Bueno-Guerra N. Working in the Times of COVID-19. Psychological Impact of the Pandemic in Frontline Workers in Spain. Int J Environ Res Public Health 2020;17:E8149. [PMID: 33158180 DOI: 10.3390/ijerph17218149] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
349 Furuse Y, Oshitani H. Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2. Front Microbiol 2020;11:583252. [PMID: 33042101 DOI: 10.3389/fmicb.2020.583252] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
350 Namasivayam V, Jain A, Agrawal V, Prakash R, Dehury B, Becker M, Blanchard J, Isac S, Prasad AM. Understanding the Prevalence and Geographic Heterogeneity of SARS-CoV-2 Infection: Findings of the First Serosurvey in Uttar Pradesh, India. J Epidemiol Glob Health 2021;11:364-76. [PMID: 34734386 DOI: 10.1007/s44197-021-00012-6] [Reference Citation Analysis]
351 Contreras S, Dehning J, Mohr SB, Bauer S, Spitzner FP, Priesemann V. Low case numbers enable long-term stable pandemic control without lockdowns. Sci Adv 2021;7:eabg2243. [PMID: 34623913 DOI: 10.1126/sciadv.abg2243] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
352 Pérez-olmeda M, Saugar JM, Fernández-garcía A, Pérez-gómez B, Pollán M, Avellón A, Pastor-barriuso R, Larrea NF, Martín M, Cruz I, Sanmartín JL, Fedele G, Paniagua JL, Muñoz-montalvo JF, Blanco F, Yotti R, Oteo-iglesias J. Evolution of antibodies against SARS-CoV-2 over seven months: experience of the Nationwide Seroprevalence ENE-COVID Study in Spain. Journal of Clinical Virology 2022. [DOI: 10.1016/j.jcv.2022.105130] [Reference Citation Analysis]
353 O'Hare AM, Berry K, Fan VS, Crothers K, Eastment MC, Dominitz JA, Shah JA, Green P, Locke E, Ioannou GN. Age differences in the association of comorbid burden with adverse outcomes in SARS-CoV-2. BMC Geriatr 2021;21:415. [PMID: 34229623 DOI: 10.1186/s12877-021-02340-5] [Reference Citation Analysis]
354 Domenech de Cellès M, Casalegno JS, Lina B, Opatowski L. Estimating the impact of influenza on the epidemiological dynamics of SARS-CoV-2. PeerJ 2021;9:e12566. [PMID: 34950537 DOI: 10.7717/peerj.12566] [Reference Citation Analysis]
355 Stringari LL, de Souza MN, de Medeiros Junior NF, Goulart JP, Giuberti C, Dietze R, Ribeiro-Rodrigues R. Covert cases of Severe Acute Respiratory Syndrome Coronavirus 2: An obscure but present danger in regions endemic for Dengue and Chikungunya viruses. PLoS One 2021;16:e0244937. [PMID: 33406122 DOI: 10.1371/journal.pone.0244937] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
356 Claro F, Silva D, Rodriguez M, Rangel R, de Waard JH. IgG Antibody response to the Sputnik V vaccine: previous SARS-CoV-2 seropositive individuals might need just one vaccine dose. Int J Infect Dis 2021:S1201-9712(21)00626-3. [PMID: 34343704 DOI: 10.1016/j.ijid.2021.07.070] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
357 Franceschi VB, Santos AS, Glaeser AB, Paiz JC, Caldana GD, Machado Lessa CL, de Menezes Mayer A, Küchle JG, Gazzola Zen PR, Vigo A, Winck AT, Rotta LN, Thompson CE. Population-based prevalence surveys during the Covid-19 pandemic: A systematic review. Rev Med Virol 2021;31:e2200. [PMID: 34260777 DOI: 10.1002/rmv.2200] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
358 Buss LF, Prete CA Jr, Abrahim CMM, Mendrone A Jr, Salomon T, de Almeida-Neto C, França RFO, Belotti MC, Carvalho MPSS, Costa AG, Crispim MAE, Ferreira SC, Fraiji NA, Gurzenda S, Whittaker C, Kamaura LT, Takecian PL, da Silva Peixoto P, Oikawa MK, Nishiya AS, Rocha V, Salles NA, de Souza Santos AA, da Silva MA, Custer B, Parag KV, Barral-Netto M, Kraemer MUG, Pereira RHM, Pybus OG, Busch MP, Castro MC, Dye C, Nascimento VH, Faria NR, Sabino EC. Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 2021;371:288-92. [PMID: 33293339 DOI: 10.1126/science.abe9728] [Cited by in Crossref: 183] [Cited by in F6Publishing: 136] [Article Influence: 91.5] [Reference Citation Analysis]
359 Llorca J, Lechosa-Muñiz C, Lasarte-Oria L, Cuesta-González R, López-Hoyos M, Gortázar P, Gómez-Acebo I, Dierssen-Sotos T, Cabero-Pérez MJ, The Moacc-Group. Influence of Socioeconomic Status on SARS-CoV-2 Infection in Spanish Pregnant Women. The MOACC-19 Cohort. Int J Environ Res Public Health 2021;18:5133. [PMID: 34066163 DOI: 10.3390/ijerph18105133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
360 Bajracharya S, Shrestha A, Rajbhandari B. Symptoms of COVID-19 Confirmed Cases Presenting to Emergency Department in a Tertiary Care Centre: A Descriptive Cross-sectional Study. JNMA J Nepal Med Assoc 2020;58:1041-5. [PMID: 34506378 DOI: 10.31729/jnma.5519] [Reference Citation Analysis]
361 Joshi K, Rumpler E, Kennedy-Shaffer L, Bosan R, Lipsitch M. Comparative performance of between-population allocation strategies for SARS-CoV-2 vaccines. medRxiv 2021:2021. [PMID: 34212161 DOI: 10.1101/2021.06.18.21259137] [Reference Citation Analysis]
362 Swaminathan A, Subramanian SV. Reflections on designing population surveys for COVID-19 infection and prevalence. Geroscience 2020;42:1445-8. [PMID: 32809094 DOI: 10.1007/s11357-020-00253-6] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
363 Fernandez-Fuertes M, Corma-Gomez A, Torres E, Rodriguez-Pineda E, Fuentes-Lopez A, Rincon P, Fernandez N, Garcia F, Bernal S, Real LM, Macias J, Pineda JA. Incidence of and factors associated with SARS-CoV-2 infection among people living with HIV in Southern Spain after one year of pandemic. Transbound Emerg Dis 2021. [PMID: 34405560 DOI: 10.1111/tbed.14293] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
364 Woskie LR, Hennessy J, Espinosa V, Tsai TC, Vispute S, Jacobson BH, Cattuto C, Gauvin L, Tizzoni M, Fabrikant A, Gadepalli K, Boulanger A, Pearce A, Kamath C, Schlosberg A, Stanton C, Bavadekar S, Abueg M, Hogue M, Oplinger A, Chou K, Corrado G, Shekel T, Jha AK, Wellenius GA, Gabrilovich E. Early social distancing policies in Europe, changes in mobility & COVID-19 case trajectories: Insights from Spring 2020. PLoS One 2021;16:e0253071. [PMID: 34191818 DOI: 10.1371/journal.pone.0253071] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
365 Melka AB, Louzoun Y. Evaluation of the number of undiagnosed infected in an outbreak using source of infection measurements. Sci Rep 2021;11:3601. [PMID: 33574387 DOI: 10.1038/s41598-021-82691-6] [Reference Citation Analysis]
366 Chunchu SR, Ravula U, Gente VK, Bacchu S, Pandu Ranga Rao S, Mooli S. SARS-CoV-2 Seroprevalence Among Whole Blood Donors During First Wave of Covid-19 Pandemic in India. Indian J Hematol Blood Transfus. [DOI: 10.1007/s12288-021-01512-y] [Reference Citation Analysis]
367 Bubba L, Simmonds P, Fischer TK, Harvala H. Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020. J Glob Health 2021;11:05014. [PMID: 34408857 DOI: 10.7189/jogh.11.05014] [Reference Citation Analysis]
368 Gelanew T, Seyoum B, Mulu A, Mihret A, Abebe M, Wassie L, Gelaw B, Sorsa A, Merid Y, Muchie Y, Teklemariam Z, Tesfaye B, Osman M, Jebessa G, Atinafu A, Hailu T, Habte A, Kenea D, Gadissa A, Admasu D, Tesfaye E, Bates TA, Bulcha J, Tschopp R, Tsehay D, Mullholand K, Howe R, Genetu A, Tafesse FG, Abdissa A. High Seroprevalence of Anti-SARS-CoV-2 Antibodies Among Ethiopian Healthcare Workers. Res Sq 2021:rs. [PMID: 34312618 DOI: 10.21203/rs.3.rs-676935/v1] [Reference Citation Analysis]
369 Bogogiannidou Z, Vontas A, Dadouli K, Kyritsi MA, Soteriades S, Nikoulis DJ, Mouchtouri VΑ, Koureas M, Kazakos EI, Spanos EG, Gioula G, Ntzani EE, Eleftheriou AA, Vatopoulos A, Petinaki E, Papaevangelou V, Speletas M, Tsiodras S, Hadjichristodoulou C. Repeated leftover serosurvey of SARS-CoV-2 IgG antibodies, Greece, March and April 2020. Euro Surveill 2020;25. [PMID: 32762796 DOI: 10.2807/1560-7917.ES.2020.25.31.2001369] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 14.5] [Reference Citation Analysis]
370 Munoz Mendoza J, Alcaide ML. COVID-19 in a patient with end-stage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing. IDCases 2020;22:e00943. [PMID: 32923364 DOI: 10.1016/j.idcr.2020.e00943] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
371 Mas JF, Pérez-Vega A. Spatiotemporal patterns of the COVID-19 epidemic in Mexico at the municipality level. PeerJ 2021;9:e12685. [PMID: 35036159 DOI: 10.7717/peerj.12685] [Reference Citation Analysis]
372 Díaz-Vélez C, Failoc-Rojas VE, Valladares-Garrido MJ, Colchado J, Carrera-Acosta L, Becerra M, Moreno Paico D, Ocampo-Salazar ET. SARS-CoV-2 seroprevalence study in Lambayeque, Peru. June-July 2020. PeerJ 2021;9:e11210. [PMID: 33868828 DOI: 10.7717/peerj.11210] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
373 Hippich M, Holthaus L, Assfalg R, Zapardiel-Gonzalo J, Kapfelsperger H, Heigermoser M, Haupt F, Ewald DA, Welzhofer TC, Marcus BA, Heck S, Koelln A, Stock J, Voss F, Secchi M, Piemonti L, de la Rosa K, Protzer U, Boehmer M, Achenbach P, Lampasona V, Bonifacio E, Ziegler AG. A Public Health Antibody Screening Indicates a 6-Fold Higher SARS-CoV-2 Exposure Rate than Reported Cases in Children. Med (N Y) 2021;2:149-163.e4. [PMID: 33163984 DOI: 10.1016/j.medj.2020.10.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 11.0] [Reference Citation Analysis]
374 Martinez EZ, Passos ADC, Fabbro ALD, Silva ASD, Escarso AC, Pazin-Filho A, Fonseca BALD, Maciel BC, Araújo DCAE, Clé DV, Gaspar GG, Santos JLFD, Ferreira JBB, Souza JP, Mello LM, Santos LLD, Passos LMR, Siconelli MJL, Cavalli RC, Santana RC, Calado RDT, Scarpelini S, Bollela VR, Floriano VG, Bellissimo-Rodrigues F. Prevalence of virological and serological markers of SARS-CoV-2 infection in the population of Ribeirão Preto, Southeast Brazil: an epidemiological survey. Rev Soc Bras Med Trop 2021;54:e02102021. [PMID: 34231775 DOI: 10.1590/0037-8682-0210-2021] [Reference Citation Analysis]
375 Moreno López JA, Arregui García B, Bentkowski P, Bioglio L, Pinotti F, Boëlle PY, Barrat A, Colizza V, Poletto C. Anatomy of digital contact tracing: Role of age, transmission setting, adoption, and case detection. Sci Adv 2021;7:eabd8750. [PMID: 33712416 DOI: 10.1126/sciadv.abd8750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
376 Louca S. SARS-CoV-2 infections in 165 countries over time. Int J Infect Dis 2021;111:336-46. [PMID: 34487852 DOI: 10.1016/j.ijid.2021.08.067] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
377 Silva AAMD, Lima-Neto LG, Azevedo CMPES, Costa LMMD, Bragança MLBM, Barros Filho AKD, Wittlin BB, Souza BF, Oliveira BLCA, Carvalho CA, Thomaz EBAF, Simões-Neto EA, Leite Júnior JF, Cosme LMSS, Campos MAG, Queiroz RCS, Costa SS, Carvalho VA, Simões VMF, Alves MTSSBE, Santos AMD. Population-based seroprevalence of SARS-CoV-2 and the herd immunity threshold in Maranhão. Rev Saude Publica 2020;54:131. [PMID: 33331525 DOI: 10.11606/s1518-8787.2020054003278] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
378 Sánchez-Cantalejo C, Rueda MDM, Saez M, Enrique I, Ferri R, Fuente M, Villegas R, Castro L, Barceló MA, Daponte-Codina A, Lorusso N, Cabrera-León A. Impact of COVID-19 on the Health of the General and More Vulnerable Population and Its Determinants: Health Care and Social Survey-ESSOC, Study Protocol. Int J Environ Res Public Health 2021;18:8120. [PMID: 34360413 DOI: 10.3390/ijerph18158120] [Reference Citation Analysis]
379 Costa JPD, Meireles P, Rodrigues PNS, Barros H. Incidence of SARS-CoV-2 infection in a cohort of workers from the University of Porto, Portugal. Infect Dis (Lond) 2022;:1-7. [PMID: 35129057 DOI: 10.1080/23744235.2022.2035429] [Reference Citation Analysis]
380 Marian AJ. Editorial: Cardiovascular complications of COVID-19. Curr Opin Cardiol 2021;36:253-5. [PMID: 33605618 DOI: 10.1097/HCO.0000000000000846] [Reference Citation Analysis]
381 Cavataio J, Schnell S. Interpreting SARS-CoV-2 seroprevalence, deaths, and fatality rate - Making a case for standardized reporting to improve communication. Math Biosci 2021;333:108545. [PMID: 33460673 DOI: 10.1016/j.mbs.2021.108545] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
382 Gomaa MR, El Rifay AS, Shehata M, Kandeil A, Nabil Kamel M, Marouf MA, GabAllah M, El Taweel A, Kayed AE, Kutkat O, Moatasim Y, Mahmoud SH, Abo Shama NM, El Sayes M, Mostafa A, El-Shesheny R, McKenzie PP, Webby RJ, Kayali G, Ali MA. Incidence, household transmission, and neutralizing antibody seroprevalence of Coronavirus Disease 2019 in Egypt: Results of a community-based cohort. PLoS Pathog 2021;17:e1009413. [PMID: 33705496 DOI: 10.1371/journal.ppat.1009413] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
383 Santamaría L, Hortal J. COVID-19 effective reproduction number dropped during Spain's nationwide dropdown, then spiked at lower-incidence regions. Sci Total Environ 2021;751:142257. [PMID: 33181975 DOI: 10.1016/j.scitotenv.2020.142257] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 7.5] [Reference Citation Analysis]
384 Levin AT, Jylhävä J, Religa D, Shallcross L. COVID-19 prevalence and mortality in longer-term care facilities. Eur J Epidemiol. [DOI: 10.1007/s10654-022-00861-w] [Reference Citation Analysis]
385 Chavarria-Miró G, Anfruns-Estrada E, Martínez-Velázquez A, Vázquez-Portero M, Guix S, Paraira M, Galofré B, Sánchez G, Pintó RM, Bosch A. Time Evolution of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Wastewater during the First Pandemic Wave of COVID-19 in the Metropolitan Area of Barcelona, Spain. Appl Environ Microbiol 2021;87:e02750-20. [PMID: 33483313 DOI: 10.1128/AEM.02750-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
386 Gozlan Y, Reingold S, Koren R, Halpern O, Regev-Yochay G, Cohen C, Biber A, Picard O, Mendelson E, Lustig Y, Mor O. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses. Epidemiol Infect 2021;149:e153. [PMID: 34372950 DOI: 10.1017/S0950268821001369] [Reference Citation Analysis]
387 Ojeda DS, Gonzalez Lopez Ledesma MM, Pallarés HM, Costa Navarro GS, Sanchez L, Perazzi B, Villordo SM, Alvarez DE, Echavarria M, Oguntuyo KY, Stevens CS, Lee B, Carradori J, Caramelo JJ, Yanovsky MJ, Gamarnik AV; BioBanco Working Group. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina. PLoS Pathog 2021;17:e1009161. [PMID: 33444413 DOI: 10.1371/journal.ppat.1009161] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 14.0] [Reference Citation Analysis]
388 Waldner D, Harrison R, Johnstone J, Saxinger L, Webster D, Sligl W, Blais JM. COVID-19 epidemiology in Canada from January to December 2020: the pre-vaccine era. FACETS 2021;6:760-822. [DOI: 10.1139/facets-2021-0029] [Reference Citation Analysis]
389 Soriano V, Ganado-Pinilla P, Sanchez-Santos M, Gómez-Gallego F, Barreiro P, de Mendoza C, Corral O. Main differences between the first and second waves of COVID-19 in Madrid, Spain. Int J Infect Dis 2021;105:374-6. [PMID: 33684560 DOI: 10.1016/j.ijid.2021.02.115] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
390 Perez-araluce R, Martínez-gonzález MÁ, Gea A, Carlos S. Components of the Mediterranean Diet and Risk of COVID-19. Front Nutr 2022;8:805533. [DOI: 10.3389/fnut.2021.805533] [Reference Citation Analysis]
391 Lai CC, Wang JH, Hsueh PR. Population-based seroprevalence surveys of anti-SARS-CoV-2 antibody: An up-to-date review. Int J Infect Dis 2020;101:314-22. [PMID: 33045429 DOI: 10.1016/j.ijid.2020.10.011] [Cited by in Crossref: 65] [Cited by in F6Publishing: 54] [Article Influence: 32.5] [Reference Citation Analysis]
392 Wu JT, Mei S, Luo S, Leung K, Liu D, Lv Q, Liu J, Li Y, Prem K, Jit M, Weng J, Feng T, Zheng X, Leung GM. A global assessment of the impact of school closure in reducing COVID-19 spread. Philos Trans A Math Phys Eng Sci 2022;380:20210124. [PMID: 34802277 DOI: 10.1098/rsta.2021.0124] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
393 Barreiro NL, Ventura CI, Govezensky T, Núñez M, Bolcatto PG, Barrio RA. Strategies for COVID-19 vaccination under a shortage scenario: a geo-stochastic modelling approach. Sci Rep 2022;12. [DOI: 10.1038/s41598-022-05481-8] [Reference Citation Analysis]
394 Golec M, Fronczek M, Zembala-john J, Chrapiec M, Konka A, Wystyrk K, Botor H, Brzoza Z, Kasperczyk S, Bułdak RJ. Early and Longitudinal Humoral Response to the SARS-CoV-2 mRNA BNT162b2 Vaccine in Healthcare Workers: Significance of BMI, Adipose Tissue and Muscle Mass on Long-Lasting Post-Vaccinal Immunity. Viruses 2022;14:868. [DOI: 10.3390/v14050868] [Reference Citation Analysis]
395 Hoffman T, Kolstad L, Rönnberg B, Lundkvist Å. Evaluation of Production Lots of a Rapid Point-of-Care Lateral Flow Serological Test Intended for Identification of IgM and IgG against the N-Terminal Part of the Spike Protein (S1) of SARS-CoV-2. Viruses 2021;13:1043. [PMID: 34072890 DOI: 10.3390/v13061043] [Reference Citation Analysis]
396 Backer JA, Mollema L, Vos ER, Klinkenberg D, van der Klis FR, de Melker HE, van den Hof S, Wallinga J. Impact of physical distancing measures against COVID-19 on contacts and mixing patterns: repeated cross-sectional surveys, the Netherlands, 2016-17, April 2020 and June 2020. Euro Surveill 2021;26. [PMID: 33632374 DOI: 10.2807/1560-7917.ES.2021.26.8.2000994] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
397 Nogueira López J, Grasa Lozano C, Ots Ruiz C, Alonso García L, Falces-Romero I, Calvo C, García-López Hortelano M; Grupo de Trabajo de SARS-CoV-2 del Servicio de Pediatría del Hospital Universitario La Paz. [Telemedicine follow-ups for COVID-19: Experience in a tertiary hospital]. An Pediatr (Engl Ed) 2020:S1695-4033(20)30476-8. [PMID: 33328150 DOI: 10.1016/j.anpedi.2020.10.017] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
398 Milani GP, Dioni L, Favero C, Cantone L, Macchi C, Delbue S, Bonzini M, Montomoli E, Bollati V; UNICORN Consortium. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep 2020;10:20048. [PMID: 33208819 DOI: 10.1038/s41598-020-77125-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 11.5] [Reference Citation Analysis]
399 Frey K, Hagedorn B, Mccarthy KA, Hutubessy R, Wang SA. Modeling anticipated changes in numbers of SARS-CoV-2 infections within communities due to immunization campaigns. Gates Open Res 2022;6:7. [DOI: 10.12688/gatesopenres.13448.1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
400 Parr T, Bhat A, Zeidman P, Goel A, Billig AJ, Moran R, Friston KJ. Dynamic causal modelling of immune heterogeneity. Sci Rep 2021;11:11400. [PMID: 34059775 DOI: 10.1038/s41598-021-91011-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
401 Popper N, Zechmeister M, Brunmeir D, Rippinger C, Weibrecht N, Urach C, Bicher M, Schneckenreither G, Rauber A. Synthetic Reproduction and Augmentation of COVID-19 Case Reporting Data by Agent-Based Simulation. Data Science Journal 2021;20:16. [DOI: 10.5334/dsj-2021-016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
402 Larribère L, Gordejeva J, Kuhnhenn L, Kurscheidt M, Pobiruchin M, Vladimirova D, Martin M, Roser M, Schramm W, Martens UM, Eigenbrod T. Assessment of SARS-CoV-2 Infection among Healthcare Workers of a German COVID-19 Treatment Center. Int J Environ Res Public Health 2021;18:7057. [PMID: 34281000 DOI: 10.3390/ijerph18137057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
403 Hoffman T, Kolstad L, Lindahl JF, Albinsson B, Bergqvist A, Rönnberg B, Lundkvist Å. Diagnostic Potential of a Luminex-Based Coronavirus Disease 2019 Suspension Immunoassay (COVID-19 SIA) for the Detection of Antibodies against SARS-CoV-2. Viruses 2021;13:993. [PMID: 34073484 DOI: 10.3390/v13060993] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Swank Z, Michielin G, Yip HM, Cohen P, Andrey DO, Vuilleumier N, Kaiser L, Eckerle I, Meyer B, Maerkl SJ. A high-throughput microfluidic nanoimmunoassay for detecting anti-SARS-CoV-2 antibodies in serum or ultralow-volume blood samples. Proc Natl Acad Sci U S A 2021;118:e2025289118. [PMID: 33945500 DOI: 10.1073/pnas.2025289118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
405 López-Gay A, Spijker J, Cole HVS, Marques AG, Triguero-Mas M, Anguelovski I, Marí-Dell'Olmo M, Módenes JA, Álamo-Junquera D, López-Gallego F, Borrell C. Sociodemographic determinants of intraurban variations in COVID-19 incidence: the case of Barcelona. J Epidemiol Community Health 2021:jech-2020-216325. [PMID: 34158409 DOI: 10.1136/jech-2020-216325] [Reference Citation Analysis]
406 Golubev AG. COVID-19: A Challenge to Physiology of Aging. Front Physiol 2020;11:584248. [PMID: 33343386 DOI: 10.3389/fphys.2020.584248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
407 Chen Z, Wang B, Mao S, Ye Q. Assessment of global asymptomatic SARS-CoV-2 infection and management practices from China. Int J Biol Sci 2021;17:1119-24. [PMID: 33867834 DOI: 10.7150/ijbs.59374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
408 Cherif I, Kharroubi G, Chaabane S, Yazidi R, Dellagi M, Snoussi MA, Salem S, Marzouki S, Kammoun Rebai W, Rourou S, Dellagi K, Barbouche MR, Benabdessalem C, Ben Ahmed M, Bettaieb J. COVID-19 in Tunisia (North Africa): Seroprevalence of SARS-CoV-2 in the General Population of the Capital City Tunis. Diagnostics 2022;12:971. [DOI: 10.3390/diagnostics12040971] [Reference Citation Analysis]
409 Xiao C, Leung NHL, Cheng Y, Lei H, Ling S, Lin X, Tao R, Huang X, Guan W, Yang Z, Cowling BJ, Zanin M, Wong SS. Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020. Pathogens 2021;10:1505. [PMID: 34832661 DOI: 10.3390/pathogens10111505] [Reference Citation Analysis]
410 Pagani G, Conti F, Giacomelli A, Oreni L, Beltrami M, Pezzati L, Casalini G, Rondanin R, Prina A, Zagari A, Rusconi S, Galli M. Differences in the Prevalence of SARS-CoV-2 Infection and Access to Care between Italians and Non-Italians in a Social-Housing Neighbourhood of Milan, Italy. Int J Environ Res Public Health 2021;18:10621. [PMID: 34682369 DOI: 10.3390/ijerph182010621] [Reference Citation Analysis]
411 Solbach W, Schiffner J, Backhaus I, Burger D, Staiger R, Tiemer B, Bobrowski A, Hutchings T, Mischnik A. Antibody Profiling of COVID-19 Patients in an Urban Low-Incidence Region in Northern Germany. Front Public Health 2020;8:570543. [PMID: 33072707 DOI: 10.3389/fpubh.2020.570543] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
412 Castro M, Ares S, Cuesta JA, Manrubia S. The turning point and end of an expanding epidemic cannot be precisely forecast. Proc Natl Acad Sci U S A 2020;117:26190-6. [PMID: 33004629 DOI: 10.1073/pnas.2007868117] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 19.0] [Reference Citation Analysis]
413 Conley TE, Probert C, Subramanian S. Prevalence of Covid-19 Symptoms Among Inflammatory Bowel Disease Patients Treated with Biological Agents. J Crohns Colitis 2020;14:1794-5. [PMID: 32918090 DOI: 10.1093/ecco-jcc/jjaa187] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
414 Luijten LWG, Leonhard SE, van der Eijk AA, Doets AY, Appeltshauser L, Arends S, Attarian S, Benedetti L, Briani C, Casasnovas C, Castellani F, Dardiotis E, Echaniz-Laguna A, Garssen MPJ, Harbo T, Huizinga R, Humm AM, Jellema K, van der Kooi AJ, Kuitwaard K, Kuntzer T, Kusunoki S, Lascano AM, Martinez-Hernandez E, Rinaldi S, Samijn JPA, Scheidegger O, Tsouni P, Vicino A, Visser LH, Walgaard C, Wang Y, Wirtz PW, Ripellino P, Jacobs BC; IGOS consortium. Guillain-Barré syndrome after SARS-CoV-2 infection in an international prospective cohort study. Brain 2021;144:3392-404. [PMID: 34553216 DOI: 10.1093/brain/awab279] [Reference Citation Analysis]
415 Sanvisens A, Puigdemont M, Rubió-casadevall J, Vidal-vila A, López-bonet E, Martín-romero F, Marcos-gragera R. Differences in the Impact of COVID-19 on Pathology Laboratories and Cancer Diagnosis in Girona. IJERPH 2021;18:13269. [DOI: 10.3390/ijerph182413269] [Reference Citation Analysis]
416 Tsitsilonis OE, Paraskevis D, Lianidou E, Terpos E, Akalestos A, Pierros V, Kostaki EG, Kastritis E, Moutsatsou P, Politou M, Scorilas A, Sphicopoulos T, Thomaidis N, Trougakos IP, Tsakris A, Voulgaris N, Daskalaki CC, Evangelakou Z, Fouki C, Gianniou DD, Gumeni S, Kostopoulos IV, Manola MS, Orologas-Stavrou N, Panteli C, Papanagnou ED, Rousakis P, Sklirou AD, Smilkou S, Stergiopoulou D, Tsiodras S, Dimopoulos MA, Sfikakis PP. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response. Vaccines (Basel) 2021;9:207. [PMID: 33801380 DOI: 10.3390/vaccines9030207] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
417 McKee M. Learning from success: how has Hungary responded to the COVID pandemic? Geroscience 2020;42:1217-9. [PMID: 32720206 DOI: 10.1007/s11357-020-00240-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
418 Martischang R, Iten A, Arm I, Abbas M, Meyer B, Yerly S, Eckerle I, Pralong J, Sauser J, Suard JC, Kaiser L, Pittet D, Harbarth S. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) seroconversion and occupational exposure of employees at a Swiss university hospital: A large longitudinal cohort study. Infect Control Hosp Epidemiol 2021;:1-8. [PMID: 33736734 DOI: 10.1017/ice.2021.117] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
419 Ren L, Wang Y, Zhong J, Li X, Xiao Y, Li J, Yang J, Fan G, Guo L, Shen Z, Kang L, Shi L, Li Q, Li J, Di L, Li H, Wang C, Wang Y, Wang X, Zou X, Rao J, Zhang L, Wang J, Huang Y, Cao B, Wang J, Li M. Dynamics of the Upper Respiratory Tract Microbiota and Its Association with Mortality in COVID-19. Am J Respir Crit Care Med 2021;204:1379-90. [PMID: 34534435 DOI: 10.1164/rccm.202103-0814OC] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
420 Garrido JM, Martínez-Rodríguez D, Rodríguez-Serrano F, Pérez-Villares JM, Ferreiro-Marzal A, Jiménez-Quintana MM, Villanueva RJ; Grupo de Estudio COVID 19 Granada. Mathematical model optimized for prediction and health care planning for COVID-19. Med Intensiva (Engl Ed) 2021:S0210-5691(21)00034-6. [PMID: 33926752 DOI: 10.1016/j.medin.2021.02.014] [Reference Citation Analysis]
421 Dethioux L, Dauby N, Montesinos I, Rebuffat E, Hainaut M. SARS-CoV-2 seroprevalence in children and their family members, July-October 2020, Brussels. Eur J Pediatr 2021. [PMID: 34677664 DOI: 10.1007/s00431-021-04284-9] [Reference Citation Analysis]
422 Piler P, Thon V, Andrýsková L, Doležel K, Kostka D, Pavlík T, Dušek L, Pikhart H, Bobák M, Matic S, Klánová J. Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population. Commun Med 2022;2. [DOI: 10.1038/s43856-022-00080-0] [Reference Citation Analysis]
423 Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, Pérez-Olmeda M, Yotti R, Oteo-Iglesias J, Sanmartín JL, León-Gómez I, Fernández-García A, Fernández-Navarro P, Cruz I, Martín M, Delgado-Sanz C, Fernández de Larrea N, León Paniagua J, Muñoz-Montalvo JF, Blanco F, Larrauri A, Pollán M; ENE-COVID Study Group. Infection fatality risk for SARS-CoV-2 in community dwelling population of Spain: nationwide seroepidemiological study. BMJ 2020;371:m4509. [PMID: 33246972 DOI: 10.1136/bmj.m4509] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 22.5] [Reference Citation Analysis]
424 Savio A, Calza S, Guerrini G, Romano V, Marchina E. Rapid Point-Of-Care Serology and Clinical History Assessment Increase Protection Provided by RT-PCR Screening: A Pilot Study Involving Three Nursing Homes in Brescia, a Hotspot of Lombardy. Front Public Health 2021;9:649524. [PMID: 34249831 DOI: 10.3389/fpubh.2021.649524] [Reference Citation Analysis]
425 Jing M, Bond R, Robertson LJ, Moore J, Kowalczyk A, Price R, Burns W, Nesbit MA, McLaughlin J, Moore T. User experience analysis of AbC-19 Rapid Test via lateral flow immunoassays for self-administrated SARS-CoV-2 antibody testing. Sci Rep 2021;11:14026. [PMID: 34234188 DOI: 10.1038/s41598-021-93262-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
426 Galán MI, Velasco M, Casas ML, Goyanes MJ, Rodríguez-Caravaca G, Losa-García JE, Noguera C, Castilla V; Working Group Alcorcón COVID-19 investigators., Working Group Alcorcón COVID-19 investigators. Hospital-Wide SARS-CoV-2 seroprevalence in health care workers in a Spanish teaching hospital. Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30418-3. [PMID: 33485676 DOI: 10.1016/j.eimc.2020.11.015] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
427 Murtas R, Decarli A, Russo AG. Trend of pneumonia diagnosis in emergency departments as a COVID-19 surveillance system: a time series study. BMJ Open 2021;11:e044388. [PMID: 33558358 DOI: 10.1136/bmjopen-2020-044388] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
428 Gonzalez-parra G, Martínez-rodríguez D, Villanueva-micó R. Impact of a New SARS-CoV-2 Variant on the Population: A Mathematical Modeling Approach. MCA 2021;26:25. [DOI: 10.3390/mca26020025] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
429 Murhekar MV, Bhatnagar T, Selvaraju S, Rade K, Saravanakumar V, Vivian Thangaraj JW, Kumar MS, Shah N, Sabarinathan R, Turuk A, Anand PK, Asthana S, Balachandar R, Bangar SD, Bansal AK, Bhat J, Chakraborty D, Rangaraju C, Chopra V, Das D, Deb AK, Devi KR, Dwivedi GR, Salim Khan SM, Haq I, Kumar MS, Laxmaiah A, Madhuka, Mahapatra A, Mitra A, Nirmala AR, Pagdhune A, Qurieshi MA, Ramarao T, Sahay S, Sharma YK, Shrinivasa MB, Shukla VK, Singh PK, Viramgami A, Wilson VC, Yadav R, Girish Kumar CP, Luke HE, Ranganathan UD, Babu S, Sekar K, Yadav PD, Sapkal GN, Das A, Das P, Dutta S, Hemalatha R, Kumar A, Narain K, Narasimhaiah S, Panda S, Pati S, Patil S, Sarkar K, Singh S, Kant R, Tripathy S, Toteja GS, Babu GR, Kant S, Muliyil JP, Pandey RM, Sarkar S, Singh SK, Zodpey S, Gangakhedkar RR, S Reddy DC, Bhargava B. Prevalence of SARS-CoV-2 infection in India: Findings from the national serosurvey, May-June 2020. Indian J Med Res 2020;152:48-60. [PMID: 32952144 DOI: 10.4103/ijmr.IJMR_3290_20] [Cited by in Crossref: 80] [Cited by in F6Publishing: 43] [Article Influence: 40.0] [Reference Citation Analysis]
430 Jõgi P, Soeorg H, Ingerainen D, Soots M, Lättekivi F, Naaber P, Toompere K, Peterson P, Haljasmägi L, Žusinaite E, Vaas H, Pauskar M, Shablinskaja A, Kaarna K, Paluste H, Kisand K, Oona M, Janno R, Lutsar I. Prevalence of SARS-CoV-2 IgG antibodies and their association with clinical symptoms of COVID-19 in Estonia (KoroSero-EST-1 study). Vaccine 2021;39:5376-84. [PMID: 34393019 DOI: 10.1016/j.vaccine.2021.07.093] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
431 Hasan T, Pham TN, Nguyen TA, Le HTT, Van Le D, Dang TT, Van TD, Pham YN, Nguyen HV, Tran GL, Nguyen VTC, Nguyen TT, Truong VQ, Dao TH, Le CT, Truong NT, Vo HT, Le PT, Nguyen TT, Van Luu V, Nguyen VD, Toelle BG, Marks GB, Fox GJ. Sero-Prevalence of SARS-CoV-2 Antibodies in High-Risk Populations in Vietnam. Int J Environ Res Public Health 2021;18:6353. [PMID: 34208212 DOI: 10.3390/ijerph18126353] [Reference Citation Analysis]
432 Pezzati L, Giacomelli A, Mileto D, Conti F, Gagliardi G, Rizzo A, Milazzo L, Schiuma M, Covizzi A, Siano M, Bassoli C, Passerini M, Piscaglia M, Torre A, Oreni L, Rizzardini G, Galli M, Ridolfo AL, Antinori S. Rapid lateral-flow immunochromatographic tests to assess anti N/S IgG seropositivity after BNT162b2 vaccine: A cross-sectional study: Rapid lateral-flow immunochromatographic tests after BNT162b2 vaccine. J Infect 2021;83:381-412. [PMID: 34062183 DOI: 10.1016/j.jinf.2021.05.029] [Reference Citation Analysis]
433 Yanes-Lane M, Winters N, Fregonese F, Bastos M, Perlman-Arrow S, Campbell JR, Menzies D. Proportion of asymptomatic infection among COVID-19 positive persons and their transmission potential: A systematic review and meta-analysis. PLoS One 2020;15:e0241536. [PMID: 33141862 DOI: 10.1371/journal.pone.0241536] [Cited by in Crossref: 84] [Cited by in F6Publishing: 67] [Article Influence: 42.0] [Reference Citation Analysis]
434 Fai KN, Corine TM, Bebell LM, Mboringong AB, Nguimbis EBPT, Nsaibirni R, Mbarga NF, Eteki L, Nikolay B, Essomba RG, Ndifon M, Ntone R, Hamadou A, Matchim L, Tchiasso D, Abah Abah AS, Essaka R, Peppa S, Crescence F, Ouamba JP, Koku MT, Mandeng N, Fanne M, Eyangoh S, Mballa GAE, Esso L, Epée E, Njouom R, Okomo Assoumou MC, Boum Y. Serologic response to SARS-CoV-2 in an African population. Sci Afr 2021;12:e00802. [PMID: 34095639 DOI: 10.1016/j.sciaf.2021.e00802] [Reference Citation Analysis]
435 Kitano T, Kitano M, Krueger C, Jamal H, Al Rawahi H, Lee-Krueger R, Sun RD, Isabel S, García-Ascaso MT, Hibino H, Camara B, Isabel M, Cho L, Groves HE, Piché-Renaud PP, Kossov M, Kou I, Jon I, Blanchard AC, Matsuda N, Mahood Q, Wadhwa A, Bitnun A, Morris SK. The differential impact of pediatric COVID-19 between high-income countries and low- and middle-income countries: A systematic review of fatality and ICU admission in children worldwide. PLoS One 2021;16:e0246326. [PMID: 33513204 DOI: 10.1371/journal.pone.0246326] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
436 Ko JH, Joo EJ, Park SJ, Baek JY, Kim WD, Jee J, Kim CJ, Jeong C, Kim YJ, Shon HJ, Kang ES, Choi YK, Peck KR. Neutralizing Antibody Production in Asymptomatic and Mild COVID-19 Patients, in Comparison with Pneumonic COVID-19 Patients. J Clin Med 2020;9:E2268. [PMID: 32708872 DOI: 10.3390/jcm9072268] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 26.5] [Reference Citation Analysis]
437 Martínez PT, García PD, Salas MR, Sánchez RR, Avendaño-Ortíz J, Guerrero-Monjo S, García F, Llamas MÁ, López-Collazo E, Saz-Leal P, Del Fresno C. SARS-CoV-2 IgG seropositivity in a cohort of 449 non-hospitalized individuals during Spanish COVID-19 lockdown. Sci Rep 2021;11:21612. [PMID: 34732800 DOI: 10.1038/s41598-021-00990-4] [Reference Citation Analysis]
438 Agarwal A, Baghmar S, Qureshi S, Khurana A, Setia R, Khan MA, Barman P, Kapoor RK, Hasthavaram NR, Kumar R, Singh N, Sarin A, Handoo A. Persistent Antibody Responses to SARS-CoV-2 Infection in Cancer Patients: A Single-Center Retrospective Observational Study. Indian J Med Paediatr Oncol 2021;42:123-9. [DOI: 10.1055/s-0041-1733823] [Reference Citation Analysis]
439 Llorente-Alonso M, García-Ael C, Topa G, Sanz-Muñoz ML, Muñoz-Alcalde I, Cortés-Abejer B. Can Psychological Empowerment Prevent Emotional Disorders in Presence of Fear of COVID-19 in Health Workers? A Cross-Sectional Validation Study. J Clin Med 2021;10:1614. [PMID: 33920260 DOI: 10.3390/jcm10081614] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
440 Ojeda-Thies C, Cuarental-García J, García-Gómez E, Salazar-Zamorano CH, Alberti-Maroño J, Ramos-Pascua LR. Hip fracture care and mortality among patients treated in dedicated COVID-19 and non-COVID-19 circuits. Eur Geriatr Med 2021;12:749-57. [PMID: 33550563 DOI: 10.1007/s41999-021-00455-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
441 Franco F, Guirado M, Martínez-Banaclocha N, Gumà J, Lavernia J, Gómez-Codina J, Rodriguez-Abreu D, Martínez F, Barrajón E, Méndez M, Calvo V, Provencio M. Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel). Curr Oncol 2021;28:1249-55. [PMID: 33809772 DOI: 10.3390/curroncol28020118] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
442 Zyoud SH, Shakhshir M, Koni A, Shahwan M, Jairoun AA, Al-Jabi SW. Olfactory and Gustatory Dysfunction in COVID-19: A Global Bibliometric and Visualized Analysis. Ann Otol Rhinol Laryngol 2022;:34894221082735. [PMID: 35240864 DOI: 10.1177/00034894221082735] [Reference Citation Analysis]
443 Marziano V, Guzzetta G, Rondinone BM, Boccuni F, Riccardo F, Bella A, Poletti P, Trentini F, Pezzotti P, Brusaferro S, Rezza G, Iavicoli S, Ajelli M, Merler S. Retrospective analysis of the Italian exit strategy from COVID-19 lockdown. Proc Natl Acad Sci U S A 2021;118:e2019617118. [PMID: 33414277 DOI: 10.1073/pnas.2019617118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
444 Aylett-Bullock J, Cuesta-Lazaro C, Quera-Bofarull A, Icaza-Lizaola M, Sedgewick A, Truong H, Curran A, Elliott E, Caulfield T, Fong K, Vernon I, Williams J, Bower R, Krauss F. June: open-source individual-based epidemiology simulation. R Soc Open Sci 2021;8:210506. [PMID: 34295529 DOI: 10.1098/rsos.210506] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
445 Yang Q, Xiao X, Gu X, Liang D, Cao T, Mou J, Huang C, Chen L, Liu J. Surveillance of common respiratory infections during the COVID-19 pandemic demonstrates the preventive efficacy of non-pharmaceutical interventions. Int J Infect Dis 2021;105:442-7. [PMID: 33582375 DOI: 10.1016/j.ijid.2021.02.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
446 Aballay LR, Coquet JB, Scruzzi GF, Haluszka E, Franchini G, Carreño P, Raboy E, Román MD, Niclis C, Balangero M, Altamirano N, Barbás MG, López L. [A population-based study on seroprevalence and factors associated with SARS-CoV-2 infection in Córdoba, Argentina]. Cad Saude Publica 2022;38:ES219821. [PMID: 35544877 DOI: 10.1590/0102-311XES219821] [Reference Citation Analysis]
447 Kataria Y, Cole M, Duffy E, de la Cena K, Schechter-Perkins EM, Bouton TC, Werler MM, Pierre C, Ragan EJ, Weber SE, Jacobson KR, Andry C. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts. Sci Rep 2021;11:9694. [PMID: 33958668 DOI: 10.1038/s41598-021-89107-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
448 Soriano V, de Mendoza C, Gómez-Gallego F, Corral O, Barreiro P. Third wave of COVID-19 in Madrid, Spain. Int J Infect Dis 2021;107:212-4. [PMID: 33930544 DOI: 10.1016/j.ijid.2021.04.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
449 Maltezou HC, Krumbholz B, Mavrouli M, Tseroni M, Gamaletsou MN, Botsa E, Anastassopoulou C, Gikas A, Fournarakou E, Kavieri M, Koureli A, Mandilara D, Marinopoulou A, Theodorikakou A, Tsiahris P, Zarzali A, Pournaras S, Lourida A, Elefsiniotis I, Vrioni G, Sipsas NV, Tsakris A. A study of the evolution of the third COVID-19 pandemic wave in the Athens metropolitan area, Greece, through two cross-sectional seroepidemiological surveys: March, June 2021. J Med Virol 2021. [PMID: 34812522 DOI: 10.1002/jmv.27465] [Reference Citation Analysis]
450 Fotis C, Meimetis N, Tsolakos N, Politou M, Akinosoglou K, Pliaka V, Minia A, Terpos E, Trougakos IP, Mentis A, Marangos M, Panayiotakopoulos G, Dimopoulos MA, Gogos C, Spyridonidis A, Alexopoulos LG. Accurate SARS-CoV-2 seroprevalence surveys require robust multi-antigen assays. Sci Rep 2021;11:6614. [PMID: 33758278 DOI: 10.1038/s41598-021-86035-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
451 Dawood FS, Porucznik CA, Veguilla V, Stanford JB, Duque J, Rolfes MA, Dixon A, Thind P, Hacker E, Castro MJE, Jeddy Z, Daugherty M, Altunkaynak K, Hunt DR, Kattel U, Meece J, Stockwell MS. Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. JAMA Pediatr 2022;176:59-67. [PMID: 34623377 DOI: 10.1001/jamapediatrics.2021.4217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
452 Ioannidis JPA. Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations. Eur J Clin Invest 2021;51:e13554. [PMID: 33768536 DOI: 10.1111/eci.13554] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
453 Liu L, Chen HG, Li Y, Li H, Li J, Wang Y, Yao S, Qin C, Tong S, Yuan X, Luo X, Miao X, Pan A, Liu Z, Cheng L. Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort in Wuhan, China. Engineering (Beijing) 2021. [PMID: 34026297 DOI: 10.1016/j.eng.2021.04.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
454 Lee J, Kim SY, Sung H, Choe YJ, Hong KH. Letter to the Editor: The Interpretation of COVID-19 Seroprevalence Study Should Be Cautious. J Korean Med Sci 2020;35:e338. [PMID: 32989933 DOI: 10.3346/jkms.2020.35.e338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
455 Guimarães L. Antibody tests: They are more important than we thought. J Math Econ 2021;93:102485. [PMID: 33897088 DOI: 10.1016/j.jmateco.2021.102485] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
456 Bhattacharyya R, Kundu R, Bhaduri R, Ray D, Beesley LJ, Salvatore M, Mukherjee B. Incorporating false negative tests in epidemiological models for SARS-CoV-2 transmission and reconciling with seroprevalence estimates. Sci Rep 2021;11:9748. [PMID: 33963259 DOI: 10.1038/s41598-021-89127-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
457 Cerino P, Coppola A, Volzone P, Pizzolante A, Pierri B, Atripaldi L, Zollo M, Capasso M, Ascierto PA, Triassi M, Brambilla G, Perrella A, Bruzzese D, Buonerba C. Seroprevalence of SARS-CoV-2-specific antibodies in the town of Ariano Irpino (Avellino, Campania, Italy): a population-based study. Future Sci OA 2021;7:FSO673. [PMID: 33815819 DOI: 10.2144/fsoa-2020-0203] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
458 Trobajo-Sanmartín C, Martínez-Baz I, Miqueleiz A, Fernández-Huerta M, Burgui C, Casado I, Baigorría F, Navascués A, Castilla J, Ezpeleta C. Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiol Spectr 2022;:e0000822. [PMID: 35412379 DOI: 10.1128/spectrum.00008-22] [Reference Citation Analysis]
459 González-Anglada MI, Garmendia-Fernández C, Sanmartin-Fenollera P, Martín-Fernández J, García-Pérez F, Huelmos-Rodrigo AI. [Impact of the Covid-19 pandemic on specialized healthcare training in a teaching center]. J Healthc Qual Res 2021:S2603-6479(21)00075-0. [PMID: 34456180 DOI: 10.1016/j.jhqr.2021.07.006] [Reference Citation Analysis]
460 Oved K, Olmer L, Shemer-Avni Y, Wolf T, Supino-Rosin L, Prajgrod G, Shenhar Y, Payorsky I, Cohen Y, Kohn Y, Indenbaum V, Lazar R, Geylis V, Oikawa MT, Shinar E, Stoyanov E, Keinan-Boker L, Bassal R, Reicher S, Yishai R, Bar-Chaim A, Doolman R, Reiter Y, Mendelson E, Livneh Z, Freedman LS, Lustig Y. Multi-center nationwide comparison of seven serology assays reveals a SARS-CoV-2 non-responding seronegative subpopulation. EClinicalMedicine 2020;29:100651. [PMID: 33235985 DOI: 10.1016/j.eclinm.2020.100651] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 18.5] [Reference Citation Analysis]
461 Zhong S, Chen Z, Wang Y, Sheng P, Shi S, Lyu Y, Bai R, Wang P, Dong J, Ba J, Qu X, Lu J. Braking Force Model on Virus Transmission to Evaluate Interventions Including the Administration of COVID-19 Vaccines - Worldwide, 2019-2021. China CDC Wkly 2021;3:869-77. [PMID: 34703644 DOI: 10.46234/ccdcw2021.195] [Reference Citation Analysis]
462 Rodríguez-Espinosa D, Broseta JJ, Cuadrado E, Maduell F. Prevalence of COVID-19 Infection in Hemodialysis Patients Detected Using Serologic Screening. J Am Soc Nephrol 2020;31:2966-7. [PMID: 32997644 DOI: 10.1681/ASN.2020081193] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
463 Good MF, Hawkes MT. The Interaction of Natural and Vaccine-Induced Immunity with Social Distancing Predicts the Evolution of the COVID-19 Pandemic. mBio 2020;11:e02617-20. [PMID: 33097654 DOI: 10.1128/mBio.02617-20] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
464 Salto-Alejandre S, Berastegui-Cabrera J, Camacho-Martínez P, Infante-Domínguez C, Carretero-Ledesma M, Crespo-Rivas JC, Márquez E, Lomas JM, Bueno C, Amaya R, Lepe JA, Cisneros JM, Pachón J, Cordero E, Sánchez-Céspedes J; Virgen del Rocío Hospital COVID-19 Working Team. SARS-CoV-2 viral load in nasopharyngeal swabs is not an independent predictor of unfavorable outcome. Sci Rep 2021;11:12931. [PMID: 34155307 DOI: 10.1038/s41598-021-92400-y] [Reference Citation Analysis]
465 [DOI: 10.1101/2020.10.20.20213116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
466 Nagappan R, Flegel WA, Srivastava K, Williams EC, Ryzhov I, Tuzikov A, Galanina O, Shilova N, Sukhikh G, Perry H, Bovin NV, Henry SM. COVID-19 antibody screening with SARS-CoV-2 red cell kodecytes using routine serologic diagnostic platforms. Transfusion 2021;61:1171-80. [PMID: 33590501 DOI: 10.1111/trf.16327] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
467 Riley S, Atchison C, Ashby D, Donnelly CA, Barclay W, Cooke GS, Ward H, Darzi A, Elliott P; REACT study group. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Res 2020;5:200. [PMID: 33997297 DOI: 10.12688/wellcomeopenres.16228.2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
468 Altawalah H, Alfouzan W, Dhar R, Alali W, Bastaki H, Al-Fadalah T, Al-Ghimlas F, Rabaan AA, Ezzikouri S. Severe acute respiratory syndrome coronavirus 2 seroprevalence survey among 10,256 workers in Kuwait. J Clin Virol Plus 2021;1:100017. [PMID: 35262005 DOI: 10.1016/j.jcvp.2021.100017] [Reference Citation Analysis]
469 Syed MA, Al Nuaimi AS, A/Qotba HA, Nasrallah GK, Althani AA, Yassine HM, Zainel AA, Khudadad H, Marji T, Veettil ST, Al-Jighefee HT, Younes S, Shurrab F, Al-Sadeq DW, AlFehaidi AAS, Yfakhroo AI, AlMesaifri MA, Al Mujalli H, Al Abdulla SA, Al Kuwari MG, Azad FM, Al Malki BAM, Abdulmalik MA. Epidemiology of SARS-CoV2 in Qatar's primary care population aged 10 years and above. BMC Infect Dis 2021;21:645. [PMID: 34225657 DOI: 10.1186/s12879-021-06251-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
470 Riley S, Atchison C, Ashby D, Donnelly CA, Barclay W, Cooke GS, Ward H, Darzi A, Elliott P; REACT study group. REal-time Assessment of Community Transmission (REACT) of SARS-CoV-2 virus: Study protocol. Wellcome Open Res 2020;5:200. [PMID: 33997297 DOI: 10.12688/wellcomeopenres.16228.2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 34.0] [Reference Citation Analysis]
471 Reicher S, Ratzon R, Ben-Sahar S, Hermoni-Alon S, Mossinson D, Shenhar Y, Friger M, Lustig Y, Alroy-Preis S, Anis E, Sadetzki S, Kaliner E. Nationwide seroprevalence of antibodies against SARS-CoV-2 in Israel. Eur J Epidemiol 2021;36:727-34. [PMID: 33884542 DOI: 10.1007/s10654-021-00749-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
472 Cito F, Amato L, Di Giuseppe A, Danzetta ML, Iannetti S, Petrini A, Lorusso A, Bonfini B, Leone A, Salini R, Mancinelli A, Torzi G, Savini G, Migliorati G, Schael T, D'Alterio N, Calistri P. A COVID-19 Hotspot Area: Activities and Epidemiological Findings. Microorganisms 2020;8:E1711. [PMID: 33142840 DOI: 10.3390/microorganisms8111711] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
473 Byambasuren O, Dobler CC, Bell K, Rojas DP, Clark J, McLaws ML, Glasziou P. Comparison of seroprevalence of SARS-CoV-2 infections with cumulative and imputed COVID-19 cases: Systematic review. PLoS One 2021;16:e0248946. [PMID: 33798211 DOI: 10.1371/journal.pone.0248946] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
474 Winkler A, Zitt E, Sprenger-Mähr H, Soleiman A, Cejna M, Lhotta K. SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report. BMC Nephrol 2021;22:75. [PMID: 33639869 DOI: 10.1186/s12882-021-02275-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
475 Mohanraj D, Bicknell K, Bhole M, Webber C, Taylor L, Whitelegg A. Antibody Responses to SARS-CoV-2 Infection-Comparative Determination of Seroprevalence in Two High-Throughput Assays versus a Sensitive Spike Protein ELISA. Vaccines (Basel) 2021;9:1310. [PMID: 34835241 DOI: 10.3390/vaccines9111310] [Reference Citation Analysis]
476 Iruzubieta P, Fernández-Lanas T, Rasines L, Cayon L, Álvarez-Cancelo A, Santos-Laso A, García-Blanco A, Curiel-Olmo S, Cabezas J, Wallmann R, Fábrega E, Martínez-Taboada VM, Hernández JL, López-Hoyos M, Lazarus JV, Crespo J. Feasibility of large-scale population testing for SARS-CoV-2 detection by self-testing at home. Sci Rep 2021;11:9819. [PMID: 33972607 DOI: 10.1038/s41598-021-89236-x] [Reference Citation Analysis]
477 Alenazi MW, Algaisi A, Zowawi HM, Aldibasi O, Hashem AM, Khalaf Alharbi N. Seroprevalence of COVID-19 in Riyadh City during the early increase of COVID-19 infections in Saudi Arabia, June 2020. Saudi Journal of Biological Sciences 2022. [DOI: 10.1016/j.sjbs.2022.103282] [Reference Citation Analysis]
478 Moros MJS, Monge S, Rodríguez BS, Miguel LGS, Soria FS; signatories. COVID-19 in Spain: view from the eye of the storm. Lancet Public Health 2021;6:e10. [PMID: 33301724 DOI: 10.1016/S2468-2667(20)30286-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
479 Carrat F, Touvier M, Severi G, Meyer L, Jusot F, Lapidus N, Rahib D, Lydié N, Charles MA, Ancel PY, Rouquette A, de Lamballerie X, Zins M, Bajos N; SAPRIS study group. Incidence and risk factors of COVID-19-like symptoms in the French general population during the lockdown period: a multi-cohort study. BMC Infect Dis 2021;21:169. [PMID: 33568097 DOI: 10.1186/s12879-021-05864-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
480 Yang J, Zheng W, Shi H, Yan X, Dong K, You Q, Zhong G, Gong H, Chen Z, Jit M, Viboud C, Ajelli M, Yu H. Who should be prioritized for COVID-19 vaccination in China? A descriptive study. BMC Med 2021;19:45. [PMID: 33563270 DOI: 10.1186/s12916-021-01923-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 11.0] [Reference Citation Analysis]
481 Santos-Hövener C, Neuhauser HK, Rosario AS, Busch M, Schlaud M, Hoffmann R, Gößwald A, Koschollek C, Hoebel J, Allen J, Haack-Erdmann A, Brockmann S, Ziese T, Nitsche A, Michel J, Haller S, Wilking H, Hamouda O, Corman VM, Drosten C, Schaade L, Wieler LH, Lampert T; CoMoLo Study Group. Serology- and PCR-based cumulative incidence of SARS-CoV-2 infection in adults in a successfully contained early hotspot (CoMoLo study), Germany, May to June 2020. Euro Surveill 2020;25. [PMID: 33243353 DOI: 10.2807/1560-7917.ES.2020.25.47.2001752] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
482 Arnarson BT. How a school holiday led to persistent COVID-19 outbreaks in Europe. Sci Rep 2021;11:24390. [PMID: 34937860 DOI: 10.1038/s41598-021-03927-z] [Reference Citation Analysis]
483 Lenicek Krleza J, Zrinski Topic R, Stevanovic V, Lukic-Grlic A, Tabain I, Misak Z, Roic G, Kaic B, Mayer D, Hruskar Z, Barbic L, Vilibic-Cavlek T. Seroprevalence of SARS-CoV-2 infection among children in Children's Hospital Zagreb during the initial and second wave of COVID-19 pandemic in Croatia. Biochem Med (Zagreb) 2021;31:020706. [PMID: 33927556 DOI: 10.11613/BM.2021.020706] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
484 Mulchandani R, Taylor-Philips S, Jones HE, Ades AE, Borrow R, Linley E, Kirwan PD, Stewart R, Moore P, Boyes J, Hormis A, Todd N, Colda A, Reckless I, Brooks T, Charlett A, Hickman M, Oliver I, Wyllie D. Association between self-reported signs and symptoms and SARS-CoV-2 antibody detection in UK key workers. J Infect 2021;82:151-61. [PMID: 33775704 DOI: 10.1016/j.jinf.2021.03.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
485 Sander I, Kespohl S, Zahradnik E, Göcke P, Hosbach I, Herrmann BL, Brüning T, Raulf M. Quantitative measurement of IgG to SARS‐CoV‐2 antigens using monoclonal antibody‐based enzyme‐linked immunosorbent assays. Clin & Trans Imm 2022;11. [DOI: 10.1002/cti2.1369] [Reference Citation Analysis]
486 Kua J, Patel R, Nurmi E, Tian S, Gill H, Wong DJN, Moorley C, Nepogodiev D, Ahmad I, El-Boghdadly K. healthcareCOVID: a national cross-sectional observational study identifying risk factors for developing suspected or confirmed COVID-19 in UK healthcare workers. PeerJ 2021;9:e10891. [PMID: 33604201 DOI: 10.7717/peerj.10891] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
487 Shah ASV, Wood R, Gribben C, Caldwell D, Bishop J, Weir A, Kennedy S, Reid M, Smith-Palmer A, Goldberg D, McMenamin J, Fischbacher C, Robertson C, Hutchinson S, McKeigue P, Colhoun H, McAllister DA. Risk of hospital admission with coronavirus disease 2019 in healthcare workers and their households: nationwide linkage cohort study. BMJ 2020;371:m3582. [PMID: 33115726 DOI: 10.1136/bmj.m3582] [Cited by in Crossref: 101] [Cited by in F6Publishing: 85] [Article Influence: 50.5] [Reference Citation Analysis]
488 Wachtler B, Müters S, Michalski N, Koschollek C, Albrecht S, Haller S, Hamouda O, Hövener C, Hoebel J. Socioeconomic inequalities in the prevalence and perceived dangerousness of SARS-CoV-2 infections in two early German hotspots: findings from a seroepidemiological study. BMC Res Notes 2021;14:375. [PMID: 34565448 DOI: 10.1186/s13104-021-05784-5] [Reference Citation Analysis]
489 Puchades A, Daniel R, Geen J, Peden J, Lewis H, Nnoaham K. SARS-CoV-2 sero-prevalence in the workforces of three large workplaces in South Wales: a sero-epidemiological study. BMC Public Health 2022;22. [DOI: 10.1186/s12889-021-12478-x] [Reference Citation Analysis]
490 Ling ML, Cook AR, Marimuthu K, Pada S, Ang B, Thoon KC, Foo ML, Ong XY, Young A, Fisher D. A practical approach to defining aerosol-generating procedures. Infect Control Hosp Epidemiol 2021;:1-2. [PMID: 33866985 DOI: 10.1017/ice.2021.184] [Reference Citation Analysis]
491 Canto E Castro L, Gomes A, Serrano M, Pereira AHG, Ribeiro R, Napoleão P, Domingues I, Silva C, Fanczal J, Afonso Â, Lopes A, Toader I, de Sousa MJR, de Sousa JGR, de Sousa G, Mota MM, Silva-Santos B, Veldhoen M, Ribeiro RM. Longitudinal SARS-CoV-2 seroprevalence in Portugal and antibody maintenance 12 months after infection. Eur J Immunol 2021. [PMID: 34695227 DOI: 10.1002/eji.202149619] [Reference Citation Analysis]
492 Balou HA, Yaghubi Kalurazi T, Joukar F, Hassanipour S, Shenagari M, Khoshsorour M, Mansour-Ghanaei F. High Seroprevalence of SARS-CoV-2 (COVID-19)-Specific Antibodies among Healthcare Workers: A Cross-Sectional Study in Guilan, Iran. J Environ Public Health 2021;2021:9081491. [PMID: 34691195 DOI: 10.1155/2021/9081491] [Reference Citation Analysis]
493 Radev ST, Graw F, Chen S, Mutters NT, Eichel VM, Bärnighausen T, Köthe U. OutbreakFlow: Model-based Bayesian inference of disease outbreak dynamics with invertible neural networks and its application to the COVID-19 pandemics in Germany. PLoS Comput Biol 2021;17:e1009472. [PMID: 34695111 DOI: 10.1371/journal.pcbi.1009472] [Reference Citation Analysis]
494 Cento V, Alteri C, Merli M, Di Ruscio F, Tartaglione L, Rossotti R, Travi G, Vecchi M, Raimondi A, Nava A, Colagrossi L, Fumagalli R, Ughi N, Epis OM, Fanti D, Beretta A, Galbiati F, Scaglione F, Vismara C, Puoti M, Campisi D, Perno CF. Effectiveness of infection-containment measures on SARS-CoV-2 seroprevalence and circulation from May to July 2020, in Milan, Italy. PLoS One 2020;15:e0242765. [PMID: 33216817 DOI: 10.1371/journal.pone.0242765] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
495 Hwang J, Ryu HS, Kim HA, Hyun M, Lee JY, Yi HA. Prognostic Factors of COVID-19 Infection in Elderly Patients: A Multicenter Study. J Clin Med 2020;9:E3932. [PMID: 33291617 DOI: 10.3390/jcm9123932] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
496 Florin L, Maelegheer K, Vandewal W, Bernard D, Robbrecht J. Performance Evaluation of the Siemens SARS-CoV-2 Total Antibody and IgG Antibody Test. Lab Med 2021:lmab027. [PMID: 33928377 DOI: 10.1093/labmed/lmab027] [Reference Citation Analysis]
497 Garde-Noguera J, Fernández-Murga ML, Giner-Bosch V, Dominguez-Márquez V, Sánchez JG, Soler-Cataluña JJ, López Chuliá F, Honrubia B, Piera N, Llombart-Cussac A. Impact of SARS-CoV-2 Infection on Patients with Cancer: Retrospective and Transversal Studies in Spanish Population. Cancers (Basel) 2020;12:E3513. [PMID: 33255856 DOI: 10.3390/cancers12123513] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
498 Saluzzo F, Mantegani P, Poletti De Chaurand V, Quaresima V, Cugnata F, Di Serio C, Macé A, De Vos M, Sacks JA, Cirillo DM. SARS-CoV-2 Antibody Rapid Tests: Valuable Epidemiological Tools in Challenging Settings. Microbiol Spectr 2021;9:e0025021. [PMID: 34549999 DOI: 10.1128/Spectrum.00250-21] [Reference Citation Analysis]
499 Gallo V, Chiodini P, Bruzzese D, Kondilis E, Howdon D, Mierau J, Bhopal R. Comparing the COVID-19 pandemic in space and over time in Europe, using numbers of deaths, crude rates and adjusted mortality trend ratios. Sci Rep 2021;11:16443. [PMID: 34385482 DOI: 10.1038/s41598-021-95658-4] [Reference Citation Analysis]
500 Kirsten C, Unrath M, Lück C, Dalpke AH, Berner R, Armann J. SARS-CoV-2 seroprevalence in students and teachers: a longitudinal study from May to October 2020 in German secondary schools. BMJ Open 2021;11:e049876. [PMID: 34112645 DOI: 10.1136/bmjopen-2021-049876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
501 Baril-Tremblay D, Marlats C, Ménager L. Self-isolation. J Math Econ 2021;93:102483. [PMID: 33583995 DOI: 10.1016/j.jmateco.2021.102483] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
502 Burn E, Tebé C, Fernandez-Bertolin S, Aragon M, Recalde M, Roel E, Prats-Uribe A, Prieto-Alhambra D, Duarte-Salles T. The natural history of symptomatic COVID-19 during the first wave in Catalonia. Nat Commun 2021;12:777. [PMID: 33536436 DOI: 10.1038/s41467-021-21100-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
503 Gouvea-reis FA, Soares da Silva DC, Borja LS, Dias PDO, Percio J, Peterka C, de Oliveira J, Sodré G, Feres CM, Dos Santos W, Souza F, Passarella Teixeira AI, Cilião-alves DC, Romero GAS, Ferreira Noronha E, Croda J, Haddad R, Ramalho WM, de Moraes C, Araújo WND. SARS CoV-2 seroprevalence and diagnostic accuracy during a COVID-19 outbreak in a major penitentiary complex in Brazil, June to July 2020. IJPH 2022;ahead-of-print. [DOI: 10.1108/ijph-08-2021-0083] [Reference Citation Analysis]
504 Franch-Pardo I, Desjardins MR, Barea-Navarro I, Cerdà A. A review of GIS methodologies to analyze the dynamics of COVID-19 in the second half of 2020. Trans GIS 2021. [PMID: 34512103 DOI: 10.1111/tgis.12792] [Reference Citation Analysis]
505 Megasari NLA, Utsumi T, Yamani LN, Juniastuti, Gunawan E, Furukawa K, Nishimura M, Lusida MI, Mori Y. Seroepidemiological study of SARS-CoV-2 infection in East Java, Indonesia. PLoS One 2021;16:e0251234. [PMID: 33956869 DOI: 10.1371/journal.pone.0251234] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
506 Gao M, Wang Q, Wei J, Zhu Z, Li H. Severe Coronavirus disease 2019 pneumonia patients showed signs of aggravated renal impairment. J Clin Lab Anal 2020;34:e23535. [PMID: 32840917 DOI: 10.1002/jcla.23535] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
507 Wagner R, Peterhoff D, Beileke S, Günther F, Berr M, Einhauser S, Schütz A, Niller HH, Steininger P, Knöll A, Tenbusch M, Maier C, Korn K, Stark KJ, Gessner A, Burkhardt R, Kabesch M, Schedl H, Küchenhoff H, Pfahlberg AB, Heid IM, Gefeller O, Überla K. Estimates and Determinants of SARS-Cov-2 Seroprevalence and Infection Fatality Ratio Using Latent Class Analysis: The Population-Based Tirschenreuth Study in the Hardest-Hit German County in Spring 2020. Viruses 2021;13:1118. [PMID: 34200766 DOI: 10.3390/v13061118] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
508 Semmler G, Traugott MT, Graninger M, Hoepler W, Seitz T, Kelani H, Karolyi M, Pawelka E, Aragón de La Cruz S, Puchhammer-Stöckl E, Aberle SW, Stiasny K, Zoufaly A, Aberle JH, Weseslindtner L. Assessment of S1-, S2-, and NCP-Specific IgM, IgA, and IgG Antibody Kinetics in Acute SARS-CoV-2 Infection by a Microarray and Twelve Other Immunoassays. J Clin Microbiol 2021;59:e02890-20. [PMID: 33602698 DOI: 10.1128/JCM.02890-20] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
509 Grant R, Dub T, Andrianou X, Nohynek H, Wilder-Smith A, Pezzotti P, Fontanet A. SARS-CoV-2 population-based seroprevalence studies in Europe: a scoping review. BMJ Open 2021;11:e045425. [PMID: 33795310 DOI: 10.1136/bmjopen-2020-045425] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
510 Candel FJ, Viayna E, Callejo D, Ramos R, San-Roman-Montero J, Barreiro P, Carretero MDM, Kolipiński A, Canora J, Zapatero A, Runken MC. Social Restrictions versus Testing Campaigns in the COVID-19 Crisis: A Predictive Model Based on the Spanish Case. Viruses 2021;13:917. [PMID: 34063465 DOI: 10.3390/v13050917] [Reference Citation Analysis]
511 Bordas A, Soriano-arandes A, Subirana M, Malagrida R, Reyes-urueña JM, Folch C, Soler-palacin P, Gascón M, Sunyer J, Anton A, Blanco I, Fernández-morales J, Colom-cadena A, Sentís A, Pumarola T, Basora J, Casabona J. Study protocol for monitoring SARS-CoV-2 infection and its determinants in Catalonia (Spain): an observational and participatory research approach in a Sentinel Network of Schools. BMJ Open 2022;12:e055649. [DOI: 10.1136/bmjopen-2021-055649] [Reference Citation Analysis]
512 Pasqualotto AC, Pereira PC, Lana DFD, Schwarzbold AV, Ribeiro MS, Riche CVW, Castro CPP, Korsack PL, Ferreira PEB, Domingues GC, Ribeiro GT, Carneiro M, Caurio CFB, Vasconcellos ICDS, Knebel LM, Zamberlan L, Stolz AP, Vilanova M, Watte G, Kalil AN. COVID-19 seroprevalence in military police force, Southern Brazil. PLoS One 2021;16:e0249672. [PMID: 33886596 DOI: 10.1371/journal.pone.0249672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
513 Assaid N, Arich S, Charoute H, Akarid K, Ezzikouri S, Maaroufi A, Sarih M. Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers. Vaccines 2022;10:465. [DOI: 10.3390/vaccines10030465] [Reference Citation Analysis]
514 Trias-Llimós S, Bilal U, Franco M, Blanes A, Riffe T. [Decrease in life expectancy in 2020 and SARS-CoV-2 seroprevalence]. Gac Sanit 2021:S0213-9111(21)00139-4. [PMID: 34412926 DOI: 10.1016/j.gaceta.2021.07.002] [Reference Citation Analysis]
515 Flower B, Marks M. Did Laos really control the transmission of SARS-CoV-2 in 2020? Lancet Reg Health West Pac 2021;13:100202. [PMID: 34308399 DOI: 10.1016/j.lanwpc.2021.100202] [Reference Citation Analysis]
516 Díaz-Salazar C, Sánchez-García A, Rodríguez-Gutiérrez R, Camacho-Ortiz A, Saldívar-Rodríguez D, González-González JG. Prevalence and associated characteristics of anti-SARS-CoV-2 antibodies in Mexico 5 months after pandemic arrival. BMC Infect Dis 2021;21:835. [PMID: 34412620 DOI: 10.1186/s12879-021-06550-5] [Reference Citation Analysis]
517 Spielberger BD, Goerne T, Geweniger A, Henneke P, Elling R. Intra-Household and Close-Contact SARS-CoV-2 Transmission Among Children - a Systematic Review. Front Pediatr 2021;9:613292. [PMID: 33898355 DOI: 10.3389/fped.2021.613292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
518 Álvarez-Antonio C, Meza-Sánchez G, Calampa C, Casanova W, Carey C, Alava F, Rodríguez-Ferrucci H, Quispe AM. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and August, 2020: a population-based study. Lancet Glob Health 2021;9:e925-31. [PMID: 34022148 DOI: 10.1016/S2214-109X(21)00173-X] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
519 Bajos N, Jusot F, Pailhé A, Spire A, Martin C, Meyer L, Lydié N, Franck JE, Zins M, Carrat F; SAPRIS study group. When lockdown policies amplify social inequalities in COVID-19 infections: evidence from a cross-sectional population-based survey in France. BMC Public Health 2021;21:705. [PMID: 33845798 DOI: 10.1186/s12889-021-10521-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
520 Deshpande PS, Abraham IE, Pitamberwale A, Dhote RH. Review of Clinical Performance of Serology Based Commercial Diagnostic Assays for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 Antibodies. Viral Immunol 2022. [PMID: 35007431 DOI: 10.1089/vim.2020.0313] [Reference Citation Analysis]
521 Assefa N, Regassa LD, Teklemariam Z, Oundo J, Madrid L, Dessie Y, Scott J. Seroprevalence of anti-SARS-CoV-2 antibodies in women attending antenatal care in eastern Ethiopia: a facility-based surveillance. BMJ Open 2021;11:e055834. [PMID: 34819290 DOI: 10.1136/bmjopen-2021-055834] [Reference Citation Analysis]
522 Tešija Kuna A, Hanžek M, Vukasović I, Nikolac Gabaj N, Vidranski V, Ćelap I, Miler M, Stančin N, Šimac B, Živković M, Žarak M, Kmet M, Jovanović M, Tadinac S, Šupraha Goreta S, Periša J, Šamija I, Štefanović M. Comparison of diagnostic accuracy for eight SARS-CoV-2 serological assays. Biochem Med (Zagreb) 2021;31:010708. [PMID: 33594297 DOI: 10.11613/BM.2021.010708] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
523 Marra V, Quartin M. A Bayesian estimate of the early COVID-19 infection fatality ratio in Brazil based on a random seroprevalence survey. Int J Infect Dis 2021:S1201-9712(21)00648-2. [PMID: 34390858 DOI: 10.1016/j.ijid.2021.08.016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
524 Higgins RL, Rawlings SA, Case J, Lee FY, Chan CW, Barrick B, Burger ZC, Yeo KJ, Marrinucci D. Longitudinal SARS-CoV-2 antibody study using the Easy Check COVID-19 IgM/IgG™ lateral flow assay. PLoS One 2021;16:e0247797. [PMID: 33661960 DOI: 10.1371/journal.pone.0247797] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
525 Solanes A, Laredo C, Guasp M, Fullana MA, Fortea L, Garcia-Olivé I, Solmi M, Shin JI, Urra X, Radua J. No Effects of Meteorological Factors on the SARS-CoV-2 Infection Fatality Rate. Biomed Environ Sci 2021;34:871-80. [PMID: 34955147 DOI: 10.3967/bes2021.120] [Reference Citation Analysis]
526 García-García D, Vigo MI, Fonfría ES, Herrador Z, Navarro M, Bordehore C. Retrospective methodology to estimate daily infections from deaths (REMEDID) in COVID-19: the Spain case study. Sci Rep 2021;11:11274. [PMID: 34050198 DOI: 10.1038/s41598-021-90051-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
527 Kwiecińska-Piróg J, Przekwas J, Kraszewska Z, Sękowska A, Brodzka S, Wiktorczyk-Kapischke N, Grudlewska-Buda K, Wałecka-Zacharska E, Zacharski M, Mańkowska-Cyl A, Gospodarek-Komkowska E, Skowron K. The Differences in the Level of Anti-SARS-CoV-2 Antibodies after mRNA Vaccine between Convalescent and Non-Previously Infected People Disappear after the Second Dose-Study in Healthcare Workers Group in Poland. Vaccines (Basel) 2021;9:1402. [PMID: 34960148 DOI: 10.3390/vaccines9121402] [Reference Citation Analysis]
528 Mesenburg MA, Hallal PC, Menezes AMB, Barros AJD, Horta BL, Hartwig FP, Jacques N, Pellanda LC, Zelmanowicz AM, Vergani DOP, Ries EF, Harter J, Martínez-Mesa J, Carneiro M, Estima SL, Heck TG, Silveira MFD. Prevalence of symptoms of COVID-19 in the state of Rio Grande do Sul: results of a population-based study with 18,000 participants. Rev Saude Publica 2021;55:82. [PMID: 34816983 DOI: 10.11606/s1518-8787.2021055004030] [Reference Citation Analysis]
529 Nenna R, Zeric H, Petrarca L, Mancino E, Midulla F. Weighing policymaking: A narrative review of school closures as COVID-19 pandemic-mitigation strategies. Pediatr Pulmonol 2021. [PMID: 34894111 DOI: 10.1002/ppul.25787] [Reference Citation Analysis]
530 Paulino-Ramirez R, Báez AA, Vallejo Degaudenzi A, Tapia L. Seroprevalence of Specific Antibodies against SARS-CoV-2 from Hotspot Communities in the Dominican Republic. Am J Trop Med Hyg 2020;103:2343-6. [PMID: 33094710 DOI: 10.4269/ajtmh.20-0907] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
531 Horndler L, Delgado P, Abia D, Balabanov I, Martínez-Fleta P, Cornish G, Llamas MA, Serrano-Villar S, Sánchez-Madrid F, Fresno M, van Santen HM, Alarcón B. Flow cytometry multiplexed method for the detection of neutralizing human antibodies to the native SARS-CoV-2 spike protein. EMBO Mol Med 2021;13:e13549. [PMID: 33471406 DOI: 10.15252/emmm.202013549] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
532 Mulenga LB, Hines JZ, Fwoloshi S, Chirwa L, Siwingwa M, Yingst S, Wolkon A, Barradas DT, Favaloro J, Zulu JE, Banda D, Nikoi KI, Kampamba D, Banda N, Chilopa B, Hanunka B, Stevens TL Jr, Shibemba A, Mwale C, Sivile S, Zyambo KD, Makupe A, Kapina M, Mweemba A, Sinyange N, Kapata N, Zulu PM, Chanda D, Mupeta F, Chilufya C, Mukonka V, Agolory S, Malama K. Prevalence of SARS-CoV-2 in six districts in Zambia in July, 2020: a cross-sectional cluster sample survey. Lancet Glob Health 2021;9:e773-81. [PMID: 33711262 DOI: 10.1016/S2214-109X(21)00053-X] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 20.0] [Reference Citation Analysis]
533 Tupper P, Colijn C. COVID-19 in schools: Mitigating classroom clusters in the context of variable transmission. PLoS Comput Biol 2021;17:e1009120. [PMID: 34237051 DOI: 10.1371/journal.pcbi.1009120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
534 Levin AT, Hanage WP, Owusu-Boaitey N, Cochran KB, Walsh SP, Meyerowitz-Katz G. Assessing the age specificity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur J Epidemiol 2020;35:1123-38. [PMID: 33289900 DOI: 10.1007/s10654-020-00698-1] [Cited by in Crossref: 108] [Cited by in F6Publishing: 104] [Article Influence: 54.0] [Reference Citation Analysis]
535 Ward H, Cooke GS, Atchison C, Whitaker M, Elliott J, Moshe M, Brown JC, Flower B, Daunt A, Ainslie K, Ashby D, Donnelly CA, Riley S, Darzi A, Barclay W, Elliott P. Prevalence of antibody positivity to SARS-CoV-2 following the first peak of infection in England: Serial cross-sectional studies of 365,000 adults. Lancet Reg Health Eur 2021;4:100098. [PMID: 33969335 DOI: 10.1016/j.lanepe.2021.100098] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
536 Contreras S, Dehning J, Loidolt M, Zierenberg J, Spitzner FP, Urrea-Quintero JH, Mohr SB, Wilczek M, Wibral M, Priesemann V. The challenges of containing SARS-CoV-2 via test-trace-and-isolate. Nat Commun 2021;12:378. [PMID: 33452267 DOI: 10.1038/s41467-020-20699-8] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 35.0] [Reference Citation Analysis]
537 Mazzoli M, Pepe E, Mateo D, Cattuto C, Gauvin L, Bajardi P, Tizzoni M, Hernando A, Meloni S, Ramasco JJ. Interplay between mobility, multi-seeding and lockdowns shapes COVID-19 local impact. PLoS Comput Biol 2021;17:e1009326. [PMID: 34648495 DOI: 10.1371/journal.pcbi.1009326] [Reference Citation Analysis]
538 Santamaría L, Hortal J. Chasing the ghost of infection past: identifying thresholds of change during the COVID-19 infection in Spain. Epidemiol Infect 2020;148:e282. [PMID: 33183397 DOI: 10.1017/S0950268820002782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
539 Marcus GM, Olgin JE, Peyser ND, Vittinghoff E, Yang V, Joyce S, Avram R, Tison GH, Wen D, Butcher X, Eitel H, Pletcher MJ. Predictors of incident viral symptoms ascertained in the era of COVID-19. PLoS One 2021;16:e0253120. [PMID: 34138915 DOI: 10.1371/journal.pone.0253120] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
540 Tea F, Ospina Stella A, Aggarwal A, Ross Darley D, Pilli D, Vitale D, Merheb V, Lee FXZ, Cunningham P, Walker GJ, Fichter C, Brown DA, Rawlinson WD, Isaacs SR, Mathivanan V, Hoffmann M, Pöhlman S, Mazigi O, Christ D, Dwyer DE, Rockett RJ, Sintchenko V, Hoad VC, Irving DO, Dore GJ, Gosbell IB, Kelleher AD, Matthews GV, Brilot F, Turville SG. SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variants. PLoS Med 2021;18:e1003656. [PMID: 34228725 DOI: 10.1371/journal.pmed.1003656] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
541 Baxendale HE, Wells D, Gronlund J, Nadesalingham A, Paloniemi M, Carnell G, Tonks P, Ceron-Gutierrez L, Ebrahimi S, Sayer A, Briggs JAG, Ziong X, Nathan JA, Grice G, James LC, Luptak J, Pai S, Heeney JL, Lear S, Doffinger R. Critical Care Workers Have Lower Seroprevalence of SARS-CoV-2 IgG Compared with Non-patient Facing Staff in First Wave of COVID19. J Crit Care Med (Targu Mures) 2021;7:199-210. [PMID: 34722923 DOI: 10.2478/jccm-2021-0018] [Reference Citation Analysis]
542 Martin-Villares C, Bernal-Sprekelsen M, Molina-Ramirez CP, Bartolome-Benito M; COVID ORL ESP Collaborative Group. Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves". Eur Arch Otorhinolaryngol 2021;278:3571-7. [PMID: 33464400 DOI: 10.1007/s00405-020-06582-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
543 Kislaya I, Gonçalves P, Gómez V, Gaio V, Roquette R, Barreto M, Sousa-Uva M, Torres AR, Santos J, Matos R, Manita C, Almeida Santos J, Soeiro S, de Sousa R, Costa I, Verdasca N, Guiomar R, Rodrigues AP; ISN2COVID-19 Group. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19). Infect Dis (Lond) 2022;:1-7. [PMID: 35023439 DOI: 10.1080/23744235.2021.2025421] [Reference Citation Analysis]
544 Barreiro P, Candel FJ, Sanz JC, San Román J, Del Mar Carretero M, Pérez-Abeledo M, Ramos B, Viñuela-Prieto JM, Canora J, Martínez-Peromingo FJ, Zapatero A. Virological Correlates of IgM-IgG Patterns of Response to SARS-CoV-2 Infection According to Targeted Antigens. Viruses 2021;13:874. [PMID: 34068703 DOI: 10.3390/v13050874] [Reference Citation Analysis]
545 Alosaimi B, Naeem A, Alghoribi MF, Okdah L, Hamed ME, AlYami AS, Alotaibi A, Enani M. Structural Mapping of Mutations in Spike, RdRp and Orf3a Genes of SARS-CoV-2 in Influenza Like Illness (ILI) Patients. Viruses 2021;13:136. [PMID: 33477951 DOI: 10.3390/v13010136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
546 Ho HL, Wang FY, Lee HR, Huang YL, Lai CL, Jen WC, Hsieh SL, Chou TY. Seroprevalence of COVID-19 in Taiwan revealed by testing anti-SARS-CoV-2 serological antibodies on 14,765 hospital patients. Lancet Reg Health West Pac 2020;3:100041. [PMID: 34173603 DOI: 10.1016/j.lanwpc.2020.100041] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
547 Williams L, Jurado S, Llorente F, Romualdo A, González S, Saconne A, Bronchalo I, Martínez-Cortes M, Pérez-Gómez B, Ponz F, Jiménez-Clavero MÁ, Lunello P. The C-Terminal Half of SARS-CoV-2 Nucleocapsid Protein, Industrially Produced in Plants, Is Valid as Antigen in COVID-19 Serological Tests. Front Plant Sci 2021;12:699665. [PMID: 34386028 DOI: 10.3389/fpls.2021.699665] [Reference Citation Analysis]
548 Stefanou M, Palaiodimou L, Bakola E, Smyrnis N, Papadopoulou M, Paraskevas GP, Rizos E, Boutati E, Grigoriadis N, Krogias C, Giannopoulos S, Tsiodras S, Gaga M, Tsivgoulis G. Neurological manifestations of long-COVID syndrome: a narrative review. Therapeutic Advances in Chronic Disease 2022;13:204062232210768. [DOI: 10.1177/20406223221076890] [Reference Citation Analysis]
549 Mattar S, Alvis-Guzman N, Garay E, Rivero R, García A, Botero Y, Miranda J, Galeano K, de La Hoz F, Martínez C, Arrieta G, Faccini-Martínez ÁA, Guzmán C, Kerguelen H, Moscote M, Contreras H, Contreras V. Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence Among Adults in a Tropical City of the Caribbean Area, Colombia: Are We Much Closer to Herd Immunity Than Developed Countries? Open Forum Infect Dis 2020;7:ofaa550. [PMID: 33354587 DOI: 10.1093/ofid/ofaa550] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
550 Upadhyay RK, Chatterjee S, Roy P, Bhardwaj D. Combating COVID-19 crisis and predicting the second wave in Europe: an Age-structured modeling. J Appl Math Comput . [DOI: 10.1007/s12190-022-01723-0] [Reference Citation Analysis]
551 Madewell ZJ, Yang Y, Longini IM Jr, Halloran ME, Dean NE. Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate. medRxiv 2020:2020. [PMID: 32766596 DOI: 10.1101/2020.07.29.20164590] [Cited by in Crossref: 36] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
552 Hu Y, Guo J, Li G, Lu X, Li X, Zhang Y, Cong L, Kang Y, Jia X, Shi X, Xie G, Zhang L. Role of efficient testing and contact tracing in mitigating the COVID-19 pandemic: a network modelling study. BMJ Open 2021;11:e045886. [PMID: 34233974 DOI: 10.1136/bmjopen-2020-045886] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
553 Ruano-Gallego D, García-Villadangos M, Moreno-Paz M, Gómez-Elvira J, Postigo M, Simón-Sacristán M, Reyburn HT, Carolis C, Rodrigo N, Codeseira YB, Rueda P, Zúñiga S, Enjuanes L, Parro V. A multiplex antigen microarray for simultaneous IgG and IgM detection against SARS-CoV-2 reveals higher seroprevalence than reported. Microb Biotechnol 2021;14:1228-36. [PMID: 33929101 DOI: 10.1111/1751-7915.13801] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
554 Zhang L, Xu Z, Mak JWY, Chow KM, Lui G, Li TCM, Wong CK, Chan PKS, Ching JYL, Fujiwara Y, Chan FKL, Ng SC. Gut microbiota-derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID-19: An open-label pilot study. J Gastroenterol Hepatol 2022. [PMID: 35170078 DOI: 10.1111/jgh.15796] [Reference Citation Analysis]
555 Vallejo JA, Trigo-Tasende N, Rumbo-Feal S, Conde-Pérez K, López-Oriona Á, Barbeito I, Vaamonde M, Tarrío-Saavedra J, Reif R, Ladra S, Rodiño-Janeiro BK, Nasser-Ali M, Cid Á, Veiga M, Acevedo A, Lamora C, Bou G, Cao R, Poza M. Modeling the number of people infected with SARS-COV-2 from wastewater viral load in Northwest Spain. Sci Total Environ 2021;811:152334. [PMID: 34921882 DOI: 10.1016/j.scitotenv.2021.152334] [Reference Citation Analysis]
556 Ioannidis JPA. Global perspective of COVID-19 epidemiology for a full-cycle pandemic. Eur J Clin Invest 2020;50:e13423. [PMID: 33026101 DOI: 10.1111/eci.13423] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 22.0] [Reference Citation Analysis]
557 Shakiba M, Nazemipour M, Salari A, Mehrabian F, Nazari SSH, Rezvani SM, Ghasempour Z, Heidarzadeh A, Mansournia MA. Seroprevalence of SARS-CoV-2 in Guilan Province, Iran, April 2020. Emerg Infect Dis 2021;27:636-8. [PMID: 33349310 DOI: 10.3201/eid2702.201960] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
558 Smagul M, Esmagambetova A, Nusupbaeva G, Kirpicheva U, Kasabekova L, Nukenova G, Saliev T, Fakhradiyev I, Tanabayeva S, Zhussupov B. Sero‐prevalence of SARS‐CoV‐2 in certain cities of Kazakhstan. Health Science Reports 2022;5. [DOI: 10.1002/hsr2.562] [Reference Citation Analysis]
559 Simón Sacristán M, Ybarra de Villavicencio C, Collazos Blanco A, Mayo Montero ME, Ariñez Fernández MDC, Suárez Prieto A, Zamora Cintas MI, Mateo Maestre M. SARS-COV-2 Infection and Specific Antibody Detection on Health Care Workers from a Military Hospital in Madrid, Spain. Curr Microbiol 2021;78:2910-5. [PMID: 34156544 DOI: 10.1007/s00284-021-02541-6] [Reference Citation Analysis]
560 Baral S, Chandler R, Prieto RG, Gupta S, Mishra S, Kulldorff M. Leveraging epidemiological principles to evaluate Sweden's COVID-19 response. Ann Epidemiol 2021;54:21-6. [PMID: 33242596 DOI: 10.1016/j.annepidem.2020.11.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
561 Yuksel M, Akturk H, Mizikoglu O, Toroslu E, Arikan C. A single-center report of COVID-19 disease course and management in liver transplanted pediatric patients. Pediatr Transplant 2021;:e14061. [PMID: 34076953 DOI: 10.1111/petr.14061] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
562 Montolio Breva S, Molina Clavero C, Gómez Bertomeu F, Picó-Plana E, Serrat Orús N, Palau Sánchez I, Mestre-Prad MT, Sans-Mateu MT. Evaluation of five immunoassays and one lateral flow immunochromatography for anti-SARS-CoV-2 antibodies detection. Enferm Infecc Microbiol Clin (Engl Ed) 2021:S0213-005X(21)00004-5. [PMID: 33558047 DOI: 10.1016/j.eimc.2020.12.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
563 Rodríguez J, Patón M, Uratani JM, Acuña JM. Modelling the impact of interventions on the progress of the COVID-19 outbreak including age segregation. PLoS One 2021;16:e0248243. [PMID: 33720988 DOI: 10.1371/journal.pone.0248243] [Reference Citation Analysis]
564 Castilla J, Guevara M, Miqueleiz A, Baigorria F, Ibero-Esparza C, Navascués A, Trobajo-Sanmartín C, Martínez-Baz I, Casado I, Burgui C, Ezpeleta C, The Working Group For The Study Of Covid-In Navarra. Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. J Clin Med 2021;10:2608. [PMID: 34199198 DOI: 10.3390/jcm10122608] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
565 Fyles M, Fearon E, Overton C, Wingfield T, Medley GF, Hall I, Pellis L, House T; University of Manchester COVID-19 Modelling Group. Using a household-structured branching process to analyse contact tracing in the SARS-CoV-2 pandemic. Philos Trans R Soc Lond B Biol Sci 2021;376:20200267. [PMID: 34053253 DOI: 10.1098/rstb.2020.0267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
566 Šmigelskas K, Petrikonis K, Kasiulevičius V, Kalėdienė R, Jakaitienė A, Kaselienė S, Sauliūnė S, Beržanskytė A, Stankūnas M. SARS-CoV-2 Seroprevalence in Lithuania: Results of National Population Survey. Acta Med Litu 2021;28:48-58. [PMID: 34393628 DOI: 10.15388/Amed.2020.28.1.2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
567 Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, Costa C, Nunes-Cabaço H, Mendes AM, Gaspar P, Pereira-Santos MC, Rodrigues F, Condeço J, Escoval MA, Santos M, Ramirez M, Melo-Cristino J, Simas JP, Vasconcelos E, Afonso Â, Veldhoen M. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6 months post disease onset. Eur J Immunol 2020;50:2025-40. [PMID: 33084029 DOI: 10.1002/eji.202048970] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 34.0] [Reference Citation Analysis]
568 Dimeglio C, Herin F, Miedougé M, Cambus JP, Abravanel F, Mansuy JM, Soulat JM, Izopet J. Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. J Infect 2021;82:e29-32. [PMID: 33010259 DOI: 10.1016/j.jinf.2020.09.035] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
569 Trias-Llimós S, Riffe T, Bilal U. Monitoring life expectancy levels during the COVID-19 pandemic: Example of the unequal impact of the first wave on Spanish regions. PLoS One 2020;15:e0241952. [PMID: 33152009 DOI: 10.1371/journal.pone.0241952] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
570 Tocto-Erazo MR, Espíndola-Zepeda JA, Montoya-Laos JA, Acuña-Zegarra MA, Olmos-Liceaga D, Reyes-Castro PA, Figueroa-Preciado G. Lockdown, relaxation, and acme period in COVID-19: A study of disease dynamics in Hermosillo, Sonora, Mexico. PLoS One 2020;15:e0242957. [PMID: 33270705 DOI: 10.1371/journal.pone.0242957] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
571 Neipel J, Bauermann J, Bo S, Harmon T, Jülicher F. Power-law population heterogeneity governs epidemic waves. PLoS One 2020;15:e0239678. [PMID: 33052918 DOI: 10.1371/journal.pone.0239678] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
572 Martínez-Cortés M, León-Dominguez CM, Fernandez-Pinero J, Rodriguez M, Almonacid M, Ferrari MJ, Romero R, Antona A, Rivas MD, de La Fuente M, Pérez-Gómez B, Pollán M. SARS-CoV-2 surveillance strategy in essential workers of the Madrid City Council during the first epidemic wave in Spain, March-July 2020. Occup Environ Med 2021:oemed-2021-107654. [PMID: 34599009 DOI: 10.1136/oemed-2021-107654] [Reference Citation Analysis]
573 Feng S, Roguet A, Mcclary-gutierrez JS, Newton RJ, Kloczko N, Meiman JG, Mclellan SL. Evaluation of Sampling, Analysis, and Normalization Methods for SARS-CoV-2 Concentrations in Wastewater to Assess COVID-19 Burdens in Wisconsin Communities. ACS EST Water 2021;1:1955-65. [DOI: 10.1021/acsestwater.1c00160] [Cited by in Crossref: 16] [Cited by in F6Publishing: 2] [Article Influence: 16.0] [Reference Citation Analysis]
574 Clapham HE, Chia WN, Tan LWL, Kumar V, Lim JM, Shankar N, Tun ZM, Zahari M, Hsu LY, Sun LJ, Wang LF, Tam CC. Contrasting SARS-CoV-2 epidemics in Singapore: cohort studies in migrant workers and the general population. Int J Infect Dis 2021;115:72-8. [PMID: 34864193 DOI: 10.1016/j.ijid.2021.11.043] [Reference Citation Analysis]
575 Pulido-Fuentes M, Flores-Martos JA, Abad-González L, Navarta-Sánchez MV, Valera-Oviedo L, Cipriano-Crespo C. Emotions in the Time of COVID-19: Affections and Impacts among the Spanish Primary Care Workforce. Healthcare (Basel) 2021;9:1723. [PMID: 34946447 DOI: 10.3390/healthcare9121723] [Reference Citation Analysis]
576 Uribarri A, Núñez-Gil IJ, Aparisi Á, Arroyo-Espliguero R, Maroun Eid C, Romero R, Becerra-Muñoz VM, Feltes G, Molina M, García-Aguado M, Cerrato E, Capel-Astrua T, Alfonso-Rodríguez E, Castro-Mejía AF, Raposeiras-Roubín S, Espejo C, Pérez-Solé N, Bardají A, Marín F, Fabregat-Andrés Ó, D'ascenzo F, Santoro F, Akin I, Estrada V, Fernández-Ortiz A, Macaya C; en representación de los investigadores HOPE COVID-19. [Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry]. Rev Esp Cardiol 2021;74:608-15. [PMID: 33678938 DOI: 10.1016/j.recesp.2020.12.014] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
577 Galanis P, Kaitelidou D, Prezerakos P, Kotsiopoulos I, Siskou O, Konstantakopoulou O, Hadjichristodoulou C, Tsiodras S. Low seropositivity for SARS-CoV-2 antibodies among healthcare workers after the first COVID-19 pandemic wave in Greece. Public Health 2021;198:223-9. [PMID: 34482100 DOI: 10.1016/j.puhe.2021.07.029] [Reference Citation Analysis]
578 Kichatova VS, Asadi Mobarkhan FA, Potemkin IA, Zlobin SP, Perfilieva OM, Valuev-elliston VT, Ivanov AV, Solonin SA, Godkov MA, Belikova MG, Mikhailov MI, Kyuregyan KK. Assessment of Diagnostic Specificity of Anti-SARS-CoV-2 Antibody Tests and Their Application for Monitoring of Seroconversion and Stability of Antiviral Antibody Response in Healthcare Workers in Moscow. Microorganisms 2022;10:429. [DOI: 10.3390/microorganisms10020429] [Reference Citation Analysis]
579 Nicolás I, Martínez-Zamora MÁ, Gracia M, Feixas G, Rius M, Carmona F. Impact of SARS-COV2 Pandemic on Patients with Endometriosis and Their Health Care. J Womens Health (Larchmt) 2022. [PMID: 35148487 DOI: 10.1089/jwh.2021.0323] [Reference Citation Analysis]
580 Wu J, Liang BY, Fang YH, Wang H, Yang XL, Shen S, Chen LK, Li SM, Lu SH, Xiang TD, Liu J, Le-Trilling VTK, Lu MJ, Yang DL, Deng F, Dittmer U, Trilling M, Zheng X. Occurrence of COVID-19 Symptoms During SARS-CoV-2 Infection Defines Waning of Humoral Immunity. Front Immunol 2021;12:722027. [PMID: 34489971 DOI: 10.3389/fimmu.2021.722027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
581 Politi J, Martín-Sánchez M, Mercuriali L, Borras-Bermejo B, Lopez-Contreras J, Vilella A, Villar J, Orcau A, de Olalla PG, Rius C; COVID-19 Surveillance Working Group of Barcelona. Epidemiological characteristics and outcomes of COVID-19 cases: mortality inequalities by socio-economic status, Barcelona, Spain, 24 February to 4 May 2020. Euro Surveill 2021;26. [PMID: 34018483 DOI: 10.2807/1560-7917.ES.2021.26.20.2001138] [Reference Citation Analysis]
582 Heyming T, Bacon K, Lara B, Knudsen-Robbins C, Tongol A, Sanger T. SARS-CoV-2 Serology Testing in an Asymptomatic, At-Risk Population: Methods, Results, Pitfalls. Infect Dis Rep 2021;13:910-6. [PMID: 34698190 DOI: 10.3390/idr13040082] [Reference Citation Analysis]
583 Weidner L, Nunhofer V, Jungbauer C, Hoeggerl AD, Grüner L, Grabmer C, Zimmermann G, Rohde E, Laner-Plamberger S. Seroprevalence of anti-SARS-CoV-2 total antibody is higher in younger Austrian blood donors. Infection 2021. [PMID: 34132990 DOI: 10.1007/s15010-021-01639-0] [Reference Citation Analysis]
584 Dickson E, Palmateer NE, Murray J, Robertson C, Waugh C, Wallace LA, Mathie L, Heatlie K, Mavin S, Gousias P, Von Wissman B, Goldberg DJ, McAuley A. Enhanced surveillance of COVID-19 in Scotland: population-based seroprevalence surveillance for SARS-CoV-2 during the first wave of the epidemic. Public Health 2021;190:132-4. [PMID: 33453689 DOI: 10.1016/j.puhe.2020.11.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
585 Hossain A, Nasrullah SM, Tasnim Z, Hasan MK, Hasan MM. Seroprevalence of SARS-CoV-2 IgG antibodies among health care workers prior to vaccine administration in Europe, the USA and East Asia: A systematic review and meta-analysis. EClinicalMedicine 2021;33:100770. [PMID: 33718853 DOI: 10.1016/j.eclinm.2021.100770] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
586 Favalli EG, Gobbini A, Bombaci M, Maioli G, Biggioggero M, Pesce E, Favalli A, Martinovic M, Fabbris T, Marchisio E, Bandiera A, Gori A, Abrignani S, Grifantini R, Caporali R. The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study. Front Med 2022;9:850858. [DOI: 10.3389/fmed.2022.850858] [Reference Citation Analysis]
587 Gozzi N, Tizzoni M, Chinazzi M, Ferres L, Vespignani A, Perra N. Estimating the effect of social inequalities on the mitigation of COVID-19 across communities in Santiago de Chile. Nat Commun 2021;12:2429. [PMID: 33893279 DOI: 10.1038/s41467-021-22601-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
588 Ulyte A, Radtke T, Abela IA, Haile SR, Braun J, Jung R, Berger C, Trkola A, Fehr J, Puhan MA, Kriemler S. Seroprevalence and immunity of SARS-CoV-2 infection in children and adolescents in schools in Switzerland: design for a longitudinal, school-based prospective cohort study. Int J Public Health 2020;65:1549-57. [PMID: 33063141 DOI: 10.1007/s00038-020-01495-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
589 Alhazmi A, Alamer E, Abdelwahab S, Khamjan N, Hamami A, Haddad M, Darraj M, Hashem AM, Algaissi A. Community-Based Seroprevalence of SARS-CoV-2 Antibodies following the First Wave of the COVID-19 Pandemic in Jazan Province, Saudi Arabia. Int J Environ Res Public Health 2021;18:12451. [PMID: 34886175 DOI: 10.3390/ijerph182312451] [Reference Citation Analysis]
590 Feehan AK, Fort D, Garcia-Diaz J, Price-Haywood EG, Velasco C, Sapp E, Pevey D, Seoane L. Seroprevalence of SARS-CoV-2 and Infection Fatality Ratio, Orleans and Jefferson Parishes, Louisiana, USA, May 2020. Emerg Infect Dis 2020;26:2766-9. [PMID: 32731911 DOI: 10.3201/eid2611.203029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
591 Steinhardt LC, Ige F, Iriemenam NC, Greby SM, Hamada Y, Uwandu M, Aniedobe M, Stafford KA, Abimiku A, Mba N, Agala N, Okunoye O, Mpamugo A, Swaminathan M, Onokevbagbe E, Olaleye T, Odoh I, Marston BJ, Okoye M, Abubakar I, Rangaka MX, Rogier E, Audu R. Cross-Reactivity of Two SARS-CoV-2 Serological Assays in a Setting Where Malaria Is Endemic. J Clin Microbiol 2021;59:e0051421. [PMID: 33853839 DOI: 10.1128/JCM.00514-21] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
592 Martín-Sánchez FJ, Valls Carbó A, Miró Ò, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martín A, García-Lamberechts JE, Jacob J, Alquézar A, Martínez-Valero C, Miranda JD, López Picado A, Arrebola JP, López ME, Parviainen A, González Del Castillo J, Miró O, Jimenez S, Ferreras Amez JM, Rubio Díaz R, Gamazo Del Rio JJ, Alonso H, Herrero P, Ruiz de Lobera N, Ibero C, Mayan P, Peinado R, Navarro Bustos C, Manzanares JÁ, Román F, Piñera P, Burillo G, Jacob J, Bibiano C; Spanish Social-Environmental COVID-19 Register. Socio-Demographic Health Determinants Are Associated with Poor Prognosis in Spanish Patients Hospitalized with COVID-19. J Gen Intern Med 2021. [PMID: 34240284 DOI: 10.1007/s11606-020-06584-6] [Reference Citation Analysis]
593 Mas JF. Stage 1 registered report: spatiotemporal patterns of the COVID-19 epidemic in Mexico at the municipality level. PeerJ 2021;9:e10622. [PMID: 33604169 DOI: 10.7717/peerj.10622] [Reference Citation Analysis]
594 LeBlanc EV, Colpitts CC. A dual antibody test for accurate surveillance of SARS-CoV-2 exposure rates. Cell Rep Med 2021;2:100223. [PMID: 33748790 DOI: 10.1016/j.xcrm.2021.100223] [Reference Citation Analysis]
595 Chow EJ, Englund JA. SARS-CoV-2 Infections in Children. Infectious Disease Clinics of North America 2022. [DOI: 10.1016/j.idc.2022.01.005] [Reference Citation Analysis]
596 Uribarri A, Núñez-Gil IJ, Aparisi Á, Arroyo-Espliguero R, Maroun Eid C, Romero R, Becerra-Muñoz VM, Feltes G, Molina M, García-Aguado M, Cerrato E, Capel-Astrua T, Alfonso-Rodríguez E, Castro-Mejía AF, Raposeiras-Roubín S, Espejo C, Pérez-Solé N, Bardají A, Marín F, Fabregat-Andrés Ó, D'ascenzo F, Santoro F, Akin I, Estrada V, Fernández-Ortiz A, Macaya C; HOPE COVID-19 investigators. Atrial fibrillation in patients with COVID-19. Usefulness of the CHA2DS2-VASc score: an analysis of the international HOPE COVID-19 registry. Rev Esp Cardiol (Engl Ed) 2021;74:608-15. [PMID: 33583755 DOI: 10.1016/j.rec.2020.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
597 Herzog SA, De Bie J, Abrams S, Wouters I, Ekinci E, Patteet L, Coppens A, De Spiegeleer S, Beutels P, Van Damme P, Hens N, Theeten H. Seroprevalence of IgG antibodies against SARS-CoV-2 - a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020. Euro Surveill 2022;27. [PMID: 35241216 DOI: 10.2807/1560-7917.ES.2022.27.9.2100419] [Reference Citation Analysis]
598 García-Lamberechts EJ, Miró Ò, Fragiel M, Llorens P, Jiménez S, Piñera P, Burillo-Putze G, Martín A, Martín-Sánchez FJ, Jacob J, Alquézar-Arbé A, Ejarque Martínez L, Rodríguez Miranda B, Ruiz Grinspan M, Domínguez MJ, Teigell Muñoz FJ, Gayoso Martín S, García García Á, Iglesias Vela M, Carbajosa V, Salido Mota M, Marchena González MJ, Agüera Urbano C, Porta-Etessam J, Calvo E, González Del Castillo J; Spanish Investigators on Emergency Situations TeAm (SIESTA) network. A case-control analysis of stroke in COVID-19 patients: Results of unusual manifestations of COVID-19-study 11. Acad Emerg Med 2021;28:1236-50. [PMID: 34490961 DOI: 10.1111/acem.14389] [Reference Citation Analysis]
599 Català M, Pino D, Marchena M, Palacios P, Urdiales T, Cardona PJ, Alonso S, López-Codina D, Prats C, Alvarez-Lacalle E. Robust estimation of diagnostic rate and real incidence of COVID-19 for European policymakers. PLoS One 2021;16:e0243701. [PMID: 33411737 DOI: 10.1371/journal.pone.0243701] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
600 Yoshiyama T, Saito Y, Masuda K, Nakanishi Y, Kido Y, Uchimura K, Mitarai S, Suzuki T, Nakagama Y, Kubota H, Satomi M, Uchikoba S, Ohnishi M, Wakita T, Kato S, Kato K. Prevalence of SARS-CoV-2-Specific Antibodies, Japan, June 2020. Emerg Infect Dis 2021;27:628-31. [PMID: 33496235 DOI: 10.3201/eid2702.204088] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
601 Augustine R, Das S, Hasan A, S A, Abdul Salam S, Augustine P, Dalvi YB, Varghese R, Primavera R, Yassine HM, Thakor AS, Kevadiya BD. Rapid Antibody-Based COVID-19 Mass Surveillance: Relevance, Challenges, and Prospects in a Pandemic and Post-Pandemic World. J Clin Med 2020;9:E3372. [PMID: 33096742 DOI: 10.3390/jcm9103372] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 9.5] [Reference Citation Analysis]
602 Velikova T. INFECTION-ACQUIRED VERSUS VACCINE-INDUCED IMMUNITY AGAINST COVID-19. CAJMHE 2021;2:29-35. [DOI: 10.47316/cajmhe.2021.2.1.05] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
603 Quirós-González V, Rubio R, Pulido F, Rial-Crestelo D, Martín-Jurado C, Hernández-Ros MÁ, Jiménez EAL, Miguel Ferrari J, Manuel Caro-Teller J, Pinar Ó, Pedrera-Jiménez M, García-Barrio N, Serrano P, Luis Bernal J. Healthcare Outcomes In Patients With Hiv Infection At A Tertiary Hospital During The COVID-19 Pandemic. Enferm Infecc Microbiol Clin (Engl Ed) 2021. [PMID: 34456409 DOI: 10.1016/j.eimc.2021.07.013] [Reference Citation Analysis]
604 Bloomfield M, Pospisilova I, Cabelova T, Sediva A, Ibrahimova M, Borecka K, Magner M. Searching for COVID-19 Antibodies in Czech Children-A Needle in the Haystack. Front Pediatr 2020;8:597736. [PMID: 33304869 DOI: 10.3389/fped.2020.597736] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
605 Flower B, Brown JC, Simmons B, Moshe M, Frise R, Penn R, Kugathasan R, Petersen C, Daunt A, Ashby D, Riley S, Atchison CJ, Taylor GP, Satkunarajah S, Naar L, Klaber R, Badhan A, Rosadas C, Khan M, Fernandez N, Sureda-Vives M, Cheeseman HM, O'Hara J, Fontana G, Pallett SJC, Rayment M, Jones R, Moore LSP, McClure MO, Cherepanov P, Tedder R, Ashrafian H, Shattock R, Ward H, Darzi A, Elliot P, Barclay WS, Cooke GS. Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey. Thorax 2020;75:1082-8. [PMID: 32796119 DOI: 10.1136/thoraxjnl-2020-215732] [Cited by in Crossref: 60] [Cited by in F6Publishing: 45] [Article Influence: 30.0] [Reference Citation Analysis]
606 Grantz KH, Lee EC, D'Agostino McGowan L, Lee KH, Metcalf CJE, Gurley ES, Lessler J. Maximizing and evaluating the impact of test-trace-isolate programs: A modeling study. PLoS Med 2021;18:e1003585. [PMID: 33930019 DOI: 10.1371/journal.pmed.1003585] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
607 Haq M, Rehman A, Haq M, Haq H, Rajab H, Ahmad J, Ahmed J, Anwar S, Ahmad S, Haq NU. Identifying higher risk subgroups of health care workers for priority vaccination against COVID-19. Therapeutic Advances in Vaccines and Immunotherapy 2022;10:251513552210807. [DOI: 10.1177/25151355221080724] [Reference Citation Analysis]
608 Martínez-Baz I, Trobajo-Sanmartín C, Arregui I, Navascués A, Adelantado M, Indurain J, Fresán U, Ezpeleta C, Castilla J. Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers. Vaccines (Basel) 2020;8:E611. [PMID: 33076405 DOI: 10.3390/vaccines8040611] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
609 Opoka-Winiarska V, Grywalska E, Korona-Glowniak I, Matuska K, Malm A, Roliński J. Seroprevalence of Antibodies against SARS-CoV-2 in Children with Juvenile Idiopathic Arthritis a Case-Control Study. J Clin Med 2021;10:1771. [PMID: 33921679 DOI: 10.3390/jcm10081771] [Reference Citation Analysis]
610 Capai L, Ayhan N, Masse S, Canarelli J, Priet S, Simeoni MH, Charrel R, Lamballerie X, Falchi A. Seroprevalence of SARS-CoV-2 IgG Antibodies in Corsica (France), April and June 2020. J Clin Med 2020;9:E3569. [PMID: 33167563 DOI: 10.3390/jcm9113569] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
611 Ripperger TJ, Uhrlaub JL, Watanabe M, Wong R, Castaneda Y, Pizzato HA, Thompson MR, Bradshaw C, Weinkauf CC, Bime C, Erickson HL, Knox K, Bixby B, Parthasarathy S, Chaudhary S, Natt B, Cristan E, Aini TE, Rischard F, Campion J, Chopra M, Insel M, Sam A, Knepler JL, Capaldi AP, Spier CM, Dake MD, Edwards T, Kaplan ME, Scott SJ, Hypes C, Mosier J, Harris DT, LaFleur BJ, Sprissler R, Nikolich-Žugich J, Bhattacharya D. Detection, prevalence, and duration of humoral responses to SARS-CoV-2 under conditions of limited population exposure. medRxiv 2020:2020. [PMID: 32817969 DOI: 10.1101/2020.08.14.20174490] [Cited by in Crossref: 16] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
612 Petersen MS, Strøm M, Fjallsbak JP, Hansen JL, Larsen S, Eliasen EH, Johansen M, Veyhe AS, Kristiansen MF, Weihe P. Low Seroprevalence among Undetected COVID-19 Cases, Faroe Islands, November 2020. Emerg Infect Dis 2022;28:242-4. [PMID: 34757895 DOI: 10.3201/eid2801.210917] [Reference Citation Analysis]
613 Alsuwaidi AR, Al Hosani FI, Al Memari S, Narchi H, Abdel Wareth L, Kamal H, Al Ketbi M, Al Baloushi D, Elfateh A, Khudair A, Al Mazrouei S, AlHumaidan HS, Alghaithi N, Afsh K, Al Kaabi N, Altrabulsi B, Jones M, Shaban S, Sheek-Hussein M, Zoubeidi T. Seroprevalence of COVID-19 infection in the Emirate of Abu Dhabi, United Arab Emirates: a population-based cross-sectional study. Int J Epidemiol 2021:dyab077. [PMID: 33893483 DOI: 10.1093/ije/dyab077] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
614 Prakash O, Solanki B, Sheth J, Oza D, Kadam M, Vyas S, Shukla A, Pethani J, Tiwari H. Population-based seropositivity for IgG antibodies against SARS-CoV-2 in Ahmedabad city. J Family Med Prim Care 2021;10:2363-8. [PMID: 34322439 DOI: 10.4103/jfmpc.jfmpc_2062_20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
615 Shaw JA, Meiring M, Cummins T, Chegou NN, Claassen C, Du Plessis N, Flinn M, Hiemstra A, Kleynhans L, Leukes V, Loxton AG, MacDonald C, Mtala N, Reuter H, Simon D, Stanley K, Tromp G, Preiser W, Malherbe ST, Walzl G. Higher SARS-CoV-2 seroprevalence in workers with lower socioeconomic status in Cape Town, South Africa. PLoS One 2021;16:e0247852. [PMID: 33630977 DOI: 10.1371/journal.pone.0247852] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
616 de Souza Araújo AA, Quintans-Júnior LJ, Heimfarth L, Schimieguel DM, Corrêa CB, de Moura TR, Cavalcante RCM, Rodrigues Bomfim R, Grespan R, Santana Rodrigues L, Dos Santos DM, de Sá Resende A, de Lima Silva N, da Silva Santos ACR, Dantas Araújo JM, de Souza MF, de Oliveira Góes MA, Santana Santos V, Martins-Filho PR. Seroprevalence of SARS-CoV-2 antibodies in the poorest region of Brazil: results from a population-based study. Epidemiol Infect 2021;149:e130. [PMID: 34001292 DOI: 10.1017/S0950268821001163] [Reference Citation Analysis]
617 Landier J, Paireau J, Rebaudet S, Legendre E, Lehot L, Fontanet A, Cauchemez S, Gaudart J. Cold and dry winter conditions are associated with greater SARS-CoV-2 transmission at regional level in western countries during the first epidemic wave. Sci Rep 2021;11:12756. [PMID: 34140557 DOI: 10.1038/s41598-021-91798-9] [Reference Citation Analysis]
618 Siqueira CADS, Freitas YNL, Cancela MC, Carvalho M, Oliveras-Fabregas A, de Souza DLB. The effect of lockdown on the outcomes of COVID-19 in Spain: An ecological study. PLoS One 2020;15:e0236779. [PMID: 32726363 DOI: 10.1371/journal.pone.0236779] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 13.5] [Reference Citation Analysis]
619 Arokiaraj MC. Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality-Perspectives. Front Public Health 2020;8:444. [PMID: 33072682 DOI: 10.3389/fpubh.2020.00444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
620 Ares-Blanco S, Pérez Álvarez M, Gefaell Larrondo I, Muñoz C, Aguilar Ruiz V, Castelo Jurado M, Guisado-Clavero M. SARS-CoV-2 pneumonia follow-up and long COVID in primary care: A retrospective observational study in Madrid city. PLoS One 2021;16:e0257604. [PMID: 34551007 DOI: 10.1371/journal.pone.0257604] [Reference Citation Analysis]
621 Vignesh R, Shankar EM, Velu V, Thyagarajan SP. Is Herd Immunity Against SARS-CoV-2 a Silver Lining? Front Immunol 2020;11:586781. [PMID: 33101320 DOI: 10.3389/fimmu.2020.586781] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
622 Costa A, Almeida H, Moniz M, Alves C. COVID-19 screening in a Portuguese pediatric population. Enferm Infecc Microbiol Clin (Engl Ed) 2020:S0213-005X(20)30294-9. [PMID: 33268186 DOI: 10.1016/j.eimc.2020.09.004] [Reference Citation Analysis]
623 Le Vu S, Jones G, Anna F, Rose T, Richard JB, Bernard-Stoecklin S, Goyard S, Demeret C, Helynck O, Escriou N, Gransagne M, Petres S, Robin C, Monnet V, Perrin de Facci L, Ungeheuer MN, Léon L, Guillois Y, Filleul L, Charneau P, Lévy-Bruhl D, van der Werf S, Noel H. Prevalence of SARS-CoV-2 antibodies in France: results from nationwide serological surveillance. Nat Commun 2021;12:3025. [PMID: 34021152 DOI: 10.1038/s41467-021-23233-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
624 Roques L, Bonnefon O, Baudrot V, Soubeyrand S, Berestycki H. A parsimonious approach for spatial transmission and heterogeneity in the COVID-19 propagation. R Soc Open Sci 2020;7:201382. [PMID: 33489282 DOI: 10.1098/rsos.201382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
625 Mercier MR, Galivanche AR, Brand JP, Pathak N, Medvecky MJ, Varthi AG, Rubin LE, Grauer JN. COVID-positive ankle fracture patients are at increased odds of perioperative surgical complications following open reduction internal fixation surgery. PLoS One 2021;16:e0262115. [PMID: 34972190 DOI: 10.1371/journal.pone.0262115] [Reference Citation Analysis]
626 Infantino M, Pieri M, Nuccetelli M, Grossi V, Lari B, Tomassetti F, Calugi G, Pancani S, Benucci M, Casprini P, Manfredi M, Bernardini S. The WHO International Standard for COVID-19 serological tests: towards harmonization of anti-spike assays. Int Immunopharmacol 2021;100:108095. [PMID: 34619529 DOI: 10.1016/j.intimp.2021.108095] [Reference Citation Analysis]
627 De Salazar PM, Gómez-Barroso D, Pampaka D, Gil JM, Peñalver B, Fernández-Escobar C, Lipsitch M, Larrauri A, Goldstein E, Hernán MA. Lockdown measures and relative changes in the age-specific incidence of SARS-CoV-2 in Spain. Epidemiol Infect 2020;148:e268. [PMID: 33081851 DOI: 10.1017/S0950268820002551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
628 Oliveira LMDS, Tiyo BT, Silva LTD, Fonseca LAM, Rocha RC, Santos VAD, Ceneviva C, Bedin AA, Almeida A, Duarte AJDS, Oshiro TM. Prevalence of anti-SARS-CoV-2 antibodies in outpatients of a large public university hospital in Sao Paulo, Brazil. Rev Inst Med Trop Sao Paulo 2020;62:e91. [PMID: 33206865 DOI: 10.1590/S1678-9946202062091] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
629 Horta BL, Silveira MF, Barros AJD, Barros FC, Hartwig FP, Dias MS, Menezes AMB, Hallal PC, Victora CG. Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian survey. Rev Panam Salud Publica 2020;44:e135. [PMID: 33165337 DOI: 10.26633/RPSP.2020.135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
630 Goldstein E, Lipsitch M, Cevik M. On the Effect of Age on the Transmission of SARS-CoV-2 in Households, Schools, and the Community. J Infect Dis 2021;223:362-9. [PMID: 33119738 DOI: 10.1093/infdis/jiaa691] [Cited by in Crossref: 61] [Cited by in F6Publishing: 61] [Article Influence: 61.0] [Reference Citation Analysis]
631 Saadoun D, Vieira M, Vautier M, Baraliakos X, Andreica I, da Silva JAP, Sousa M, Luis M, Khmelinskii N, Gracía JMA, Castrejon I, Gonzalez JCN, Scirè CA, Silvagni E, Bortoluzzi A, Penn H, Hamdulay S, Machado PM, Fautrel B, Cacoub P, Resche-Rigon M, Gossec L. SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study. Lancet Rheumatol 2021;3:e481-8. [PMID: 33942031 DOI: 10.1016/S2665-9913(21)00112-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
632 Ayerdi O, Puerta T, Clavo P, Vera M, Ballesteros J, Fuentes ME, Estrada V, Rodríguez C, Del Romero J; Sandoval Study Group . Preventive Efficacy of Tenofovir/Emtricitabine Against Severe Acute Respiratory Syndrome Coronavirus 2 Among Pre-Exposure Prophylaxis Users. Open Forum Infect Dis 2020;7:ofaa455. [PMID: 33200081 DOI: 10.1093/ofid/ofaa455] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
633 Medina-Perucha L, García-Sangenís A, Moragas A, Gálvez-Hernández P, Cots JM, Lanau-Roig A, Borràs A, Amo I, Monfà R, Llor C, Berenguera A. Autonomy, power dynamics and antibiotic use in primary healthcare: A qualitative study. PLoS One 2020;15:e0244432. [PMID: 33338078 DOI: 10.1371/journal.pone.0244432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Boyton RJ, Altmann DM. The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions? Nat Rev Immunol 2021;21:762-8. [PMID: 34667307 DOI: 10.1038/s41577-021-00631-x] [Reference Citation Analysis]
635 Martin CA, Patel P, Goss C, Jenkins DR, Price A, Barton L, Gupta P, Zaccardi F, Jerina H, Duraisingham S, Brunskill NJ, Khunti K, Pareek M. Demographic and occupational determinants of anti-SARS-CoV-2 IgG seropositivity in hospital staff. J Public Health (Oxf) 2020:fdaa199. [PMID: 33200200 DOI: 10.1093/pubmed/fdaa199] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 9.5] [Reference Citation Analysis]
636 Llorca J, Lechosa-Muñiz C, Gortazar P, Fernández-Ortiz M, Jubete Y, Cabero MJ; MOACC-19 group. COVID-19 in a cohort of pregnant women and their descendants, the MOACC-19 study. BMJ Open 2021;11:e044224. [PMID: 33637549 DOI: 10.1136/bmjopen-2020-044224] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
637 Campos-Varela I, Len O, Villagrasa A, Márquez-Algaba E, Esperalba J, Dopazo C, Los-Arcos I, Antón A, Castells L. Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort. Transpl Int 2021. [PMID: 34121244 DOI: 10.1111/tri.13946] [Reference Citation Analysis]
638 Horta BL, Silveira MF, Barros AJD, Barros FC, Hartwig FP, Dias MS, Menezes AMB, Hallal PC, Victora CG. [Prevalence of antibodies against SARS-CoV-2 according to socioeconomic and ethnic status in a nationwide Brazilian surveyPrevalência de anticorpos contra o SARS-CoV-2 de acordo com o status socioeconômico e étnico em uma pesquisa nacional no Brasil]. Rev Panam Salud Publica 2021;45:e105. [PMID: 34703458 DOI: 10.26633/RPSP.2021.105] [Reference Citation Analysis]
639 Banholzer N, van Weenen E, Lison A, Cenedese A, Seeliger A, Kratzwald B, Tschernutter D, Salles JP, Bottrighi P, Lehtinen S, Feuerriegel S, Vach W. Estimating the effects of non-pharmaceutical interventions on the number of new infections with COVID-19 during the first epidemic wave. PLoS One 2021;16:e0252827. [PMID: 34077448 DOI: 10.1371/journal.pone.0252827] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
640 Brotons P, Launes C, Buetas E, Fumado V, Henares D, de Sevilla MF, Redin A, Fuente-Soro L, Cuadras D, Mele M, Jou C, Millat P, Jordan I, Garcia-Garcia JJ, Bassat Q, Muñoz-Almagro C; Kids Corona Study Group. Susceptibility to Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Children and Adults: A Seroprevalence Study of Family Households in the Barcelona Metropolitan Region, Spain. Clin Infect Dis 2021;72:e970-7. [PMID: 33180914 DOI: 10.1093/cid/ciaa1721] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
641 Khan SMS, Qurieshi MA, Haq I, Majid S, Ahmad J, Ayub T, Bhat AA, Fazili AB, Ganai AM, Jan Y, Kaul RU, Khan ZA, Masoodi MA, Mushtaq B, Nazir F, Nazir M, Raja MW, Rasool M, Asma A, Ayoub S, Aziz M, Bhat AA, Chowdri IN, Ismail S, Kawoosa MF, Khan MA, Khan MS, Kousar R, Lone AA, Nabi S, Obaid M, Qazi TB, Sabah I, Sumji IA. Seroprevalence of SARS-CoV-2-specific IgG antibodies in Kashmir, India, 7 months after the first reported local COVID-19 case: results of a population-based seroprevalence survey from October to November 2020. BMJ Open 2021;11:e053791. [PMID: 34556519 DOI: 10.1136/bmjopen-2021-053791] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
642 Lin YC, Brooks JD, Bull SB, Gagnon F, Greenwood CMT, Hung RJ, Lawless J, Paterson AD, Sun L, Strug LJ; Genetic Epidemiology Committee of the Canadian COVID Genomics Network (CanCOGeN) HostSeq Project. Statistical power in COVID-19 case-control host genomic study design. Genome Med 2020;12:115. [PMID: 33371892 DOI: 10.1186/s13073-020-00818-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
643 Sakalle S, Saroshe S, Shukla H, Mutha A, Vaze A, Arora A, Athotra A, Ramaswamy S, Jain A, Dhuria M, Patil AD, Rai A, Garg S, Jain SK, Bindal J, Singh SK. Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020. J Family Med Prim Care 2021;10:1479-84. [PMID: 34041197 DOI: 10.4103/jfmpc.jfmpc_2015_20] [Reference Citation Analysis]
644 Linares C, Culqui D, Belda F, López-Bueno JA, Luna Y, Sánchez-Martínez G, Hervella B, Díaz J. Impact of environmental factors and Sahara dust intrusions on incidence and severity of COVID-19 disease in Spain. Effect in the first and second pandemic waves. Environ Sci Pollut Res Int 2021. [PMID: 33993402 DOI: 10.1007/s11356-021-14228-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
645 Liu M, Huang H, Bian X, Zheng Z, Li N, Sun B, Wu J. A prospective cohort study of the presence of SARS-CoV-2 in clinical samples from multiple bodily sites: implications for transmission routes of COVID-19. Journal of Bio-X Research 2022;5:27-34. [DOI: 10.1097/jbr.0000000000000114] [Reference Citation Analysis]
646 Carta A, Conversano C. Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients - a hypothetical study. BMC Health Serv Res 2021;21:986. [PMID: 34537034 DOI: 10.1186/s12913-021-06998-w] [Reference Citation Analysis]
647 Singh DE, Marinescu MC, Guzmán-Merino M, Durán C, Delgado-Sanz C, Gomez-Barroso D, Carretero J. Simulation of COVID-19 Propagation Scenarios in the Madrid Metropolitan Area. Front Public Health 2021;9:636023. [PMID: 33796497 DOI: 10.3389/fpubh.2021.636023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
648 Tran Kiem C, Crépey P, Bosetti P, Levy Bruhl D, Yazdanpanah Y, Salje H, Boëlle PY, Cauchemez S. Lockdown as a last resort option in case of COVID-19 epidemic rebound: a modelling study. Euro Surveill 2021;26. [PMID: 34085634 DOI: 10.2807/1560-7917.ES.2021.26.22.2001536] [Reference Citation Analysis]
649 Águas R, Mahdi A, Shretta R, Horby P, Landray M, White L; CoMo Consortium. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19. Nat Commun 2021;12:915. [PMID: 33568665 DOI: 10.1038/s41467-021-21134-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
650 Copley HC, Gragert L, Leach AR, Kosmoliaptsis V. Influence of HLA Class II Polymorphism on Predicted Cellular Immunity Against SARS-CoV-2 at the Population and Individual Level. Front Immunol 2021;12:669357. [PMID: 34349756 DOI: 10.3389/fimmu.2021.669357] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
651 López MG, Chiner-Oms Á, García de Viedma D, Ruiz-Rodriguez P, Bracho MA, Cancino-Muñoz I, D'Auria G, de Marco G, García-González N, Goig GA, Gómez-Navarro I, Jiménez-Serrano S, Martinez-Priego L, Ruiz-Hueso P, Ruiz-Roldán L, Torres-Puente M, Alberola J, Albert E, Aranzamendi Zaldumbide M, Bea-Escudero MP, Boga JA, Bordoy AE, Canut-Blasco A, Carvajal A, Cilla Eguiluz G, Cordón Rodríguez ML, Costa-Alcalde JJ, de Toro M, de Toro Peinado I, Del Pozo JL, Duchêne S, Fernández-Pinero J, Fuster Escrivá B, Gimeno Cardona C, González Galán V, Gonzalo Jiménez N, Hernáez Crespo S, Herranz M, Lepe JA, López-Causapé C, López-Hontangas JL, Martín V, Martró E, Milagro Beamonte A, Montes Ros M, Moreno-Muñoz R, Navarro D, Navarro-Marí JM, Not A, Oliver A, Palop-Borrás B, Parra Grande M, Pedrosa-Corral I, Pérez González MC, Pérez-Lago L, Pérez-Ruiz M, Piñeiro Vázquez L, Rabella N, Rezusta A, Robles Fonseca L, Rodríguez-Villodres Á, Sanbonmatsu-Gámez S, Sicilia J, Soriano A, Tirado Balaguer MD, Torres I, Tristancho A, Marimón JM, Coscolla M, González-Candelas F, Comas I; SeqCOVID-Spain consortium. The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant. Nat Genet 2021;53:1405-14. [PMID: 34594042 DOI: 10.1038/s41588-021-00936-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]